

A low-angle, upward-looking photograph of the Space Needle tower in Seattle, Washington. The tower's iconic circular observation deck is at the top, with its lattice structure and support beams clearly visible. The sky is a clear, bright blue with some light, wispy clouds. The foreground is dominated by a large, curved, metallic surface that reflects the tower and the sky, creating a distorted, rippling mirror image of the scene. The overall color palette is dominated by blues and oranges, with the tower's structure appearing in shades of grey and white.

Seattle

Spring Group Meeting

APRIL 3-6, 2024 | SEATTLE, WASHINGTON



Spring into Group Meeting at the Home of Our SDMC

Welcome to SWOG's spring 2024 group meeting in Seattle, homebase to our Statistics and Data Management Center.

With almost 80 sessions on the calendar – many offering continuing medical education (CME) credit – this group meeting has something for everyone.

Our translational medicine (TM) plenary on Thursday includes a mini-symposium on how to pilot NCTN Navigator to find and request SWOG biobank specimens for your TM research. Friday's general plenary session features my group update and state-of-the-art presentations on the achievements and vision of our breast, palliative and end-of-life care, and lymphoma committees.

I also recommend the SWOG Clinical Trials Partnerships update forum. Site selection is soon to begin for our first SWOG CTP-run trial (21CTPLEUK01), and Wednesday's session (in-person and virtual) is your chance to get answers to your questions about the study.



To reduce tech costs for group meeting, which are considerable, we will not provide virtual attendance options for most closed sessions this spring (although please note select session leaders will run their own virtual components). We do continue to support virtual attendance for almost all open sessions, and we will post recordings of those sessions for member access.

I wish you a highly productive – and enjoyable – week. See you at the plenaries!

Charles D. Blanke, MD
SWOG Chair

Group Meeting Index

Chair’s Welcome Message	2
Top Accruals	4
Top Performing Sites	5
Schedule of Events	6-8
Hotel Maps	9
Plenary Sessions	10
SWOG Clinical Trials Partnerships (CTP) Update Forum	11
Nicholas J. Vogelzang, MD, GU Symposium	12
Take Action Symposium	13
Film Screening of “Trans Dudes with Lady Cancer”	14
S2408 Pre-Launch Meeting	15
S2210 Kickoff Meeting	16
Funding Opportunities	17
Robert B. Livingston Lecture	18
Frank and Linda Meyskens Annual Endowed Lectureship	18
Group Meeting App	19
CME Credit Information	20-21
Adolescent and Young Adult Committee	22
Clinical Trials Training Course (CTTC)	23
Digital Engagement Committee	24
SWOG Latin America Initiative Symposium	25
Pharmaceutical Sciences and Drug Information Joint Meeting	26
VA Committee	27-28
SWOG Administrative and Research Support Committees	29
Future Meeting Dates	29
Committee Agendas and Accrual Reports	
Barlogie-Salmon Myeloma Committee	30-32
Breast Committee	33-37
Cancer Control & Prevention Committee Leadership	38
Cancer Care Delivery Committee	39-42
Cancer Survivorship Committee	43-44
Early Therapeutics & Rare Cancers Committee	53-57
Gastrointestinal Committee	58-65
Genitourinary Committee	66-75
Immunotherapeutics Committee	76-77
Leukemia Committee	78-80
Lung Committee	81-89
Lymphoma Committee	90-95
Melanoma Committee	96-98
Palliative & End of Life Care Committee	45
Prevention & Epidemiology Committee	46-48
Radiation Oncology Committee	99-100
Symptom Control & Quality of Life Committee	49-52
SWOG Publications	101-106



Our Top Accruers

Patient volunteers power our trials —
and SWOG members connect us to them.

These members led in SWOG-credited registrations to
SWOG-managed trials July 1 to December 31, 2023



- Moffitt Cancer Center
- University of Texas Health Science Center at San Antonio
- University of Colorado Cancer Center LAPS
 - DHR Health Institute for Research and Development
- Yale University - Yale Cancer Center LAPS

- Heartland Cancer Research NCORP
 - University of Kansas Cancer Center – MCA Rural MU NCORP
- Southeast Clinical Oncology Research Consortium NCORP
 - Essentia Health NCORP
 - Kaiser Permanente NCORP



a National Cancer Institute program



A program of the National Cancer Institute
of the National Institutes of Health



THANKS TO

Our Top Performing Sites

To help our data management sites track their performance relative to that of others, we have developed a new metric based on the quality and timeliness of data and biospecimen submissions. Data management institutions with at least 10 SWOG accruals in the prior 13 months are scored on this scale.

The members below are SWOG's top-performing sites for the period of July through December of 2023.

- DHR Health Institute for Research & Development
- Lahey Hospital & Medical Center
- Baylor College of Medicine
- Baptist Memorial Healthcare / Mid-South MU-NCORP
- Instituto Nacional de Enfermedades Neoplásicas (INEN, Peru)
- Cleveland Clinic Foundation
- Oregon Health & Science University
- Banner University Medical Center – Tucson
- University of Arkansas for Medical Sciences
- Audie L Murphy VA Hospital
- Carle Cancer Center NCORP
- Massachusetts Veterans Epidemiology Research & Information Center (MAVERIC)

SPRING PROGRAM-AT-A-GLANCE

GROUP MEETING REGISTRATION & INFORMATION DESK LEVEL 3 FOYER *



WEDNESDAY-FRIDAY

7:00 AM - 5:00 PM

SATURDAY

7:00 AM - 11:00 AM

◀ **GO TO THE MEETING APP ONLINE**

WEDNESDAY, APRIL 3, 2024

		MEETING ROOM/LEVEL
7:00 AM -7:20 AM	CRA Clinical Trials Training Course Check-In	COLUMBIA A FOYER
7:20 AM-12:00 PM	CRA Clinical Trials Training Course	COLUMBIA A
8:30 AM-11:30 AM	Advocates Committee (Invitation Only)	CHEHALIS / 305
9:30 AM-11:00 AM	Quality Initiative Meeting (Invitation Only)	COWLITZ / 502
10:00 AM-11:45 AM	Nursing Research Subcommittee (Invitation Only)	CHELAN / 401
11:00 AM-12:00 PM	ORP Oishi/Open Forum Working Meeting (Invitation Only)	CHIWAHA / 501
12:30 PM-2:00 PM	Core Office Staff Meeting (Invitation Only)	COWLITZ / 502
12:30 PM-2:30 PM	Digital Engagement Committee [CME]	ELWHA B
1:45 PM-5:00 PM	CRA Clinical Trials Training Course Practicum	COLUMBIA C
2:00 PM-3:30 PM	SWOG Tissue Banking Meeting (Invitation Only)	CHELAN / 401

2:30 PM-4:30 PM	VA Program Development Strategic Team Meeting (Invitation Only)	CHEHALIS / 305
2:30 PM-4:30 PM	Take Action Symposium presented by the SWOG Recruitment and Retention Committee [CME]	COLUMBIA A
3:30 PM-4:30 PM	ORP Liaison Subcommittee (Invitation Only)	COWLITZ / 502
3:30 PM-5:00 PM	Hope Foundation Board Meeting (Board Members Only)	CHIWAHA / 501
5:00 PM-6:00 PM	Clinical Trials Partnerships Update Forum	COLUMBIA D
5:30 PM-7:30 PM	Site Operations	COLUMBIA A
5:30 PM-8:00 PM	NCORP Research Base Executive Committee (Invitation Only)	COWLITZ / 502

THURSDAY, APRIL 4, 2024

7:00 AM-8:00 AM	Leukemia Working Group (Invitation Only; Virtual Only)	VIRTUAL MEETING
7:30 AM-8:00 AM	Jeri & Noboru Oishi Symposium Check-In	COLUMBIA A FOYER
7:30 AM-9:30 AM	Melanoma Working Group (Invitation Only; Virtual Only)	VIRTUAL MEETING
7:30 AM-10:00 AM	Nicholas Vogelzang Symposium presented by the GU Committee	COLUMBIA D
8:00 AM-10:00 AM	Leukemia Committee [CME] (Virtual Only)	VIRTUAL MEETING
8:00 AM-10:00 AM	Lung-MAP Administrative Meeting (Invitation Only)	COWLITZ / 502
8:00 AM-10:00 AM	Cancer Care Delivery Committee [CME]	ELWHA AB
8:00 AM-11:00 AM	Jeri & Noboru Oishi Symposium	COLUMBIA A
8:30 AM-10:00 AM	Survivorship Committee "Coffee and Concepts"	METHOW / 307

SPRING 2024 PROGRAM-AT-A-GLANCE

10:00 AM-12:00 PM	Melanoma Committee [CME] (Virtual Only)	VIRTUAL MEETING
10:15 AM-12:15 PM	Symptom Control and Quality of Life Committee [CME]	ELWHA AB
10:15 AM-3:15 PM	GU Working Group (Invitation Only)	QUINAULT
10:30 AM-12:30 PM	Early Therapeutics and Rare Cancers Committee [CME]	COLUMBIA D
11:00 AM-1:00 PM	SWOG Latin America Initiative Symposium	BECKLER / 302
11:30 AM-1:30 PM	Lung-MAP Site Coordinators Committee (Invitation Only)	COWLITZ / 502
12:00 PM-1:00 PM	Clinical Trials Partnerships Scientific Advisory Board (Invitation Only)	CHEHALIS / 305
12:30 PM-2:00 PM	ORP Open Forum	COLUMBIA C
12:30 PM-2:30 PM	Prevention and Epidemiology Committee [CME]	ELWHA AB
1:00 PM-3:00 PM	Sarcoma Working Group of the ETxRC Committee	CHELAN / 401
1:00 PM-3:00 PM	Immunotherapeutics Committee [CME]	CHILIWACK / 402
1:30 PM-3:30 PM	Lung Radiation/Surgery Subcommittee (Invitation Only)	ASHNOLA / 301
2:00 PM-3:00 PM	S2408 Pre-Launch	BECKLER / 302
2:30 PM-3:30 PM	VA Liaison Meeting (Invitation Only)	DUWAMISH / 306
2:30 PM-3:30 PM	Lung Community Engagement Subcommittee (Invitation Only)	COWLITZ / 502
2:30 PM-3:30 PM	Plenary I Reception (Light Hors D'oeuvres)	COLUMBIA FOYER
2:30 PM-4:15 PM	APP Task Force (Invitation Only)	CHIWAHA / 501
3:30 PM-4:30 PM	DEI Leadership Council (Invitation Only)	CHEHALIS / 305

SEATTLE 2024

3:30 PM-5:00 PM	Plenary I (Translational Medicine) [CME]	COLUMBIA AB
5:15 PM-7:15 PM	Palliative and End of Life Care Committee [CME]	ELWHA AB
5:15 PM-7:15 PM	Lung Working Group (Invitation Only)	BECKLER / 302
5:15 PM-7:15 PM	CNS Working Group	ASHNOLA / 301
7:15 PM-9:15 PM	Early Therapeutics and Rare Cancers Committee Retreat (Invitation Only)	COWLITZ / 502

FRIDAY, APRIL 5, 2024

7:00 AM-8:30 AM	Professional Review Committee (Invitation Only)	CHELAN / 401
7:00 AM-9:00 AM	Imaging Committee (Invitation Only)	CHEHALIS / 305
7:15 AM-9:15 AM	Cancer Survivorship Committee [CME]	COLUMBIA D
7:30 AM-9:30 AM	SWOG Data and Safety Monitoring Committee (Invitation Only)	CHIWAHA / 501
8:00 AM-9:00 AM	S2210 Kickoff Meeting	BECKLER / 302
8:00 AM-9:00 AM	GI Translational Research Subcommittee (Invitation Only)	ASHNOLA / 301
8:00 AM-10:00 AM	Lymphoma Working Group (Invitation Only)	COWLITZ / 502
8:30 AM-11:30 AM	Lung Committee [CME]	QUINAULT
9:00 AM-10:30 AM	Quality Assurance Committee (Invitation Only)	CHELAN / 401
9:00 AM-11:00 AM	Adolescent & Young Adult (AYA) Committee [CME]	CHILIWACK / 402
9:00 AM-12:00 PM	GI Working Group (Invitation Only)	ASHNOLA / 301
9:30 AM-12:00 PM	GU Committee (Open Session) [CME]	ELWHA AB
10:00 AM-12:00 PM	Pharmaceutical Sciences Committee and Drug Information Subcommittee	KACHESS / 405

SEATTLE 2024 PROGRAM-AT-A-GLANCE

10:15 AM-12:00 PM	Bone Marrow & Stem Cell Transplantation Committee [CME]	BECKLER / 302
10:30 AM-11:30 AM	ORP Executive Committee (Invitation Only)	CHIWAHA / 501
11:00 AM-12:00 PM	Plenary II Reception (Light Hors D'oeuvres)	COLUMBIA FOYER
11:30 AM-12:00 PM	Publications Committee (Invitation Only)	CHEHALIS / 305
12:00 PM-2:00 PM	Plenary II (General) [CME]	COLUMBIA AB
2:15 PM-3:15 PM	NCORP/MU-NCORP Site PI Meeting	CHILIWACK / 402
2:15 PM-4:15 PM	Lymphoma Committee [CME]	ELWHA AB
2:30 PM-4:00 PM	Breast Translational Medicine Working Group (Invitation Only)	QUINAULT
3:00 PM-5:00 PM	VA Committee	BECKLER / 302
4:00 PM-6:00 PM	Radiation Oncology Committee Retreat	CHELAN / 401
4:00 PM-6:30 PM	Myeloma Working Group (Invitation Only)	COWLITZ / 502
4:30 PM-6:30 PM	Breast Working Group (Invitation Only)	QUINAULT
4:30 PM-6:30 PM	GI Committee [CME]	COLUMBIA D
5:30 PM - 7:00 PM	Film Screening of "Trans Dudes with Lady Cancer"	BECKLER / 302
6:00 PM-7:00 PM	Executive Reception (Invitation Only)	
6:45 PM-8:30 PM	Group Reception	LEVEL 3 FOYER
7:00 PM-9:00 PM	Breast Committee Social (Invitation Only)	CHILIWACK / 402

SATURDAY, APRIL 6, 2024

7:00 AM-7:45 AM	Board of Governors (Board Members Only)	ELWHA B
8:00 AM-9:00 AM	Committee Chairs (Invitation Only)	ELWHA B
9:15 AM-12:15 PM	Breast Committee [CME]	COLUMBIA D
9:30 AM-11:30 AM	Radiation Oncology Committee [CME]	ASHNOLA / 301
9:30 AM-11:30 AM	Barlogie-Salmon Myeloma Committee [CME]	ELWHA B

We've Supported **SWOG** for a Generation. **Let's Make a Plan for the Next.**

You can plant a seed for future generations of cancer researchers when you leave a gift in your will for The Hope Foundation.



SCAN THE QR CODE TO LEARN MORE


THE HOPE FOUNDATION FOR CANCER RESEARCH

SPRING 2024 PROGRAM-AT-A-GLANCE

SEATTLE 2024

Hyatt Regency Seattle Floor Levels

808 Howell Street | Seattle, WA 98101 | hyattregencyseattle.com | Phone: 206-973-1234



Plenary I • Thursday, April 4, 3:30 - 5:00 pm PT • Columbia AB

This spring's translational medicine plenary will feature the following speakers and topics:

Welcome and Introduction

Lee M. Ellis, MD, FASCO
SWOG Vice-Chair for Translational Medicine
MD Anderson Cancer Center




Characterizing the Tumor Immune Microenvironment in Alveolar Soft Part Sarcoma Using High-End Omics Approaches: Lessons Learned with Potential Implications in Rare Tumors Harboring Fusion Proteins

Abdul Rafeh Naqash, MD
University of Oklahoma



Translating Breast Cancer: Changing How We Practice

Alastair M. Thompson, BSc(Hons), MBChB, MD
Baylor College of Medicine



MINI-SYMPOSIUM – Navigating NCI Navigator: Obtaining Tissue Specimens from SWOG's Biobank for Translational Medicine Studies

SWOG's Lessons Learned Navigating Navigator

Yvonne Moyer, MBA
Nationwide Children's Hospital



The Future of Navigator and Tissue Acquisition

Grace Mishkin, PhD, MPH
Cancer Therapy and Evaluation Program, National Cancer Institute



Plenary II • Friday, April 5, 12:00 – 2:00 pm PT • Columbia AB

Year of Progress: Breast, Palliative & End-of-Life Care, and Lymphoma

Three SWOG leaders will report on their committees' most significant results and undertakings over the last year, perhaps with glimpses of the year to come. Presentations will be followed by brief Q&A sessions.



Chair's Welcome and Update

Charles D. Blanke, MD, FASCO
Group Chair
SWOG Cancer Research Network



Breast Research Updates

Lajos Pusztai, MD, PhD
Chair, SWOG Breast Committee
Yale University Cancer Center



Palliative and End-of-Life Care Research Updates

Marie Bakitas, DNSc, CRNP
Co-Chair, SWOG Palliative and End-of-Life Care Committee
University of Alabama–Birmingham School of Nursing



Lymphoma Research Updates

Jonathan W. Friedberg, MD
Chair, SWOG Lymphoma Committee
University of Rochester Medical Center

Both Plenary I and Plenary II will also be live-streamed via Zoom, and questions for speakers will be fielded both in person and via Zoom's text chat feature. Attendees can earn Continuing Medical Education (CME) credits for both plenary sessions.

WED, APR 3 • 5:00 PM – 6:00 PM PT • COLUMBIA D (LEVEL 3)

SWOG Clinical Trials Partnerships (CTP)

HOW SWOG PARTNERS WITH INDUSTRY TO CONDUCT CANCER CLINICAL TRIALS

SWOG CTP Update Forum

Attend to hear about 21CTP.LEUK01, a phase II trial for patients with newly diagnosed Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia. Site selection starting soon!

YOU WILL ALSO LEARN ABOUT:

- What sites can expect:
 - Feasibility survey outreach and site selection
 - Site funding and contracts
 - CTP systems – EDC, IRB, eISF
- Three SWOG CTP trials in development

21CTP.GU01

Phase II platform trial in first-line muscle-invasive bladder cancer with multiple arms of neoadjuvant therapy defined by molecular subtype

21CTP.HN01

Phase II study in recurrent metastatic head and neck cancer with cohorts defined by type of and/or response to prior systemic therapies

21CTP.BREAST01

Phase II platform trial using circulating tumor DNA to monitor treatment response in HR+, HER2- metastatic breast cancer

- Other SWOG CTP projects in the works
- The CTP process: from a joint SWOG Committee/Industry Partner "idea" to protocol activation

All are invited!

SWOG CLINICAL TRIALS PARTNERSHIPS

AN LLC OF THE HOPE FOUNDATION FOR CANCER RESEARCH

For more information, visit swogctp.org

Email us at CTP@swog.org

TROPION-Breast03

In another model, SWOG CTP provides scientific leadership and is lead academic group for this global AstraZeneca-sponsored registration trial. Over 40 SWOG sites selected and in process of activation or are enrolling.



Nicholas J. Vogelzang, MD, GU Symposium Translational Medicine in GU Clinical Trials

Thursday, April 4 | 7:30-10:00 am PT | Columbia D

Honoring the many valuable contributions Dr. Vogelzang made in support of his colleagues and patients throughout his career within SWOG's research network.



7:30-7:50

Introduction, welcome, and current standards for SWOG Translational Medicine protocols

David McConkey, PhD
*Greenberg Bladder Cancer Institute,
Johns Hopkins University*



8:55-9:10

Industry partnerships
Artera



7:50-8:05

The role of the biostatistician in TM projects

Cathy M. Tangen, DrPH
*SWOG Cancer Research Network &
Fred Hutchinson Cancer Center*



9:10-9:25

Funding the TM research

Amir Goldkorn, MD
USC Norris Comprehensive Cancer Center



8:05-8:25 Virtual

Core Correlative Science Committee and the NCI

Elise C. Kohn, MD
*Cancer Therapy and Evaluation Program,
National Cancer Institute*



9:25-9:45

Models of success in SWOG

Philip C. Mack, PhD
Mount Sinai Health System



8:25-8:40

Nationwide- what is the "bank" and how do we collaborate

Yvonne Moyer, MBA
Nationwide Children's Hospital



9:45-10:00

Q&A, Working discussion- what's next? (15 min)

David McConkey, PhD



Joshua J. Meeks, MD, PhD
Northwestern University

8:40-8:55 Q&A (15 min)

TAKE ACTION SYMPOSIUM:

LGBTQ+, Ensuring Equity in Clinical Research

Presented by SWOG Recruitment & Retention Committee

WEDNESDAY, APRIL 3 • 2:30-4:30 PM PT • COLUMBIA A

Target Audience: Investigators, research professionals, and patient advocates, NCORP and LAPS

OBJECTIVES:

1. Identify evidence based practical strategies for sites to ensure inclusiveness in SWOG clinical trials
2. Address considerations of LGBTQ+ populations that support trust building
3. Current environment of the LGBTQ+ populations that impacts trial participation
4. Strategies for enrolling LGBTQ+ populations in clinical trials

MODERATOR AND SPEAKER/PANELIST OUTLINE

10 min

Introduction:
Take Action Series:
Speakers & Panelists



Electra Paskett, PhD
(she/her/hers)
The Ohio State University

20 min

Sexual Orientation and Gender Identity (SOGI)



Charles Kamen, PhD, MPH
(he/him/his)
University of Rochester Cancer Center

20 min

Addressing Needs in Clinical Settings



Ash Alpert, MD, MFA
(they/them/theirs)
Yale School of Medicine

15 min

LGBTQ+ Community Advocate



Joël Pointon, MPH
(he/him/his)
SWOG Community Advocate – LGBTQ+
SWOG Patient Advocate Committee Member

15 min


Sexual and Gender Minority Cancer Curricular Advances for Research and Education (SGM Cancer CARE)



Irene Tami-Maury, DMD, DrPH, MSc
(she/her/hers)
University of Texas Health Science Center at Houston

5 min

Introduction:
Trans Dudes with Lady Cancer



Yee Won Chong
(he/him/his)



Brooks Nelson
(he/him/his)

30 min Q&A: All Speakers & Panelists

5 min Wrap-Up

Allison Caban-Holt, PhD, Moderator
(she/her/hers)



CME CREDITS ARE AVAILABLE FOR THIS SYMPOSIUM.


Please also join us for a short film viewing!

A special encore to the Take Action Symposium

Trans Dudes with Lady Cancer

Friday, April 5 | 5:30 – 7:00 pm PT

Beckler / 302 ROOM CHANGE!



5:30 pm	Welcome
5:40-6:15 pm	Film viewing
6:15 pm	Discussion, Q&A with the filmmakers

About the Filmmakers

Yee Won Chong (he/him/his)



As an advocate of transgender justice, Yee Won Chong gave a TEDx talk, “Beyond the Gender Binary”, weaving his personal story about being a transgender immigrant with practical tips on how to be a good ally. Yee Won also provides transgender inclusion training to workplaces and college campuses.

He is the co-filmmaker of “[Trans Dudes with Lady Cancer](#),” a documentary highlighting his personal experience navigating the healthcare system as a transgender person of color. Yee Won and his co-filmmaker, Brooks Nelson, were recently recognized among the [25 Champions of Health Equity](#).

Brooks Nelson (he/him/his)



Brooks Nelson is an experienced filmmaker and founder of Boxxo Productions. He made “Switch: A Community in Transition”, a documentary that explores the impact of a gender transition not on the individual going through transition but on the surrounding community.

S2408 Pre-launch Meeting

S2408: A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula

THURSDAY, APRIL 4 • 2 – 3 PM PT • BECKLER ROOM (302), LEVEL 3

The S2408 pre-launch meeting will introduce participants to this recently approved phase III multicenter trial for patients undergoing distal pancreatectomy for cancer or a pre-malignant pancreatic lesion

STUDY CHAIR:



Jonathan Sham, MD, MBEE

CO-CHAIR:



Venu Pillarisetty, MD

SPONSORING COMMITTEE CHAIR:



Robert Krouse, MD

SURGERY COMMITTEE CHAIRS:



Syed Ahmad, MD



Flavio Rocha, MD

S2408 was recently approved by the NCI's Division of Cancer Prevention to evaluate whether a single dose of the somatostatin analogue *lanreotide* may prevent the "Achilles Heel" of pancreatic surgery – postoperative pancreatic fistula (POPF). POPF delays chemotherapy, increases healthcare costs, and decreases survival.

THE SESSION WILL REVIEW:



Trial background, eligibility criteria and treatment plan



Placebo plan (a SWOG-first!)



Biospecimen collection



Patient reported outcomes


Surgeons, medical oncologists, and oncology research professionals are encouraged to attend and learn more about this unique SWOG trial!


ATTEND IN-PERSON OR VIRTUALLY.


S2210 Kickoff Meeting


Join us in Seattle, or virtually, to learn about opening and enrolling to this new phase II prostate cancer trial.

FRIDAY, APRIL 5 • 8 – 9 AM, PT • BECKLER ROOM (302), LEVEL 3

 S2210 is enrolling patients with high-risk localized prostate cancer who carry an inherited BRCA1 or BRCA2 pathogenic mutation.

 Hypothesis: these patients will benefit from neoadjuvant carboplatin chemotherapy before surgery to remove their prostate cancer. Carboplatin is a DNA-damaging drug that is especially effective against other cancers with BRCA1 or BRCA2 mutations.

 An estimated 5% of high-risk patients carry an inherited BRCA1 or BRCA2 mutation, although having a strong family history of cancer (especially breast cancers at an early age, ovarian, pancreas and metastatic prostate cancers) increases the likelihood of being a carrier.

 Genetic testing for an inherited BRCA1 or BRCA2 mutation is now clinically indicated for patients with high-risk prostate cancer (NCCN guidelines). So timely workflows will help your site implement guideline-concordant genetic testing and counseling, *and* help you find candidates for S2210.

CHAIRS



Heather H. Cheng, MD, PhD



Daniel W. Lin, MD



Evan Y. Yu, MD



Tanya Dorff, MD

PATIENT ADVOCATE



Lee Moultrie

BIostatisticians



Cathy Tangen, DrPH



Sam Callis, MS

AGENDA

- Study background and rationale
- Review of protocol and trial workflow
- Patient advocate on genetic testing experience
- Review of first patient experience
- Genetic screening workflows, logistics, helpful resources

S2210: A Phase II Study of Neoadjuvant Carboplatin for Localized, High-Risk Prostate Cancer with Germline BRCA1/2 Mutations

Upcoming Funding Opportunities

- Virtual Grant Writing Workshop: **May 1**
- Early Stage Investigator Training Course: **May 1**
 - John Crowley, PhD Award: **May 31**
 - NCORP Pilot Grant Program: **June 1**
 - SEED Fund Program: **July 1**
 - Impact Award Program: **July 1**
- VA Storefront Support Program: **August 1**
- CRA/Nurse Travel Program: **August 15**

SEE ALL HOPE FOUNDATION PROGRAMS AT
THEHOPEFOUNDATION.ORG/FUNDING-OPPORTUNITIES

THE **HOPE**
FOUNDATION
FOR CANCER RESEARCH

THE ROBERT B. LIVINGSTON LECTURE

Building a Better Biomarker: Lessons Learned from TAILORx and RxPONDER

Presented virtually with the breast committee session

Saturday, April 6 | 9:20 am PT | Columbia D

Featuring Joseph A. Sparano, MD

Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute



Joseph A.
Sparano, MD

Dr. Robert Boyd Livingston was a superb clinician and clinical trialist who greatly impacted the field of cancer research through a sweeping career at multiple institutions. Nationally, many of his discoveries in oncology were made through collaborative, multi-institutional efforts within SWOG Cancer Research Network, where he served as chair of the lung cancer committee (1974-1997) and the breast cancer committee (2000-2008).

In his honor and with the support of his wife Shirley, SWOG established the Dr. Robert B. Livingston Translational Breast and Lung Cancer Lectureship. The Hope Foundation for Cancer Research raises funds to support this lectureship in perpetuity and brings a special guest speaker to SWOG group meetings, alternating between a focus on lung and breast cancer advances in translational medicine.

THE FRANK AND LINDA MEYSKENS ANNUAL ENDOWED LECTURESHIP ON ADVANCES IN CANCER PREVENTION

Vitamins and chemoprevention, the early days, when enthusiasm ruled

Presented with the prevention committee session

Thursday, April 4 | 12:35 pm PT | Elwha AB

Featuring Gary Goodman, MD



Gary
Goodman, MD

Since the early 1980's, Dr. Meyskens has been a leader in the recognition, development, and clinical usage of Prevention in the management of cancer. Frank and Linda have directed the development of this lectureship to advance the explosion of knowledge that is expanding opportunities to engage Prevention in personalized medicine, including early detection and genetically focused treatment options.

SWOG Group Meeting App

The new SWOG group meeting mobile app is your pocket guide to the meeting.

With key features in an easily accessible format, the app not only replaces the agenda book as your on-site companion, it contains the agenda book – as a PDF you can flip through on your phone.

WITH THE APP, YOU CAN

1 create your schedule, annotate sessions, and add them to your calendar

3 claim continuing medical education (CME) credits for sessions you attend

2 access a directory of presenters and session leaders, along with other attendees who have opted in

The app also offers a single go-to source for speakers and presenters:

4 access most of the key resources you've found in the agenda book

- find travel and lodging information and links
- submit conflict-of-interest disclosure forms
- upload slides and handouts for your talk

5 access the full agenda book itself as a PDF



DON'T HAVE THE APP YET?

Download the app with the appropriate QR code or URL at left

DON'T WANT TO INSTALL YET ANOTHER APP?

Access the web browser version with the QR code or URL at right.



Procedures for CME Credit

Group Meeting Target Audience and Educational Objectives

SWOG meets semi-annually to keep its members abreast of group science. The target audience for these meetings are physicians, nurse oncologists, and clinical research associates.

The educational objectives of these meetings are: to educate attendees about active and proposed studies so that they may implement the studies at their local institutions; to educate attendees about new treatments and prevention strategies that are available; to identify areas that can be improved in cancer research and study implementation and educate attendees on the best ways to implement the solutions at the local level.

These objectives apply to the following sessions: Adolescent and Young Adult Committee; Cancer Control and Prevention, including Cancer Care Delivery Committee, Symptom Control & Quality of Life Committee, Prevention & Epidemiology Committee, Palliative & End of Life Care Committee, and Cancer Survivorship Committee; Genitourinary Committee; Early Therapeutics & Rare Cancers Committee; Myeloma Committee; Melanoma Committee; Surgery Committee; Radiation Oncology Committee; Plenary Sessions; Leukemia Committee; Breast Committee; Gastrointestinal Committee; Lung Committee; Lymphoma Committee; Immunotherapeutics Committee; Digital Engagement Committee; Bone Marrow & Stem Cell Transplantation Committee; Recruitment and Retention Committee; and Advanced Practice Providers.

Continuing Medical Education Credit

The Hope Foundation is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. In addition, nurses, CRAs, and other researchers may be able to claim credits through their respective credentialing bodies.

The Hope Foundation designates this live activity for a maximum of 28.75 AMA PRA Category 1 Credits™. Learners should only claim credit commensurate with the extent of their participation in the activity.

Speaker and Planner CME Disclosure Information

Each speaker and planner for The Hope Foundation CME courses has been requested to complete a Faculty Disclosure Form prior to the activity in accordance with ACCME standards. THF strives to provide accurate and up-to-date information regarding affiliations or interests that might be perceived as a potential conflict of interest for those who control CME content. Best attempts will also be made to provide up to date information on introductory slides at each CME session.

Our CME credit system has moved to the Conference Exchange (Confex) meeting app!

To claim credit, you must create a **Confex user account**. You may use the account to navigate the meeting through the mobile app — or alternatively, via the browser-based version online.

To download the meeting app, find it in the Apple Store or via Google Play:



To navigate the meeting and claim CME credit online, go here: swog.org/meetingappS24

1
Use the **Meeting Calendar** or **Search** options to navigate to the session you attended and click on the session title.

2
Claim CME Credit
Click on the **Claim CME** button and complete the form for the session. Repeat this process for each session that you attended.

3
⚠️ If a **Claim CME** button does not appear on the page, the session was not approved to offer CME credit.

4
At the conclusion of the group meeting, you will need to complete the **CME Meeting Evaluation**, which is linked from the **Claim CME Credit** page.

5
Once you have submitted the CME Meeting Evaluation, click the **Review Credit Hours and Certificates** link on the **Claim CME Credit** page to view and print your certificate(s).

Update Personal Information

Credits Evaluation List for Courtney Wille

Overall Certificates

Sent **Attendee Certificate - PDF**

Sent **Credit Transcript - PDF**

Wednesday, April 3, 2024

Digital Engagemant Committee [CME] (Hybrid)

Max Credit Allowed: 2.00
April 03, 2024 12:30 PM - 2:30 PM
Elwha Ballroom B (Hyatt Regency Seattle)

Credit Claimed: 2.00

Instructions

Send Certificate(s)

⚠️ The deadline for claiming credit hours is June 6th at 11:59 pm CT

Adolescent and Young Adult Committee

Friday, April 5, 2024 | 9:00 AM – 11:00 AM PT

Room: Chiliwack / 402

Agenda

- A. **Welcome** *Becky Johnson, MD*
- B. **Where are AYAs Treated?** *Melissa Beauchemin, PhD (virtual)*
- C. **Guest Speaker: Substance Use in AYA Oncology** *Karen Effinger, MD*
- D. **Guest speaker: What Should the SWOG AYA Committee Prioritize?**
Archie Bleyer, MD
- E. **Trial Updates:**
 - **S1823** *A Prospective Observational Cohort Study to Assess miRNA371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors*
Craig Nichols, MD
 - **CTSU/ANHL1931** *A Randomized Phase 3 trial of Nivolumab (NSC# 748726 IND# 125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma*
Manali Kamdar, MD
 - **S1826** *A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma*
Alex Herrera, MD
 - **NCORP Pilot Grant “TALK TO ME: Tailored AYA Trial Messaging”**
Allison Rosen, MS
- F. **Q&A and discussion** *Becky Johnson, MD*

Digital Engagement Committee

Wednesday, April 3, 2024 | 12:30 pm – 2:30 pm

Elwha B (Level 5)

Welcome and Introductions *Mark Lewis, MD*

AI and Oncology *Arturo Loaiza-Bonilla, MD, MEd*
Massive Bio

Committee Business *Mark Lewis, MD*

- *Wearables Discussion*
- *Survey Vetting*

SWOG Latin America Initiative Symposium

Thursday, April 4, 2024 | 11:00 AM – 1:00 PM PT

Beckler / 302

Agenda

Introductory Remarks, *Dr. Mariana Chávez MacGregor*

Part 1: Health resource utilization, costs and financial toxicity

Cancer care delivery research in Latin America and prospects for collaboration, *Dr. Federico Augustovski*

Health resource utilization, equity, and financial toxicity in the US, *Dr. Veena Shankaran*

Plan Esperanza, National Cancer Control Plan in Peru, *Dr. Tatiana Vidaurre*

Part 2: Committee Focus and Collaboration

Cancer Care Delivery (CCD) Committee, *Dr. Scott Ramsey*

Open Discussion: Finding common ground for US-LatAm CCD Collaborations

Part 3: SLAI Institutions

Focus on SLAI in Uruguay: An international site perspective, *Dr. Mauricio Cuello/Dr. Iván Lyra*

SLAI Institution Updates

Closing Remarks, *Dr. Mariana Chávez MacGregor*

Pharmaceutical Sciences Committee and Drug Information Subcommittee Joint Meeting (Hybrid)

Friday April 5, 2024 | 10:00 am -12:00 pm

Room: Kachess / 405 (Level 4)

Agenda

Committee Reports:

- 1. Committee Administrative reports – *Siu Fun Wong/Joyce Lee***
 - *Introduction of new members*
 - *Review of PSC Member Roster*
 - *Summary report of committee activities*
 - *NCI CTEP Policy Advanced Practice Providers (APP) Task Force*
 - *Pharmaceutical-related events and inquiries*
 - *SWOG Strategic Plans and next grant submission*
- 2. Drug Information Sub-Committee Report – *Vy Bui***
 - *Updates from the Chair – *Vy Bui**
 - *Summary of drug section requests and acknowledgment of writers and reviewers*
 - *Introduction of resident and fellow writers for 2024-2025 academic year*
 - *Expansion of resident writer program*
 - *Protocol Review activities – *Holly Chan/Jorge Avila**
 - *Aurora roll-out updates – *Matt Boron**
- 3. CPOE Focus Group – *Siu Fun Wong/Joyce Lee***

*Members: *Holly Chan, Safae Chouraichi, Dawud Ellayan, Joyce Lee, Jane Rogers, Christa Braun-Inglis, Maggie Ryan**

 - *Updates of project*
 - *Review of template*
- 4. Pharmacist Liaison Reports – *All***
 - *Review of Pharmacist Liaison Assignment List*
 - *Disease Committee Liaison Pharmacist Reports – *Open**
- 5. Open agenda – *All***

VA Committee

Friday, April 5, 2024 | 3:00 PM – 5:00 PM PT

Room: Beckler / 302

A. Introductions and Opening Comments

- *Stephen Bartlett, RPh, MSPH*

B. Studies for VA Consideration from the VA Oncology Consortium

FORTE (NRG-NC005) – Five to Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

- *Dr. Lisa A. Kachnic, SWOG Study Champion, Columbia Univ Irving Med Ctr*

C. Treatment Perspectives

The Effectiveness of MRD in the Treatment of Myeloma

- *Dr. Thomas R. Chauncey, MAVERIC/VA Puget Sound Health Care System*

- *Dr. J. Christine Ye, MD Anderson Cancer Center*

D. Studies for VA Consideration from SWOG

1. **S2302, “Lung: A Prospective Randomized Study of Ramucirumab (LY3009806; NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer)”**

- **Study Updates:**

- *Dr. Cheryl M. Czerlanis, Loyola Univ, Hines VA Medical Center*

VA Liaison on Lung Committee

2. **S2414, “INcorporating pathologic reSponse in patlents with early staGe lung cancer to optimize immunoTherapy in the adjuvanT setting (INSIGHT)”**

- *Dr. Chao Hui Huang, VAMC Kansas City*

VA Liaison on Lung Committee

3. **S1937, “A Phase III Randomized Trial of Eribulin (NSC #707389) with Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.”**

- *Dr. Sarmad Sadeghi, University of Southern California*

VA Committee, continued

E. VA Disease Committee Liaisons Updates and Needs

1. New Disease VA Committee Members:

<i>Cancer Survivorship</i>	<i>Neha Patel, MD – VAMC Long Beach</i>
<i>Gastrointestinal</i>	<i>Rangaswamy Govindarajan, MD – Central Arkansas VA</i>
<i>Symptom Control & Quality of Life</i>	<i>Jacqueline Gesek, BSN, RN – White River Junction VA</i>

2. Open Committee Needs:

<i>Cancer Care Delivery</i>	<i>Melanoma</i>
<i>Early Therapeutics</i>	<i>Palliative & End of Life</i>
<i>Immunotherapeutics</i>	<i>Prevention & Epidemiology</i>

How to Apply – vamember@swog.org

F. VA Program Development Team

Mission goals in place; definable action items and strategies well under way. Several accomplishments thus far, to include:

- Defined VA Liaison responsibilities and expectations*
- VA Liaison meet/greet April Group Meeting*

G. Current VA Stats

Accrual/sites – SWOG Report

H. Other

- 1. NRG collaboration*
- 2. VA GUPOP (GU Precision Oncology Program)*
- 3. FoundationOne®CDx + FoundationOne RNA testing for LungMAP*

I. Future Meetings

- 1. AVAHO Annual Meeting, Atlanta, September 20-22, 2024*
- 2. SWOG Fall Group Meeting, Chicago, October 16-19, 2024*

Committees

Administrative Committees

Board of Governors

Charles D. Blanke, MD

Publications

Hagen F. Kennecke, MD

Conflict Management

Paul Okunieff, MD

Professional Review

Paul Hesketh, MD

Research Support Committees

Adolescent and Young Adult

Rebecca Johnson, MD

Patient Advocates

Anne Marie Mercurio

Barbara Segarra-Vazquez, DHS

Bone Marrow and Stem Cell Transplantation

Patrick J. Stiff, MD

Pharmaceutical Sciences

Siu-Fun Wong, PharmD

Digital Engagement

Mark Lewis, MD

Radiation Oncology

Chul Ha, MD

Imaging

Lawrence H. Schwartz, MD

Recruitment and Retention

Allison Caban-Holt, PhD

Oncology Research Professionals

Connie Szczepanek, RN, BSN, CCRP

Surgery

Syed A. Ahmad, MD

Veterans Affairs

Stephen D. Bartlett, RPh

Future Meeting Dates

2024	2025	2026
FALL	SPRING	SPRING
October 16-19 Chicago, IL	April 30-May 3 San Francisco, CA	April 29-May 2 San Francisco, CA
	FALL	FALL
	September 17-20 Chicago, IL	October 7-10 Chicago, IL

Barlogie-Salmon Myeloma Committee

Leadership

Chair:Robert Z. Orlowski, MD, PhD
 Vice-Chair:Sikander Ailawadhi, MD
 Vice-Chair:.....Jing Christine Ye, MD, MSc
 Executive Officer.....Susan M. O'Brien, MD
 Statisticians:Antje Hoering, PhD
Rachael Sexton, MS
Adam Rosenthal, MS

Scientific Leadership

Translational Medicine: Brian A. Walker, BSc, PhD
 Radiation:.....Chelsea Camille Pinnix, MD, PhD
 Surgery: TBD
 Imaging:.....Eric M. Rohren, MD, PhD
 Pathology:.....Pei Lin, MD
 Early Therapeutics:.....Frits van Rhee, MD, PhD

Designates

DEI Champion:.....Manuel Ricardo Espinoza-Gutarra, MD
 Digital Engagement:.....TBD
 NCORP Representative:.....Charles S. Kuzma, MD
 Veterans Affairs:.....Thomas R. Chauncey, MD, PhD
 Data Coordinators:.....Aubrey Gilmore, BA
Daria Chugina, MD, CCRPS
Pasarlai Ahmadzai, MD, MPH
 Oncology Research Professionals:
 CRA: Brandon Richard Labadie, CCRP
 Nurse:.....Teresa Witcher, BSN, RN
 Patient Advocate:.....Paul Gater, MPhil
Jack Aiello, MS (Emeritus)
 Pharmaceutical Science: Craig Elg, PharmD
Ila M. Saunders, PharmD
 Sr. Protocol Project Manager:Sharon Palmer
 Clinical Trials Program Manager:Laura Gildner, MS

Time/Location

Saturday, April 6, 2024 9:30 a.m. - 11:30 a.m.
 Room: Elwha B (Level 5)

Active Studies

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. A. Krishnan and P. Hari. Activated: 6/27/19.

S2005, "A Phase II Randomized Study Comparing Ibrutinib and Rituximab vs. Venetoclax and Rituximab in Previously Untreated Waldenström's Macroglobulinemia (WM) /Lymphoplasmacytic Lymphoma (LPL)." Drs. S. Ailawadhi and D. Bhutani. Activated: 6/24/21.

S2209, "A Phase III Randomized Trial for Newly Diagnosed Multiple Myeloma (NDMM) Patients Considered Frail or Ineligible for Stem Cell Transplant Comparing Upfront Bortezomib-Lenalidomide-Dexamethasone-Lite (VRd-Lite) with Daratumumab-Lenalidomide-Dexamethasone (DRd)." Drs. S. Ailawadhi, J.C. Ye, B. Lipe, T. Chauncey, and K. Gowin. Activated 05/30/23.

S2213, "Daratumumab, Cyclophosphamide, Bortezomib, and Dexamethasone (D-VCD) Induction Followed by Autologous Stem Cell Transplant or D-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis." Drs. P. Hagen, T. Parker, and S. Sidana. Activated 12/01/2023.

EEA173, "Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma." Activated: 4/30/19.

EEA181, "Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial." Activated: 10/27/20.

Developing Studies-Post Triage

S2416, "Phase III Study of Optimal Induction and MRD Driven Maintenance Therapy for Newly Diagnosed High-Risk Multiple Myeloma (HRMM)." Drs. B. Lipe, J.C. Ye, and K. Gowin.

Closed Studies-Updates

S1702, "A Phase II Study of Isatuximab (SAR650984) (NSC-795145) for Patients with Previously Treated AL Amyloidosis." Drs. T. Parker and V. Sanchorawala. Activated: 3/08/18; Closed: 9/30/19.

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1803	S2209	EAA173	EAA181
<i>Ascension Providence Hospitals - Southfield</i>	2	-	1	-
<i>Banner University Medical Center - Tucson</i>	8	-	-	5
<i>Boston Medical Center</i>	5	-	-	-
<i>CWRU Case Comprehensive Cancer Center LAPS</i>	24	-	3	-
<i>Cancer Research for the Ozarks NCORP</i>	2	-	-	-
<i>Cancer Research of Wisconsin and Northern Michigan Consortium</i>	4	-	-	-
<i>Cedars-Sinai Medical Center</i>	6	-	-	-
<i>City of Hope Comprehensive Cancer Center</i>	97	-	-	-
<i>Columbus NCI Community Oncology Research Program</i>	8	-	-	-
<i>CommonSpirit Health Research Institute</i>	3	2	-	-
<i>Dayton NCI Community Oncology Research Program</i>	5	-	-	-
<i>Duke University - Duke Cancer Institute LAPS</i>	3	-	-	-
<i>Fred Hutchinson Cancer Research Center LAPS</i>	-	-	6	-
<i>Froedtert and the Medical College of Wisconsin LAPS</i>	7	-	-	-
<i>Georgia NCI Community Oncology Research Program</i>	13	-	-	-
<i>Gulf South Minority Underserved NCORP</i>	4	-	-	-
<i>Heartland Cancer Research NCORP</i>	14	1	-	-
<i>Houston Methodist Hospital</i>	4	-	-	-
<i>Kaiser Permanente NCI Community Oncology Research Program</i>	41	-	-	-
<i>Lahey Hospital and Medical Center</i>	3	-	-	-
<i>Loyola University Medical Center</i>	22	-	3	-
<i>Massachusetts Veterans Epidemiology Research and Information Center</i>	-	-	-	2
<i>Medical University of South Carolina Minority Underserved NCORP</i>	43	-	1	1
<i>Mercy Medical Center - Des Moines</i>	1	-	-	-
<i>Michigan Cancer Research Consortium NCORP</i>	7	-	-	-
<i>Moffitt Cancer Center</i>	41	-	-	-
<i>Montana Cancer Consortium NCORP</i>	4	-	-	-
<i>Nevada Cancer Research Foundation NCORP</i>	-	-	1	-

Barlogie-Salmon Myeloma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1803	S2209	EAA173	EAA181
New Mexico Minority Underserved NCORP	11	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	4	-	-	-
Oregon Health and Science University	26	-	3	9
Pacific Cancer Research Consortium NCORP	16	1	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	-	-	-
UC Davis Comprehensive Cancer Center LAPS	21	2	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	10	-	-	-
University of Arkansas for Medical Sciences	-	-	-	2
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2
University of Kansas Cancer Center - MCA Rural MU NCORP	30	-	-	-
University of Kentucky/Markey Cancer Center	3	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	14	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-
University of Rochester LAPS	15	-	-	1
University of Texas Health Science Center at San Antonio	14	-	-	-
University of Texas MD Anderson Cancer Center LAPS	24	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	16	-	4	1
Upstate Carolina Consortium Community Oncology Research Program	4	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	13	-	-	-
Wisconsin NCI Community Oncology Research Program	19	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	4	7
ALLIANCE	184	1	-	-
CCTG	6	-	-	-
ECOG-ACRIN	156	1	-	-
NRG	87	-	-	-
Total	1,049	8	26	30

Breast Committee

Leadership

Chair: Lajos Pusztai, MD, PhD
 Vice-Chair: Priyanka Sharma, MD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Allison Meisner, PhD
 Danika Lew, MA
 Jieling Miao, MS

Scientific Leadership

Translational Medicine: Alastair M. Thompson, MD
 Andrew K. Godwin, PhD
 Radiation Oncology: Reshma Jagsi, MD
 Surgery: Joshua M.V. Mammen, MD, PhD
 Imaging: Joanne E. Mortimer, MD
 Wei Tse Yang, MBBS
 Pathology: David L. Rimm, MD, PhD
 Early Therapeutics: Stephanie L. Graff, MD

Designates

Cancer Control Liaisons: Mariya Rozenblit, MD (Cancer Survivorship)
 Dawn L. Hershman, MD (Cancer Care Delivery)
 Banu Arun, MD (Prevention)
 Helen K. Chew, MD (Symptom Control & QOL)
 DEI Champion: Gayathri Nagaraj, MD
 Digital Engagement: Sarah S. Mougalian, MD
 NCORP Representative: Philip E. Lammers, MD
 Veterans Affairs: Sarah V. Colonna, MD
 Data Coordinators: Aubrey Gilmore, BA
 Gabi Herbert, MS, BS
 Kevin Moralda, BS
 Larry G. Kaye
 Oncology Research Professionals:
 CRAs: Karyn N. Hart, CCRP
 Avidanka Baftirovska, BS, CCRP
 Nurse: Cameo Windham, BSN, RN
 Patient Advocates: Roberta A. Albany
 Ginny Mason, RN, BSN
 Pharmaceutical Science: Jorge G. Avila, PharmD
 Dawud Nael Dawud Ellayan, Pharm D
 Protocol Project Manager: Alicia Aranda
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Saturday, April 6, 2024 9:15 a.m. - 12:15 p.m.
 Room: Columbia D (Level 3)

Agenda

9:15 - 9:20 am Welcome and Introductions - Lajos Pusztai, MD, DPhil (Chair) and Priyanka Sharma, MD (Vice-chair)

9:20 - 9:50 am Robert Livingston lecture: "Building a Better Biomarker: Lessons Learned from TAILORx and RxPONDER"
 Dr. Joseph Sparano MD, FACP, Chief, Division of Hematology/Oncology, Icahn School of Medicine at Mt. Sinai, Deputy Director, Tisch Cancer Institute

9:50 - 10:00 am Q&A

10:00 - 10:10 am Publication update – Allison Meisner, PhD

10:10 - 10:25 am Patient Advocate update – Ginny Mason and Roberta Albany

10:25 - 10:35 am Translational Medicine Subcommittee update - Alastair Thompson, MD and Andrew K. Godwin, PhD

10:35- 11:30 am Review of open CTSU trials

11:30 - 11:50 am Recently approved and developing concepts.

11:50 - 12:10 pm Reports from Committee Liaisons

Radiotherapy: Reshma Jagsi, MD
 Surgery: Joshua Mammen, MD
 Survivorship: Melinda L. Irwin, PhD, MPH
 Cancer Care Delivery: Dawn Hershman, MD
 Prevention: Banu Arun, MD
 Symptom Control & QOL: Helen K. Chew, MD
 NCORP: Philip Lammers, MD
 DEI: Gayathri Nagaraj, MD

12:15 pm Closing Comments and Adjourn

Developing Breast Cancer Committee Studies

S2428, "Randomized Phase III trials of multimodality therapy versus palliative therapy in triple negative (TNBC) and HER2 positive (HER2+) de novo (AJCC stage IV) oligometastatic breast cancer." Drs. Rozenblit, Stecklein, and Lin.

Active Breast Cancer Committee Studies

S2206, "Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer." Drs. Cobain and Pusztai. Activated: 10/30/23.

Breast Committee

S2212, "Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study." Drs. Sharma and Mitri. Activated: 07/21/23.

S2007, "A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases." Drs. Brenner and Kaklamani. Activated: 12/15/20.

S1706, "A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer." Drs. Jagsi and Chalasani. Activated: 09/12/18.

CTSU/A011801, "The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib." Dr. O'Sullivan. SWOG Champion: Dr. Murthy. Activated: 01/06/21.

CTSU/CCTG MA.39, "Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive and T3N0 Breast Cancer." Dr. Whelan. SWOG Champion: Dr. Jagsi. Activated: 05/30/18.

CTSU/NRG-BR007, "A Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)." Dr. White. SWOG Champion: Dr. Shumway. Activated: 06/07/21.

Closed Breast Cancer Committee Studies

S1418, "A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN1mi, ypN1-3) after Neoadjuvant Chemotherapy." Drs. Puztai and Mammen. Activated: 11/15/16; Permanently closed: 06/30/21.

S1207, "Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer. e³ Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy." Drs. Chavez-MacGregor and Puztai. Activated: 09/04/13; Permanently closed: 05/01/19.

CTSU/A011202, "A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3

N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy." Dr. Boughey. SWOG Champion: Dr. Mammen. Activated: 02/07/14; Permanently closed: 07/01/22.

CTSU/EA1181, "(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSESSment to Optimize Therapy in HER2-Positive Breast Cancer)" Dr. Tung. SWOG Champions: Breast Committee: Dr. Tang, Imaging Committee: Dr. Lu. Activated: 02/11/20; Permanently closed: 10/19/23.

CTSU/EA1183, "FDG PET to Assess Therapeutic Response in Patients with Bone-Dominant Metastatic Breast Cancer, FEATURE." Dr. Specht. SWOG Champions: Breast Committee: Dr. Linden, Imaging Committee: Dr. Wright. Activated: 04/02/20; Permanently closed: 12/22/23.

CTSU/NRG-BR002, "A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer." Drs. Chmura and White. SWOG Champion: Dr. Jagsi. Activated: 12/24/14; Permanently closed: 05/27/22.

CTSU/NRG-BR003, "A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer." Dr. Valero. SWOG Champion: Dr. Makhoul. Activated: 06/26/15; Permanently closed: 04/22/22.

CTSU/NRG-BR004, "A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer." Dr. Geyer. SWOG Champion: Dr. Cobain. Activated: 03/12/19; Permanently closed: 07/01/22.

CTSU/NRG-BR005, "A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without Surgery." Dr. Basik. SWOG Champion: Dr. Thompson. Activated: 04/13/17; Permanently closed: 12/02/22.

Active Cancer Survivorship Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. Floyd and Leja. Activated: 09/15/17; Temporary closure: 02/01/24.

Breast Committee

Closed Symptom Control and Quality of Life Studies

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang and Lok. Activated: 02/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi and Hershman. Activated 03/01/19; Permanently closed: 11/15/21.

Active Cancer Care Delivery Studies

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer." Drs. Accordino and Hershman. Activated: 07/16/18.

CTSU/EA1151, "Tomosynthesis Mammographic Imaging Screening Trial (TMIST)." Dr. Pisano. SWOG Champion: Dr. Arun. Activated: 07/06/17.

Active Cancer Prevention Study

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, and Kukafka. Activated: 09/01/20.

Closed Early Therapeutics and Rare Cancers Studies

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors." Drs. Patel and Chae. Activated 01/13/17; Permanently closed: 03/15/23.

CTSU/EAY131, "Molecular Analysis for Therapy Choice (MATCH)". Dr. Flaherty. Activated 08/12/15; Permanently closed: 12/30/22.

Breast Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2212	A011202	A011801	A012103	EA1181	EA1183	MA39	NRGBR005	NRGBR007
Ascension Providence Hospitals - Southfield	2	-	-	4	2	2	5	-	1	-	-
Banner MD Anderson Cancer Center	-	-	-	-	7	-	-	-	-	-	-
Banner University Medical Center - Tucson	1	-	-	1	-	-	10	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	3	-	-	1	-	-	1	-	-	-	-
Baylor University Medical Center	-	-	-	1	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	-	5	-	15	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	-	-	-	-	4	-	1	-	-
Cancer Research Consortium of West Michigan NCORP	1	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	2	-	-	-	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	2	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	4	-	-	-	-	-	3	-	-	-	-
CommonSpirit Health Research Institute	1	-	3	-	-	-	-	-	1	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	-	-	-	1	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	1	-	-	-	-	6	2	-	-	-
Desert Regional Medical Center	-	-	-	7	-	-	2	-	1	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	1	-	-	-	2	-	-	-	-
Heartland Cancer Research NCORP	4	-	4	-	1	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	1	-	-	-	2	1	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	1	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	6	-	-	-	-
Loma Linda University Medical Center	-	-	-	3	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	1	-	-	-	-
Medical Univ of South Carolina Minority Underserved NCORP	1	-	-	-	-	-	-	3	-	-	-
Michigan Cancer Research Consortium NCORP	2	-	4	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	-	-	1	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	3	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1	-	-	-	-
New Mexico Minority Underserved NCORP	5	1	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	-	-	-	-	-	-	2
Northwestern University LAPS	1	2	1	-	1	-	4	1	-	-	-

Breast Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1706	S2007	S2212	A011202	A011801	A012103	E01181	E01183	MA39	NRGBR005	NRGBR007
Ohio State University Comprehensive Cancer Center LAPS	3	-	-	-	-	-	1	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	3	-	-	1
Pacific Cancer Research Consortium NCORP	2	-	-	-	-	-	-	-	2	-	-
Salem Hospital	-	-	-	4	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	1	1	-	1	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	1	-	2	-	5	-	-	-	-
The Don and Sybil Harrington Cancer Center	3	-	-	11	3	-	-	-	-	-	-
The James Graham Brown Cancer Cntr at University of Louisville	-	-	-	2	-	-	-	-	-	-	-
The West Clinic - Wolf River	-	-	-	9	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	-	-	2	-	-	4	-	-	-	1
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	1	-	3	2	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	4	1	-	-	-	2	-	-
U of Alabama at Birmingham/Deep South Rsrch Consortium LAPS	-	2	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	2	-	-	-	2	2	-	-	-	-	-
University of Colorado Cancer Center LAPS	1	-	-	42	1	-	11	-	1	2	1
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	2	4	-	-	-	-	1	1	-
University of Michigan Comprehensive Cancer Center LAPS	3	-	-	-	1	-	1	-	9	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	1	-	-	-	-
University of Rochester LAPS	1	-	-	-	-	-	1	-	-	-	1
University of Texas Health Science Center at San Antonio	-	1	-	6	-	-	-	-	-	-	2
University of Texas MD Anderson Cancer Center LAPS	1	1	-	-	-	-	-	-	-	3	-
University of Utah - Huntsman Cancer Institute LAPS	4	-	-	-	1	-	7	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	1	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	11	2	-	14	4	1	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	2	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	6	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	5	3	-	13	-	-	-	-
ALLIANCE	17	7	2	-	-	-	-	-	-	-	-
CCTG	6	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	8	2	1	-	-	-	-	-	-	-	-
NRG	43	-	5	-	-	-	-	-	-	-	-
Total	143	23	25	129	39	4	120	13	22	7	8

Cancer Control & Prevention Committees

Leadership

Vice-Chair NCORP: Dawn L. Hershman, MD, MS
 Cancer Care Delivery Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Cancer Survivorship Co-Chairs: Halle C.F. Moore, MD
 Melinda L. Irwin, PhD, MPH
 Palliative & End of Life Co-Chairs: Robert S. Krouse, MD, FACS
 Marie Bakitas, DNSc, CRNP
 Prevention and Epidemiology Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD
 Symptom Control & QOL Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD
 Executive Officers: Katherine D. Crew, MD (CCD, Prevention,
 Symptom Control)
 Virginia Sun, PhD, MSN, RN (Palliative, Survivorship)
 Senior Advisor: Frank L. Meyskens, Jr., MD
 Statisticians: Katherine Guthrie, PhD
 Cathy Tangen, DrPH
 Joseph M. Unger, PhD
 Kathryn B. Arnold, MS
 Amy K. Darke, MS
 Danika Lew, MA
 Sarah Colby, MS
 Administrative Lead SDMC: Monica Yee, CCRP

Scientific Leadership

NCORP Representative: Scott Edward Delacrois, Jr., MD
 Helen Heng-Shan Moon, MD
 Radiation Oncology: Eileen P. Connolly, MD, PhD (CCD, Prevention)
 Kiri A. Cook, MD (Survivorship, Symptom Control)
 Erin F. Gillespie, MD (Symptom Control)
 Surgery Committee: Robert S. Krouse, MD, FACS
 Translational Medicine: James Rae, PhD
 Liaisons:
 Barlogie-Salmon Myeloma Committee: Charles S. Kuzma, MD
 Breast Committee: Mariya Rozenblit, MD (Survivorship)
 Helen K. Chew, MD (Symptom Control)
 Dawn Hershman, MD, MS (CCD)
 Banu Arun, MD (Prevention)
 Philip Lammers, MD
 Early Therapeutics & Rare Cancers: Lara E. Davis, MD (Survivorship)
 Jason M. Prosek, MD
 Gastrointestinal Committee: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Genitourinary Committee: Clara Hwang, MD
 Sarah P. Psutka, MD

International Liaison: Kathy S. Albain, MD
 Leukemia Committee: Stephanie B. Tsai, MD
 Lung Committee: Gary E. Goodman, MD
 Lymphoma Committee: Hayder Saeed, MD
 Melanoma Committee: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Recruitment & Retention: Allison M. Caban-Holt, PhD
 Digital Engagement: Jennifer R. Klemp, PhD (Survivorship)
 Krishna Soujanya Gunturu, MD (Survivorship)
 Mina S. Sedrak, MD (CCD)
 Katherine D. Crew, MD (Prevention)
 Michael J. Fisch, MD (Symptom Control)
 Veterans Affairs: Yeun-Hee Anna Park, MD (Symptom Control)
 Neha Patel, MD (Survivorship)
 Jacqueline Ann Gesek, BSN, RN (Nursing)

Designates

Oncology Research Professionals:

CRA: Amanda R. Dinsdale, MHA, CCRC
 Amy Jo Koffarnus, BS, CCRP
 Samantha Wright, MS, CCRP
 Shirley S. Sui, BS
 Nurses: Connie Szczepanek, RN, BSN
 Melyssa W. Foust, MSN, RN
 Pharmaceutical Sciences Committee: Kimberly McConnell, PharmD
 Siu-Fun Wong, PharmD
 Sun "Coco" Yang, PharmD, PhD
 SDMC Data Coordinators: Kimberly Carvalho, BA
 Sam Dzingle, BA
 Matthew Eng, PharmD
 Diane Liggett, BS, CCRP
 Roxanne Topacio, CCRP
 Monica Yee, BA, CCRP
 Recruitment & Retention Specialist: Jamie Sundstrom, BS
 Patient Advocates: Barbara Segarra-Vazquez, DHSc (CCD)
 Amy Geschwender, PhD (Symptom Control)
 Hartley "Lee" M. Jones, MBA (Survivorship)
 Cheryl L. Jernigan, CPA (Prevention)
 Valerie Fraser (Palliative)
 Sr. Protocol Project Manager (CCD and Prevention): Patricia O'Kane
 Protocol Project Manager (Survivorship): Megan Keim
 Protocol Project Manager (Symptom Control): Justine Trevino
 Protocol Project Manager (Palliative Care): Andrea Garcia
 Clinical Trials Program Manager (Palliative Care): Laura Gildner, MS
 Clinical Trials Program Manager (CCD; Prevention;
 Survivorship; Symptom Control): Mariah Norman, MS

Cancer Care Delivery (CCD) Committee

Leadership

Co-Chairs: Dawn L. Hershman, MD, MS
 Scott D. Ramsey, MD, PhD
 Veena Shankaran, MD, MS

Time/Location

Thursday, April 4, 2024 8:00 a.m. - 10:00 a.m.
 Room: Elwha AB (Level 5)

Agenda

Presentations:

Digital Strategies to Promote Physical Activity During Cancer Treatment:

A Pragmatic Hybrid Implementation-effectiveness Trial, Erin Gillespie, MD, University of Washington, Fred Hutchinson Cancer Center

A Prospective, Longitudinal Study of Employment and Related

Outcomes in Newly Diagnosed Patients with Metastatic Breast Cancer, Claire Sathe, MD, Columbia University Irving Medical Center

The University of New Mexico CREDIT Trial Experience, Bernard Tawfik,

MD, University of New Mexico Comprehensive Cancer Center

Committee Strategic Planning: Drs. Scott Ramsey, Dawn Hershman, Veena Shankaran

Active Studies

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. V. Shankaran. Activated 7/26/21.

S2108CD, "Randomized Comparison of an Educationally Enhanced Genomic Tumor Board (eGTB) Intervention to Usual Practice of Incorporating Genomic Test Results into Clinical Care." Drs. J. Rueter, M. Trivedi, B Symington, P. Tseng, D. Hershman, S. Ramsey. Activated 8/22/22.

Active studies with CCD/CCP Components

S1703, "Randomized Non-inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patients with Metastatic Hormone Receptor Positive HER-2 Breast Cancer," Dr. M. Accordini. Activated 7/16/18.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In

Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Dr. K. Crew. Activated: 9/1/20. (Committee: Prevention/Epidemiology)

Developing Studies/Miscellaneous Updates

S2309CD, Preventing Financial Adversity Among Early-stage Cancer Patients through Unrestricted Cash (PAYMENT) – Dr. V. Shankaran.
 • Resubmitted U34 in October 2023

S2417CD, A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance – Dr. C. Veenstra.
 • Submitted R01 in October 2023

S2424CD, Lay Health Worker-led Intervention to Promote Goals of Care Communication – Drs. M. Patel, R. Parikh, and C. Manz.
 • Submitted R01 in February 2024

Patient-centered Video Education Intervention to Improve Rural Cancer Care Delivery – Drs. R. Holcombe and I. Okado.

Closed Studies

S1415CD, "A Pragmatic Trial To Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia – Trial Assessing CSF Prescribing, Effectiveness and Risk (TrACER)." Drs. S. Ramsey, D. Hershman, G. Lyman, et al. Activated: 10/7/16. Closed: 4/15/20.

S1417CD, "Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer." Dr. V. Shankaran. Activated: 4/15/16. Closed: 2/1/19.

Substudies (Economic Analyses / Cost Effectiveness from NCTN trials)

S1806, Healthcare Cost Comparison of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle-invasive Bladder Cancer, Drs. R. Vaidya and J. Unger.

Published Studies

Sex Differences in Adverse Event Reporting in SWOG Chemotherapy, Biologic/Immunotherapy and Targeted Agent Cancer Clinical Trials. Dr. J. Unger.

Cancer Care Delivery Committee

Trends in Obesity Prevalence Among Patients Enrolled in Clinical Trials for Obesity-related Cancers, 1986 to 2016. Dr. R. Vaidya.

Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation, Dr. R. Vaidya.

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD	NHLBIMDS	NRGCC007
Ascension Providence Hospitals - Southfield	-	-	-	4	-	-	-	-	1	-
Banner University Medical Center - Tucson	1	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	1	-	5	3	-
Bay Area Tumor Institute NCORP	-	2	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	24	-	-	-	-	-	-	-	5	-
Cancer Research Consortium of West Michigan NCORP	-	5	-	-	-	1	3	-	-	-
Cancer Research for the Ozarks NCORP	-	10	25	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	11	5	29	1	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	8	1	96	-	-	-	-	-	1	-
Columbia University Minority Underserved NCORP	25	8	-	-	-	-	-	-	22	-
Columbus NCI Community Oncology Research Program	5	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	10	-	31	-	-	-	-	-	-	-
Cotton O'Neil Cancer Center / Stormont Vail Health	1	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	3	1	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	109	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	22	-
Georgia Cares Minority Underserved NCORP	-	2	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	29	-	-	-	17	-	-	-
Gulf South Minority Underserved NCORP	6	2	-	-	2	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	3	71	-	-	-	-	-	5	-
Heartland Cancer Research NCORP	18	7	117	-	-	-	-	-	-	1
Kaiser Permanente NCI Community Oncology Research Program	4	10	-	-	-	-	34	-	8	-
Kansas City Veterans Affairs Medical Center	-	-	-	-	-	-	-	-	4	-
Kansas Institute of Medicine Cancer and Blood Center	-	-	-	-	-	-	-	-	2	-
Lahey Hospital and Medical Center	4	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	-	5	-	-	-	-	-	-
Mass Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	36	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	5	-
Michigan Cancer Research Consortium NCORP	11	15	44	-	-	-	-	-	-	-

Cancer Care Delivery (CCD) Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1703	S1912CD	S2108CD	A191901	A231601C	A231901C	ACCL16N1	EAQ171CD	NHLBIMDS	NRGCC007
Moffitt Cancer Center	-	-	-	-	-	-	-	-	8	-
Montana Cancer Consortium NCORP	9	1	51	-	-	-	-	-	-	-
Mount Sinai Hospital	3	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	-	-	-	22	-	-	-	1	-	-
NCORP of the Carolinas (Prisma Health NCORP)	6	1	-	-	-	-	-	-	2	-
Nevada Cancer Research Foundation NCORP	2	2	-	1	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	15	11	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	18	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	11	-
Pacific Cancer Research Consortium NCORP	10	13	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	5	16	9	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	1	-	-	3	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	23	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	32	-
University of Arkansas for Medical Sciences	4	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	-	-	-	13	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	4	62	-	-	-	-	-	-	22
University of Rochester LAPS	4	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	2	-	-	-	-	-	-
Upstate Carolina Consortium Comm Oncology Research Program	-	5	35	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	1	-	1	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	2	-
Wisconsin NCI Community Oncology Research Program	3	4	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	39	-	-	-	-	-	-	-	7	-
ALLIANCE	14	9	40	-	-	-	-	-	-	-
ECOG-ACRIN	26	20	24	-	-	-	-	-	-	-
NRG	18	8	-	-	-	-	-	-	-	-
Total	310	169	772	39	2	2	54	6	230	23

Cancer Survivorship Committee

Leadership

Co-Chairs: Melinda Irwin, PhD, MPH
 Halle Moore, MD

Time/Location

Friday, April 5, 2024 7:15 a.m. - 9:15 a.m.
 Room: Columbia D (Level 3)

Agenda

Welcome: Melinda Irwin and Halle Moore

Patient Advocate Update: Lee Jones

Updates:

Justin Floyd and Monika Leja: S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer."

Discussion

Suzie Zick and Heather Greenlee: Testing the Fatigue Reduction Diet in People with Early Stage Breast Cancer: A Randomized Controlled Trial, The GUIDE Study

Discussion

Rina Fox and Terry Badger: App-supported sleep coaching among cancer survivors and their bedroom partners

Discussion

Pragmatic Trial Emerging Concept

Krishna Gunturu: S2013 I-CHECKIT: Immune CHECKpoint Inhibitor Toxicity analysis (QOL and Symptom Control Committee)

Group: Late and lasting effects for cancer survivors following immunotherapy.

Liaison Updates/Other Business

Active Study

S1501, "Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III." Drs. J. Floyd and M. Leja. Activated 9/15/2017. Temporarily Closed to new patient enrollments 2/1/24 for study redesign.

Concepts in Development

S2423, "Testing the Fatigue Diet in People with Early-Stage Breast Cancer: The GUIDE Study". Drs. S. Zick and H. Greenlee. Triage informally reviewed on 1/22/24. R01 application submitted February 8th.

XXXXX, "Randomized, phase II trial of vortioxetine for the reduction of ADT-induced cognitive impairment". Dr. L. Graham. Pending drug procurement plan.

XXXXX, "Phase III Trial of an App-Supported Sleep Coaching Intervention in Post-Treatment Survivors of Diverse Cancers and their Bedroom Partners". Drs. Rina Fox and Terry Badger. One-pager reviewed by DCP leadership on 1/26/24. Planned R01 submission for June deadline.

Closed Study

S1316, "Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction." Drs. R. Krouse, J. Denevee, and V. Sun. Activated: 3/9/15; Permanently Closed: 5/15/20.

Cancer Survivorship Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1501	A211901
Ascension Providence Hospitals - Southfield	4	-
Baptist Mem Health Care/Mid South MU-NCORP	7	-
Bay Area Tumor Institute NCORP	2	-
CWRU Case Comprehensive Cancer Center LAPS	14	-
Cancer Research for the Ozarks NCORP	11	-
City of Hope Comprehensive Cancer Center	49	-
Columbia University Minority Underserved NCORP	2	-
CommonSpirit Health Research Institute	1	-
Fred Hutchinson Cancer Research Center LAPS	4	-
Georgia NCI Community Oncology Research Program	13	-
Gulf South Minority Underserved NCORP	4	-
Heartland Cancer Research NCORP	20	-
Henry Ford Hospital	2	-
Kaiser Permanente NCI Comm Oncology Research Program	1	-
King Faisal Specialist Hospital and Research Centre	3	-
Lahey Hospital and Medical Center	6	-
Loyola University Medical Center	8	-
Medical U of South Carolina Minority Underserved NCORP	1	-
Michigan Cancer Research Consortium NCORP	3	-
Moffitt Cancer Center	23	-
Montana Cancer Consortium NCORP	1	-
NCORP of the Carolinas (Prisma Health NCORP)	2	-
National Cancer Center-Korea	1	-
New Mexico Minority Underserved NCORP	7	-
Oregon Health and Science University	1	-
UC Davis Comprehensive Cancer Center LAPS	2	-
USC Norris Comprehensive Cancer Center LAPS	4	-
University of Kansas Cancer Center - MCA Rural MU NCORP	7	1
University of Michigan Comprehensive Cancer Center LAPS	10	-
University of Utah - Huntsman Cancer Institute LAPS	-	2
Wayne State University - Karmanos Cancer Institute LAPS	6	-
ALLIANCE	23	-
ECOG-ACRIN	43	-
NRG	24	-
Total	309	3

Palliative & End of Life Care Committee

Leadership

Co-Chairs: Robert S. Krouse, MD
 Marie Bakitas, DNSc, CRNP

Time/Location

Thursday, April 4, 2024 5:15 p.m. - 7:15 p.m.
 Room: Elwha AB (Level 5)

Agenda

Welcome & Updated Committee Objectives – Co-Chairs

Committee Liaison Updates – Patient Advocates/ORP (5 min)

Plenary

R01 funded study by NCI evaluating the efficacy and psychological mechanisms of single-dose psilocybin-assisted therapy (PAP) to treat psychiatric and existential distress in people with late-stage cancer – Stacy Fischer, MD. (30 mins)

New Proposal

Psilocybin Treatment for Cancer-Associated Psychological Distress in Hawaii – Ilan Bernstein, MD. (15 min)

Protocols in Development

S2408 A Randomized Phase III Multicenter Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula – Jonathan G. Sham, MD, Venu G. Pillarisetty, MD. (5 min)

SWOG Triage Approved Developing Studies

S2418 Distress Screening for Family Caregivers of Persons with Advanced Cancer: The FamilySTRONG Randomized Clinical Trial – J. Nicholas Odom, PhD, RN. (15 min)

S2422 Telehealth Intervention for Personalized Self-Management (TIPS) for Eating after Gastroesophageal Cancer Surgery – Jae Kim, MD and Virginia Sun, PhD, RN. (5 min)

Pre- SWOG Triage Approved Developing Studies

PIPAC in Refractory Colorectal/ Appendiceal Carcinomatosis – Mustafa Raoof, MD, MS, Robert S. Krouse, MD. (5 min)

Secondary analysis

Depression in SWOG Advanced Cancer Trials: Incidence and Importance – Drs. Nehemiah, Blanke, Fairman, and Krouse. (2 min)

Closed Studies Update

S1316, Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction – Robert S. Krouse, MD Activated: 3/9/15; Closed: 5/15/20. (4 min)

S1820, A Personalized Dietary Intervention to Manage Bowel Dysfunction in Rectal Cancer Survivors – Virginia Sun PhD, RN. Activated:12/9/19; Closed: 4/12/22. (4 min)

Pre-SWOG Pilot Study Updates

Study of Breast Cancer Survivor Symptoms Correlation with Fatigue Measured by Prolonged Wrist Actigraphy – Lauren A. Fowler PhD and Jamie S. Myers PhD, RN. (5 min)

Sleep Hygiene Education, ReadiWatch™ actigraphy, and telehealth cognitive behavioral training for insomnia Effect on Symptom Relief for Men with Prostate Cancer Receiving Androgen Deprivation Therapy (ADT) (SHERE-Relief 2) (funded by the Oncology Nursing Foundation as an RE03 two-year grant.) – Jamie S. Myers, PhD, RN and Lauren A. Fowler, PhD. (5 min)

Feasibility Study of a Hope Workshop Intervention Designed to Improve Cancer Survivor Hopefulness and Endocrine Therapy Adherence – David Feldman, PhD and Ben Corn, MD. (5 min)

Feasibility and Acceptability of an Online Intervention to Enhance Hopefulness Among Oncology Professionals – David Feldman, PhD and Ben Corn, MD. (5 min)

Closing Comments and Adjourn – Co-Chairs (5 min)

Prevention & Epidemiology Committee

Leadership

Co-Chairs: Banu Arun, MD
 Marian L. Neuhouser, PhD, RD

Time/Location

Thursday, April 4, 2024 12:30 p.m. - 2:30 p.m.
 Room: Elwha AB (Level 5)

Agenda

Welcome and Opening Comments: Dr. Marian Neuhouser &
 Dr. Banu Arun

Frank and Linda Meyskens Endowed Lectureship on Advances in Cancer Prevention

Inaugural Speaker: Dr. Gary Goodman

Cancer Prevention Keynote Presentation

“The Cancer Screening Research Network: A New NCI-funded Initiative to Evaluate Emerging Technologies for Cancer Screening”

Dr. Scott Ramsey, Professor, Fred Hutchinson Cancer Center

Dr. Lori Minasian, Division of Cancer Prevention, National Cancer Institute

Patient Advocate update Cheryl Jernigan

Active Studies

S1823, “A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Newly Diagnosed Germ Cell Tumors”. Drs. C. Nichols and L. Nappi. Activated: 6/1/20.

S1904, “Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ – Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE).” Drs. K. Crew, R. Kukafka, et al. Activated 9/1/20.

Closed Studies

S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).” Drs. J. Zell, P. Brown, M.P. Lance, et al. Activated: 3/1/13. Closed: 6/30/23.

Other Group Studies with SWOG Study Champions

CTSU A151804, “Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events.” Dr. G. Lyman. Activated: 1/31/20.

CTSU A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests.” Dr. J. McGuinness. Activated: 8/1/22.

CTSU EA1151, “Tomosynthesis Mammographic Imaging Screening Trial (TMIST).” Dr. B. Arun. Activated: 7/6/17.

CTSU/NHLBI-MDS, “The National Myelodysplastic Syndromes (MDS) Study.” Drs. D. Hill and C. Arana Yi. Activated: 4/5/16.

CTSU/EA8184, “A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers.” Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-CC005, “FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)”. Dr. L. Kachnic. Activated: 10/6/21.

Concept Reviewed by Cancer Prevention Steering Committee

S2311, Treatment Persistence with Alternate Doses of Exemestane or Tamoxifen among Postmenopausal Women with Atypical Hyperplasia, Lobular Carcinoma in situ or Hormone Receptor-Positive Ductal Carcinoma in situ. Dr. J. McGuinness.

Studies approved by triage to be submitted for federal funding

Potential amendments to existing or completed studies

Amendment to S1007, “Effects of Chemoprevention and Adjuvant Endocrine Therapy on a Convolutional Neural Network-Based Breast Cancer Risk Model Using Mammographic Datasets from S0812 and S1007.” Drs. K. Crew, K. Kalinsky, R. Ha.

Amendment to S1207, “Effects of Adjuvant Endocrine Therapy on a Convolutional Neural Network (CNN)-Based Breast Cancer Risk Model Using Breast Imaging Datasets from S1207.” Drs. K. Crew, J. McGuinness, R. Ha.

Prevention & Epidemiology Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
Ascension Providence Hospitals - Southfield	1	-	-	-	-	-	-	-	-	-
Ascension Via Christi Hospitals Wichita	12	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	17	-	-	3	-	-
Banner MD Anderson Cancer Center	10	5	-	-	-	1	-	-	-	-
Banner University Medical Center - Tucson	-	14	-	-	-	56	-	-	-	-
Baptist Mem. Health Care/Mid South Minority Underserved NCORP	4	-	10	-	-	8	-	-	-	-
Bay Area Tumor Institute NCORP	1	6	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	-	-	-	3	-	-	4
Brooke Army Medical Center	1	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	236	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	2	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	4	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	5	24	-	-	2	-	-	-	-
City of Hope Comprehensive Cancer Center	1	-	18	2	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	1	-	33	1	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	6	10	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	4	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	5	5	-	-	-	100	-	-	-	-
Georgia Cares Minority Underserved NCORP	2	-	-	-	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	2	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	13	-	-	-	-	-	-	-	1
Hawaii Minority Underserved NCORP	10	3	17	-	-	50	-	-	-	-
Heartland Cancer Research NCORP	2	14	9	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	4	133	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	40	156	10	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	3	-	-	-	-	-	-	-
Loma Linda University Medical Center	2	7	-	-	-	-	-	-	-	-
Loyola University Medical Center	2	-	3	-	-	-	-	-	-	-
Mass. Veterans Epidemiology Research and Information Center	3	-	-	-	15	-	8	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	4	-	-	-	-
Meharry Medical College	1	-	-	-	-	-	-	-	-	-
Memorial Hermann Texas Medical Center	-	-	-	-	-	8	-	-	-	-
Mercy Medical Center - Des Moines	1	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	12	-	-	-	-	-	-	-	-	-
MultiCare Tacoma General Hospital	2	-	-	-	-	-	-	-	-	-

Prevention & Epidemiology Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S0820	S1823	S1904	A211102	A212102	EA1151	EA2185	EA8184	NRGCC005	NRGCC008
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	460	-	-	-	-
Nevada Cancer Research Foundation NCORP	1	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	2	11	-	-	-	-	-	-	-	-
Northwell Health NCORP	2	11	-	-	-	-	-	-	-	1
Ohio State University Comprehensive Cancer Center LAPS	-	8	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	16	-	-	-	-	3	1	-	1
Pacific Cancer Research Consortium NCORP	2	-	1	-	-	-	-	-	-	-
Salem Hospital	-	3	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	3	2	-	-	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	1	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	33	3	-	-	10	-	-	-	-	-
UC San Diego Moores Cancer Center	-	23	-	-	-	-	1	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	30	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	32	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	381	3	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	5	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	8	24	-	-	5	2	-	-	1	-
University of Kansas Cancer Center - MCA Rural MU NCORP	4	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	9	-	-	-	-
University of Mississippi Medical Center	1	6	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	7	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	18	-	-	-	263	-	-	-	-
University of Texas Health Science Center at San Antonio	9	-	-	-	14	-	-	-	-	1
University of Texas MD Anderson Cancer Center LAPS	5	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	21	-	-	-	-	-	-	-
Upstate Carolina Consortium Comm. Oncology Research Program	-	-	-	-	-	619	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	7	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	11	16	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	2	-	-	-	-	8	-	-	-	-
Western States Cancer Research NCORP	1	-	-	-	-	69	-	-	-	-
Wisconsin NCI Community Oncology Research Program	1	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	25	-	-	-	-	-	-	-	-	-
ALLIANCE	37	86	98	-	-	-	-	-	-	-
CCTG	-	188	-	-	-	-	-	-	-	-
ECOG-ACRIN	34	69	36	-	-	-	-	-	-	-
NRG	38	51	69	-	-	-	-	-	-	-
Total	354	877	352	3	66	2,409	18	4	1	8

Symptom Control & Quality of Life Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, April 4, 2024 10:15 a.m. - 12:15 p.m.
 Room: Elwha AB (Level 5)

Agenda

Presentations

Integrative Oncology: Emerging Paradigms of Care Delivery and Priority Research Questions; Plenary speaker: Richard T. Lee, MD

Immunotherapy response and toxicity: the role of lifestyle factors; Plenary Speaker: Jennifer L. McQuade MD, MS, MA, LAc

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Drs. Gunturu, Hershman, Kuderer, et al. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Drs. Accordino, Pennington, Hershman, et al. Activated: 3/16/23.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Drs. Henry, Hershman, and Skaar. Activated: 1/17/23.

Other Concepts in Development

Weight management prior to radical prostatectomy to improve quality of life and obesity-driven prostate cancer biomarkers. Dr. Hamilton-Reeves

A phase III study evaluating a mindfulness tool to ameliorate treatment-related fatigue in patients with advanced renal cell carcinoma (RCC) Drs. Bergerot and Pal

Emerging from the Haze™ (Haze)- A multi-dimensional, psycho-educational, cognitive rehabilitation program to improve perceived cognitive function for cancer survivors. Dr. Myers

Acupuncture to decrease symptom burden in patients with metastatic breast cancer. Dr. Greenlee

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Drs. Hamilton-Reeves, Holzbeierlein, Kukreja, et al. Permanently closed 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Hwang, Lok, Gehring, et al. Permanently closed 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Drs. Trivedi, Hershman, Brannagan, et al. Activated: 3/1/19; Permanently closed 11/15/21.

S0702 "A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients with Bone Metastases Starting Zoledronic Acid Treatment." Dr. Van Poznak, Activated 12/15/2008. Closed 12/13/2013.

S1200, "Randomized Blinded Sham- and Waitlist-Controlled Trial of Acupuncture for Joint Symptoms Related to Aromatase Inhibitors in Women with Early Stage Breast Cancer." Dr. Hershman. Activated: 3/27/2012. Closed: 2/15/2017

Committee Business

1. What other studies are we planning?
2. What is happening with our open studies?
3. What other updates should we know about?
 - Patient Advocate Update
 - Statistical Center Update

Other SWOG Studies with Symptom Control and QOL Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Dr. Jagsi. Activated: 9/12/18.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease

Symptom Control & Quality of Life Committee

Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Drs. Accordino, Hershman, and Ramsey. Activated: 7/16/18.

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Drs. Shankaran, Carlos, Hershman, et al. Activated: 7/26/21.

S2108CD, "A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy." Drs. Reuter, Trivedi, Symington, et al. Activated: 8/22/22.

GU

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Dr. Chapin. Activated: 9/17/18.

S1806, "Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer." Dr. Singh. Activated: 4/19/18.

Leukemia

S1925, "Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Drs. Stephens, Hill, Pagel, et al. Activated: 12/14/20.

Lung

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activated: 3/25/20.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activated: 1/10/20.

Lymphoma

S1826, "A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma." Drs. Herrera, Friedberg. Activated: 7/19/19.

S1918, "A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem, Smith, Henry, et al. Activated: 3/19/21.

Myeloma

S1803, "Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)." Drs. Krishnan, Chhabra, and Callander. Activated: 6/27/19.

Prevention and Epidemiology

S0820, "A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)." Drs. Zell, Brown, Lance, et al. Activated: 3/1/13.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)." Drs. Crew, Kukafka, Hershman, et al. Activated: 9/1/20.

NCTN Studies

CTSU/NRG-G1004, "Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/ Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer." Dr. Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21.

Symptom Control & Quality of Life Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221805	A222004	EAQ202	NRGCC010
Ascension Providence Hospitals - Southfield	-	-	-	29	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	11	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	-	-	1	-	-	-
Banner University Medical Center - Tucson	-	-	-	4	-	-	-	-	-
Bay Area Tumor Institute NCORP	-	-	-	-	3	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	5	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	2	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	1	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	97	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	1	14	-	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	2	24	8	-	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-	29	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	7	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-
Fred Hutchinson Cancer Research Center LAPS	13	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	14	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	-	4	64	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	4	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	2	22	-	-	-	-	5
Hawaii Minority Underserved NCORP	-	-	3	1	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	15	210	-	-	-	-	-
Henry Ford Hospital	8	-	-	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-	13	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	2	9	57	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	5	52	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	-	-	47	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	9	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	2	-	-	-	-	-	-

Symptom Control & Quality of Life Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1600	S1614	S2010	S2013	S2205	A221805	A222004	EAQ202	NRGCC010
Montana Cancer Consortium NCORP	-	-	-	4	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	39	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	4	-
New Mexico Minority Underserved NCORP	-	-	7	-	1	-	-	-	-
Northwestern University LAPS	-	-	4	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	12	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	-	2	2	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	-	-	1	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	8	40	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	1	120	14	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	2	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	5	9	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	6	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	78	-	-	10	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	-	-	-	13	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	4	21	-	-	-	-	-
University of Colorado Cancer Center LAPS	14	-	-	30	-	2	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	51	-	6	69	8	2	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	13	-	-	-	-	-	-
University of Mississippi Medical Center	-	-	1	-	-	-	-	-	-
University of Rochester LAPS	16	-	-	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	-	7	45	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	1	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	1	3	-	-	2	-	-
Wisconsin NCI Community Oncology Research Program	-	-	2	24	-	-	-	-	-
ALLIANCE	5	-	9	280	15	-	-	-	-
ECOG-ACRIN	4	-	8	90	2	-	-	-	-
NRG	2	1	19	194	7	-	-	-	-
Total	203	4	162	1,662	58	8	3	43	5

Early Therapeutics & Rare Cancers Committee

Leadership

Chair: Razelle Kurzrock, MD
 Vice-Chair: Young Kwang Chae, MD, MPH
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Megan Othus, PhD
 Anna B. Moseley, MS

Designates

Data Coordinator: Christine Magner
 Digital Engagement: Kanwal Raghav, MD, MBBS
 Oncology Research Professionals:
 CRAs: TBD
 Nurse: TBD
 Pharmaceutical Science: Craig Elg, PharmD
 Sun "Coco" Yang, PharmD, PhD
 Patient Advocate: Marcia K. Horn, JD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS
 Early Therapeutics Liaisons
 Breast Committee Liaison: Stephanie L. Graff, MD
 Cancer Control Liaison: Jason M. Prosek, MD
 Lara E. Davis, MD (Survivorship)
 Genitourinary Committee Liaison: Parminder Singh, MD
 Imaging: TBD
 Lung Committee Liaison: Shirish M. Gadgeel, MD
 Lymphoma Committee Liaison: Nasheed Mohammad Hossain, MD
 Melanoma Committee Liaison: Jeffrey A. Sosman, MD
 Myeloma Committee Liaison: Frits van Rhee, MD, PhD

Time/Location

Thursday, April 4, 2024 10:30 a.m. - 12:30 p.m.
 Room: Columbia D (Level 3)

Agenda

10:30 - 10:35 am Welcome and Introduction - Razelle Kurzrock, MD
 10:35 - 10:55 am Updates from Sarcoma Working Group - Lara Davis, MD
 10:55 - 11:15 am S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas" - David Zhen, MD
 11:15 - 11:35 am CIMAC and Translational Immunology in DART - Young Chae, MD

11:35 - 11:55 am Clinical Update: DART Results - Sandip Patel, PhD
 11:55 - 12:10 pm Update from CNS Working Group - Manmeet Ahluwalia, MD
 12:10 - 12:25 pm ComboMatch Update – Reva Basho, MD
 12:25 - 12:30 pm Wrap Up - Razelle Kurzrock, MD

Active Studies

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)." Drs. Zhen, Chiorean, Burgess, Swisher. Activated: 12/2/21.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma." Dr. Uboho. SWOG Champion: Dr. Saeed. Activated: 2/6/20.

CTSU/A071601, "Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas." Dr. Brastianos. SWOG Champion: Dr. Ahluwalia. Activated: 8/4/17. Temporarily Closed (Cohort A): 9/8/20.

CTSU/A071401, "Phase II Trial of SMO/AKT/NF2/CDK Inhibitors in Progressive Meningiomas with SMO/AKT/NF2/CDK Pathway Mutations." Dr. Brastianos. SWOG Champion: Dr. Piccioni. Activated: 8/28/2015. New patient registration (Step 1) to the NF2, CDKN2A, CDK4, CDK6, CCND1, CCND2, CCND3, and CCNE1 Cohort (Abemaciclib Cohort) is closed to accrual as of 10/03/2022.

CTSU/A092001, "Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma". SWOG Champion: Dr. P.S.K. Raghav. Activated: 10/15/21.

CTSU/AGCT1531, "A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors" SWOG Champion: Dr. D'Souza Activated: 5/8/17. Stratum 2 is temporarily closed to accrual 10/19/23

CTSU/AOST2031, "A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma" SWOG Champion: Dr. Hofstetter. Activated: 2/15/22

CTSU/AOST2032, "A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic

Early Therapeutics & Rare Cancers Committee

Chemotherapy for Newly Diagnosed Osteosarcoma” SWOG Champion: Dr. J. A. Livingston. Activated: 2/17/23

CTSU/A071702, “A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hyper-mutated Recurrent Glioblastoma.” SWOG Champion: Dr. M. Ahluwalia. Activated: 10/30/20. Pre-Registration is temporarily Closed to accrual 12/12/23

CTSU/HN.11 (CCTG-HN11), “SPECT-CT Guided Elective Contralateral Neck Treatment (SELECT) for Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial SWOG” Champion: Dr. Paul Swiecicki. Activated: 9/29/22

Studies in Development

S24310, “Phase II Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma”. Dr. Harris

S2425, “A Randomized Phase II Study of Temozolomide in Combination with Atezolizumab (Tem-Atezo) versus Temozolomide Alone in Adults with Advanced Bronchopulmonary Neuroendocrine Tumors.” Dr. Sukrithan

S2426, “A Randomized Phase II Study of Amivantamab versus Cetuximab in Immunocompromised Patients with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma”. Dr. Swiecicki.

Closed Studies

S1609, “DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors.” Drs. Patel, Chae, and Kurzrock. Activated: 1/13/17. Closed: 3/15/23.

CTSU/NRG-GY006, “A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer.” Dr. Leath. SWOG Champion: Dr. Robinson. Activated: 1/15/16. Closed: 9/22/22

CTSU/NRG-GY020, “A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer.” Dr. Backes. SWOG Champion: Dr. Robinson. Activated: 2/7/20. Closed: 8/29/22.

NICICOVID, “NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study.” Dr. Karim. Activated: 5/21/20. Closed: 2/1/2022.

CTSU/NRG-GY009, “A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer.” Dr. O’Cearbhaill. SWOG Champion: Dr. Robinson. Activated: 5/12/17. Closed 10/14/2021

CTSU/NRG-HN007, “An Open-Label, Phase III Study of Platinum-Gemcitabine with or without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma.” Dr. Brigitte B. Y. Activated: 9/8/20; Closed: 10/28/21

CTSU/EAY131, “Molecular Analysis for Therapy Choice (MATCH).” Activated: 8/12/2015. Closed: 12/23/2022

CTSU/NRG-BN007, “A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab versus Temozolomide in Patients with Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma.” Dr. Lassman. SWOG Champion: Dr. Ahluwalia. Activated: 8/6/20. Closed: 3/29/23.

CTSU/EA3163, “Phase II Randomized Trial of Neoadjuvant Chemotherapy Followed by Surgery and Post-Operative Radiation versus Surgery and Post-Operative Radiation for Organ Preservation of T3 and T4a (and Selected T4b) Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC).” Dr. Saba. SWOG Champion: Dr. Swiecicki. Activated: 3/28/18. Closed: 11/7/23

Proposed Studies

NRG-BN1803, “NRG-COG Phase II Trial of Radiation Plus Concurrent and Adjuvant ONC201 for Newly Diagnosed, H3 K27M-Mutant Gliomas.” SWOG Champion: Dr. Ahluwalia.

NRG-OV1821, “A Randomized Phase II Trial of Olaparib Versus Olaparib + Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer.” Dr. Robinson.

NRG-BN1855, “A Randomized Phase II/III Open Label Study of Ipilimumab and Nivolumab Vs Te-mozolomide in Patients with Newly Unmethylated MGMT (Tumor O-6-Methylguanine DNA Methyltransfer-ase) Glioblastoma.” Dr. M. Ahluwalia.

NRG-HN1854, “An Open-label, Phase III Study of Platinum-Gemcitabine with or Without Nivolumab in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma.” Dr. P. Swiecicki.

Early Therapeutics & Rare Cancers Committee

NRG-UC1805, “Randomized Phase III Trial of Radiation +/- Pembrolizumab for High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer.” Dr. W. Robinson.

ComboMatch

Active Studies

EAY191-S3, “Phase 2 Study of Paclitaxel + Ipatasertib in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors.”
Study Chairs: Reva Basho, M.D., Haider Mahdi, M.

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	EAY191-S3	S1609	S2012	A071401	AGCT1531	EAY131	EAY191	EAY191E4
Ascension Providence Hospitals - Southfield	-	1	-	-	-	3	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	7	-	-	-	10	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	3	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	8	-	-	-	6	-	-
City of Hope Comprehensive Cancer Center	-	2	-	-	-	6	-	-
Columbus NCI Community Oncology Research Program	-	3	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	15	1	1	-	9	-	-
Dayton NCI Community Oncology Research Program	-	2	-	-	-	1	-	-
Essentia Health NCI Community Oncology Research Program	-	4	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	10	3	-	-	2	-	-
Georgia NCI Community Oncology Research Program	-	6	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	2	1	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	1	-	-
Heartland Cancer Research NCORP	-	15	-	-	-	1	-	-
Henry Ford Hospital	-	17	2	-	-	11	-	-
Houston Methodist Hospital	-	-	-	-	-	1	-	-
Intermountain Medical Center	-	1	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	27	1	-	-	6	-	-
Loma Linda University Medical Center	-	6	-	-	-	1	-	-
Loyola University Medical Center	-	4	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	6	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	4	-	-	-	2	-	-
Mercy Medical Center - Des Moines	-	2	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	12	2	-	-	-	-	-
Mission Hospital	-	-	-	-	-	3	-	-
Moffitt Cancer Center	-	22	2	-	-	-	-	-
Montana Cancer Consortium NCORP	-	16	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	1	-	-	-
MultiCare Tacoma General Hospital	-	2	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	18	-	-	-	-	-	-

Early Therapeutics & Rare Cancers Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	EAY191-S3	S1609	S2012	A071401	AGCT1531	EAY131	EAY191	EAY191E4
New Mexico Minority Underserved NCORP	-	18	-	-	-	-	-	-
Northwestern University LAPS	-	16	2	1	-	-	-	-
Oregon Health and Science University	-	12	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	12	-	-	-	-	-	-
Saint Luke's Hospital of Kansas City	-	-	-	-	-	1	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	1	-	-	5	-	-
Sutter Cancer Research Consortium	-	2	-	-	-	4	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	1	-	-	-
Tulane University School of Medicine	-	-	-	-	-	1	-	-
UC Davis Comprehensive Cancer Center LAPS	-	11	-	-	-	9	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	8	-	1	-	19	3	3
UC San Diego Moores Cancer Center	-	27	-	2	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	4	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	5	-	-	-	3	-	-
University of Colorado Cancer Center LAPS	-	6	-	1	-	9	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	35	-	-	-	6	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	13	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	32	1	-	-	24	-	-
University of Mississippi Medical Center	-	5	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	3	-	-	-	-	-	-
University of Rochester LAPS	-	5	-	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	5	-	-	-	7	-	-
University of Texas MD Anderson Cancer Center LAPS	1	19	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	3	1	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	4	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	1	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	3	-	-
Wisconsin NCI Community Oncology Research Program	-	12	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	2	-	13	-	-
ALLIANCE	-	106	8	-	-	-	-	-
ECOG-ACRIN	-	78	1	-	-	-	-	-
NRG	-	138	5	-	-	-	-	-
Total	1	798	32	8	2	183	3	3

Gastrointestinal Committee

Leadership

Chair: Philip A. Philip, MD, PhD, FRCP
 Vice-Chair: Elena G. Chiorean, MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Katherine A. Guthrie, PhD
 Sarah Colby, MS

Scientific Leadership

Gastroesophageal: Syma Iqbal, MD
 Zev A. Wainberg, MD
 Pancreatic: Davendra P.S. Sohal, MD
 Andrew M. Lowy, MD (Surgical representative)
 Hepatobiliary: Anthony B. El-Khoueiry, MD
 Rachna T. Shroff, MD
 Syed A. Ahmad, MD (Surgical representative)
 Colon: Marwan G. Fakih, MD
 Philip J. Gold, MD
 Sepideh Gholami, MD (Surgical representative)
 Neuroendocrine Tumors: Nageshwara Arvind Dasari, MD
 Jonathan R. Strosberg, MD
 Ano-Rectal: Lisa A. Kachnic, MD
 Hagen F. Kennecke, MD
 Imaging: Anthony F. Shields, MD, PhD
 Pathology: Mary Kay Washington, MD, PhD
 Radiation Oncology: Lisa A. Kachnic, MD
 Surgery: Stephen W. Behrman, MD
 Syed A. Ahmad, MD
 Flavio Rocha, MD
 Translational Medicine: Gabriel N. Duda, PhD, DMD
 Maheswari Senthil, MD

Designates

Cancer Control Liaisons: Jason A. Zell, DO (Prevention)
 Afsaneh Barzi, MD (CCD)
 Community Liaisons: Gary L. Buchsacher, MD, PhD (Medical Oncology)
 Mohamed E. Salem, MD (Medical Oncology)
 Flavio Rocha, MD (Surgical)
 David Horowitz, MD (Radiation Oncology)
 DEI Champion: Colmar Figueroa-Moseley, PhD, MPH
 Rachael Ann Safyan, MD
 Digital Engagement: Heloisa Soares, MD, PhD
 Veterans Affairs: Rangaswamy Govindarajan, MD
 Data Coordinators: Alex Rangel, BS
 Brian Zeller
 Christine Magner

Oncology Research Professionals:

CRA: Michelle A. Springer, BA
 Nurse: TBD
 Patient Advocate (Pancreatic): Carole Seigel, MBA
 Patient Advocate (Colon): Florence Kurttila, MS
 Pharmaceutical Science: Jane E. Rogers, PharmD
 Safae Chouraichi, PharmD
 Protocol Project Manager: Andrea Garcia
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Friday, April 5, 2024 4:30 p.m. - 6:30 p.m.
 Room: Columbia D (Level 3)

Agenda

1. Welcome
2. Announcements & Introductions Philip Philip
E. Gabriela Chiorean
3. HEARD Subcommittee Initiatives Rachel Safyan, Colmar Figueroa-Moseley, Carole Seigel, Florence Kurttila
4. SWOG Led Trials Updates
 - a. S1922 Michael Overman
 - b. S2001 Vincent Chung
 - c. S2104 Heloisa Soares/S. Ahmad
 - d. S2107 Van Morris
 - e. S2012 David Zhen/E. Gabriela Chiorean
 - f. S2303 Anwaar Saeed/Paul Oberstein
5. SWOG Co-Led Trials Updates
 - a. A022104 Arvind Dasari
 - b. A022001 Heloisa Soares
 - c. EA2192 Anup Kasi
 - d. NRG-GI004 Michael Overman
 - e. NRG-GI008 Christopher Lieu
 - f. CCTG NE1 Aman Chauhan
6. Anal and Rectal
 - a. Major recent clinical results Hagen Kennecke, Lisa Kachnic
 - b. NCTN trials update
 - c. Future SWOG plans

Gastrointestinal Committee

- | | |
|---|--|
| 7. Colon | Marwan Fakh, Philip Gold,
Sepideh Gholami |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 8. Gastroesophageal | Syma Iqbal, Zev Wainberg |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 9. Hepatobiliary | Anthony El-Khoueiry
Rachna Shroff |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 10. Neuroendocrine | Jon Strosberg, Arvind Dasari |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 11. Pancreatic | Davendra Sohal, Andrew Lowy |
| <ul style="list-style-type: none"> a. Major recent clinical results b. NCTN trials update c. Future SWOG plans | |
| 12. Discussion/Other business | |
| 13. Adjourn | |

Gastroesophageal

Active Studies

S2303, "Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS \geq 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)", Drs. Saeed and Obertstein. Activated: 3/15/24.

CTSU/A022102, "Randomized Phase III Trial of mFOLFIRINOX +/- Nivolumab vs. FOLFOX +/- Nivolumab for First-Line Treatment of Metastatic HER2-Negative Gastroesophageal Adenocarcinoma." Dr. Oberstein. Activated: 1/17/19.

CTSU/EA2174, "A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma." Dr. Kelly. Activated: 1/17/19. Temporarily Closed to Accrual as of 12/29/2022.

CTSU/EA2183, "A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA)." Dr. Horowitz. Activated: 2/6/2020.

CTSU/NRG-GI006, "Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer." Dr. Zhen. Activated: 3/16/19.

Pancreatic

Developing Studies

SXXXX, "Randomized Phase II Study of Second-Line Chemotherapy with or Without Panitumumab for Locally Advanced or Metastatic KRAS/ BRAFV600E Wild-Type Pancreatic Ductal Adenocarcinoma." Drs R. Safyan and EG Chiorean. Presented at Pancreas Cancer Task Force 02/2023.

Active Studies

S2001, "Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations." Dr. Chung. Activated: 12/4/20.

CTSU/A021806, "A Phase III Trial of Perioperative Versus Adjuvant Chemotherapy for Resectable Pancreatic Cancer." Dr. Noel. Activated: 7/1/20.

CTSU/A022106, "Phase II/III Second-Line Nabplagem Vs. Nab-Paclitaxel/ Gemcitabine In Brca1/2 Or Palb2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM)." Dr. Greg Botta, Activated: 12/1/23.

CTSU/EA2186, "A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)." Dr. Zhen. Activated: 6/18/20.

CTSU/EA2192, "APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation." Drs. Chiorean and Philip. Activated: 4/29/21.

CTSU/EA2185, "Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs." Dr. Pillarisetty. Activated: 01/16/2020.

Neuroendocrine

Active Studies

S2104, "Randomized Phase II Trial of Postoperative Adjuvant Capecitabine

Gastrointestinal Committee

and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors." Dr. Soares. Activated: 10/14/21.

S2012, "Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC #783608) in Patients with Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)" Activated Drs. D. Zhen, E. Chiorean, E. Burgess, E. Swisher, L. Byers. Activated: 12/02/2021

CTSU/A021602, "Randomized Double-Blinded Phase III Study of CABozantinib versus Placebo IN Advanced NEuroendocrine Tumors after Progression on Prior Therapy (CABINET)." Dr. Strosberg. Activated: 7/18/18. Temporarily Closed to Accrual as of 08/07/2023

CTSU/A021804, A Prospective, Multi-institutional Phase II Trial Evaluating Temozolomide vs. Temozolomide and Olaparib for Advanced Pheochromocytoma and Paraganglioma. Dr C. Lopez. Activated: 11/02/2020.

CTSU/A021901, Randomized Phase II Trial of Lutetium Lu 177 Dotatate Versus Everolimus in Somatostatin Receptor Positive Bronchial Neuroendocrine Tumors. Dr. Hendifar. Activated: 09/10/2021

CTSU/A022001, Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors. Dr. Soares. Activated: 03/16/2022

CTSU/CCTG NE1, Comparing retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment. Dr A. Chauhan. Activated: 06/14/2023.

Colon/Small Bowel

Developing Studies

S2420, "A Randomized Phase II Trial of Regorafenib, Ipilimumab, and Nivolumab Versus Trifluridine/Tipiracil Plus Bevacizumab in Metastatic Colorectal Cancer Without Liver Metastases", Dr. Fakhri. Approved by SWOG Executive Committee on 12/22/23

XXXX, PreOpEraTive Immunotherapy and Chemotherapy for Colon Cancer (POETIC) Drs Krishnamurthy and Senthil. Presented at Colon Cancer Task Force 09/2023.

Active Studies

S2107, Randomized phase II trial of encorafenib and cetuximab with or without nivolumab for patients with previously treated microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer. Dr. V. Morris. Activated: 6/06/2022.

S1922, Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma. Dr. M. Overman. Activated: 12/16/2019.

CTSU/A022004, Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab Versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer. Drs. Krishnamurthi, Subramanyan. Activated: 05/30/2023.

CTSU/A022101, "A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)" Dr. S. Gholami. Activated: 1/10/23.

CTSU/NRG-GI004/S1610, Colorectal Cancer Metastatic MSI-High Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Microsatellite Instability-High (MSI-H) Metastatic Colorectal Cancer. Dr. M. Overman. Activated: 11/07/2017.

CTSU/NRG-GI008, Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US) Dr. C. Lieu. Activated 03/10/2022.

Rectal/Anal

Active Studies

CTSU/A022104, "The Janus Rectal Cancer Trial: A Randomized Phase II Trial Testing the Efficacy of Triplet Versus Doublet Chemotherapy to Achieve Clinical Complete Response in Patients with Locally Advanced Rectal Cancer" Activated 11/9/2022. SWOG Champion: A. Dasari

CTSU/EA2176, "Randomized Phase III Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Naive Metastatic Anal Cancer Patients." Dr. Morris. Activated: 10/15/20.

CTSU/EA2182, "A Randomized Phase II Study of De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)." Dr. Murphy. Activated: 11/12/19.

Hepatobiliary

Developing Studies

XXXX, Randomized Phase 2 trial of Liposomal Irinotecan, Fluorouracil, Leucovorin, and Onvansertib in Second-Line Treatment of KRAS-Mutated Advanced Biliary Tract Cancer. Dr. R. Kim. Presented at the Hepatobiliary Task Force 06/2023.

Gastrointestinal Committee

Active Studies

CTSU/NRG-GI003, "A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular Carcinoma." Dr. El-Khoueiry. Activated: 6/21/17.

CTSU/EA2197, "Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial." Dr. Rocha. Activated: 12/22/20.

CTSU/EA2205, A Randomized Phase II Trial Evaluating Chemotherapy Plus Atezolizumab vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma. Activated: 02/11/2022

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806	A022001	A022102
Ascension Providence Hospitals - Southfield	-	2	-	-	3	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	4	-	2	3	-	1	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	2	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan CCC	-	-	-	-	-	-	1	-	-	-
Boston Medical Center	-	-	-	-	1	3	-	1	-	2
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	6	-	-	2	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	2	-	-	-	-	-	-
Carle Cancer Center NCORP	1	-	-	1	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	-	-	-	1	-	-	-	-
Columbia University Minority Underserved NCORP	-	1	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	3	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	4	-	-	1	-	-
Gulf South Minority Underserved NCORP	-	-	-	3	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	1	-	3	-	-	-	-	-	-
Henry Ford Hospital	-	1	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	-	3	17	-	-	-	-	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-
Medical U of South Carolina Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	2	-	1	-	-	-	-	-	-
Moffitt Cancer Center	-	-	1	-	-	4	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	1	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	9	1	-	-
Northwestern University LAPS	1	-	-	-	1	-	8	1	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	1	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	1	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	1	2	2	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1922	S2001	S2104	S2107	A021502	A021602	A021703	A021806	A022001	A022102
Southeast Clinical Oncology Research Consortium NCORP	-	2	4	2	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	3	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	2	-	-
The West Clinic - Wolf River	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	4	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	2	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	2	-	1	-	-	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-	-	1
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	3	-	-	-
University of Colorado Cancer Center LAPS	-	2	-	3	6	-	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	3	-	1	-	-	2
University of Kentucky/Markey Cancer Center	-	-	3	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	3	2	1	-	-	4	-	4	-	-
University of Rochester LAPS	1	-	-	-	2	8	-	9	-	-
University of Texas Health Science Center at San Antonio	-	-	-	-	-	-	-	3	-	-
University of Texas MD Anderson Cancer Center LAPS	9	-	-	7	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	1	3	-	-	-	-	-	1	-
Vanderbilt University - Ingram Cancer Center LAPS	-	4	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	4	2	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	1	-	-	2	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	1	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	1	1	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	4	-	8	2	-	-
ALLIANCE	9	5	1	6	-	-	-	-	-	-
ECOG-ACRIN	1	9	4	6	-	-	-	-	-	-
NRG	3	4	6	7	-	-	-	-	-	-
Total	30	45	33	48	68	25	32	27	1	5

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGGI004	NRGGI005	NRGGI008
Ascension Providence Hospitals - Southfield	-	-	1	2	2	-	-	-	-	5	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	-	-	-	-	-	-	-	-	3	1
Baylor College of Medicine/Duncan CCC	1	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	2	2	-	2	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	2	-	3	1	3	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	3	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	1	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	1	-	-	-	1	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	2	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-	1	-
Houston Methodist Hospital	-	-	-	-	-	-	-	-	1	-	-
Kaiser Permanente NCI Comm Oncology Research Program	-	-	5	-	-	-	-	-	-	11	-
Loma Linda University Medical Center	-	-	-	-	-	-	-	-	-	-	1
Medical U of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	1	-
Moffitt Cancer Center	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	2	-	-	-	-	1	1
Northwestern University LAPS	-	-	1	-	1	-	-	-	-	-	-
Ohio State U Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	2	1	-	-	2	3	-	1	-
Pacific Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
STCC at DHR Health Institute for Research & Development	-	-	-	-	-	-	-	-	-	1	-

Gastrointestinal Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A022104	EA2174	EA2176	EA2182	EA2186	EA2187	EA2192	EA2197	NRGG1004	NRGG1005	NRGG1008
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	1	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	1	-	-	-	-	-	-	-	-	-	-
The West Clinic - Wolf River	5	-	-	-	-	-	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	1	-	1	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	3	1	2	-	-	-	-	1	-
USC Norris Comprehensive Cancer Center LAPS	1	1	1	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	2	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	1	1	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	2	1	-	-	-	-	-	4
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	1	-	-	-	2	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	6	-	-	-	7	2	-	-	1	-	2
University of Texas Health Science Center at San Antonio	3	-	-	-	3	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	8	-	-	-	-	-	13	1	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	5	-	-	-	-	-	-	-	-	1	2
Virginia Mason Medical Center	2	-	-	-	-	-	-	1	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	1	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	4	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	29	6	24	13	26	7	2	5	15	35	13

Genitourinary Committee

Leadership

Chair: Seth P. Lerner, MD
 Vice-Chair: Daniel P. Petrylak, MD
 Chair Emeritus: Ian M. Thompson, Jr., MD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Cathy M. Tangen, DrPH
 Melissa Plets, MS
 Sam Callis, MS

Scientific Leadership

Translational Medicine: David J. McConkey, PhD (GU Chair)
 Joshua J. Meeks, MD, PhD (Bladder)
 Amir Goldkorn, MD (Prostate)
 Sumanta “Monty” K. Pal, MD (Renal)
 Radiation Oncology: James B. Yu, MD
 Daniel A. Hamstra, MD
 Imaging: Evan Y. Yu, MD
 Hiram Shaish, MD
 John D. Hazle, PhD
 Immunotherapeutics: Shuchi Gulati, MD (Medical Onc)
 Robert Svatek, MD (Urologic Onc)
 Pathology: M. Scott Lucia, MD
 Surgery: Kelly L. Stratton, MD
 Early Therapeutics: Parminder Singh, MD
 Bladder Organ Site Chairs: Siamak Daneshmand, MD (Localized)
 Thomas W. Flaig, MD (Advanced)
 Prostate Organ Site Chairs: Daniel W. Lin, MD (Localized)
 Tanya B. Dorff, MD (Advanced)
 Renal Organ Site Chairs: Brian Shuch, MD (Localized)
 Ulka N. Vaishampayan, MD (Advanced)

Designates

Cancer Control: Clara Hwang, MD
 Sarah P. Psutka, MD, MSC
 DEI Champion: Jessica D. McDermott, MD
 Digital Engagement: Neema Navai, MD
 NCORP: Scott Edward Delacroix, Jr., MD
 Helen Heng-Shan Moon, MD
 Veterans Affairs: Michael M. Goodman, MD
 Data Coordinators: Laura Wells, BA
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRAs: Abigail L. Cornette, MS
 Cheryl Farlow, RN, OCN
 Nurse: Gary Lee Duvall, RN

Patient Advocates: Rick Bangs, MBA (Emeritus, Bladder)
 Darrell Nakagawa (Bladder)
 Tony Crispino (Emeritus, Prostate)
 Lee Henry Moultrie (Prostate)
 Laura B. Esfeller, MA (Renal)
 Pharmaceutical Science: Joyce Lee, PharmD
 Allison Schepers, PharmD
 Protocol Project Manager: Megan Keim
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Friday, April 5, 2024 9:30 a.m. - 12:00 p.m.
 Room: Elwha AB (Level 5)

Agenda

9:30 - 9:45 am: Chair’s Welcome and Opening Remarks - Seth Lerner
 9:45 - 10:15 am: Cancer Control - Clara Hwang and Sarah Psutka
 10:15 - 12:00 pm: Review of open approved trials - all organ site chairs
 Prostate – Dan Lin and Tanya Dorff
 Renal – Brian Shuch and Ulka Vaishampayan
 Bladder – Sia Daneshmand and Tom Flaig

Bladder

Organ Site Chairs: Dr. Thomas Flaig (Advanced) and Dr. Siamak Daneshmand (Local).

Priority Study

S1937, “A Phase III Trial of Eribulin (NSC #707389) with or Without Gemcitabine Versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy.” Drs. S. Sadeghi and P. Lara. Activated: 2/16/21. Temporary Closure: 5/30/23. Re-opened Arms 1&3 to accrual and permanently closed Arm 2 on 2/15/24.

Concepts in Development

S2427, “Bladder preservation with chemoradiotherapy or immunoradiotherapy after a good response to neoadjuvant chemotherapy in patients with muscle invasive bladder cancer (BRIGHT).” Dr. L. Ballas. Presented to SWOG triage 2/5/24. Triage approved with recommendations 2/13/24.

Genitourinary Committee

Active Studies

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” Drs. P. Singh, S. Lerner, J. Efstathiou, et al. Activated: 4/19/19. Step 1 accrual closed 3/1/24.

CTSU/A031701, “A Phase II Study of Dose-Dense Gemcitabine Plus Cisplatin (ddGC) in Patients with Muscle-Invasive Bladder Cancer with Bladder Preservation for Those Patients Whose Tumors Harbor Deleterious DNA Damage Response (DDR) Gene Alterations.” Drs. A. Gupta and S. Gupta. Activated: 8/1/18.

CTSU/A031803, “Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. D. Tyson and C. Ramamurthy. Activated: 1/6/20.

CTSU/EA8185, “Phase II Study of Bladder-Sparing Chemoradiation with MEDI4736 (Durvalumab) in Clinical Stage III, Node Positive Bladder Cancer (INSPIRE).” Drs. T. Mitin and J. Meeks. Activated: 8/25/20.

CTSU/EA8192, “A Phase II/III Trial of MED14736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy” Drs. S. Psutka and A. Tripathi. Activated: 5/6/21.

Closed Studies

S1011, “A Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Pelvic Lymphadenectomy Performed at Time of Radical Cystectomy for Muscle Invasive Urothelial Cancer.” Drs. S. Lerner, A. Alva, and T. Koppie, et al. Activated: 8/1/11; Permanently Closed: 4/15/17.

S1602, “A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG Naïve High-Grade Non-Muscle Invasive Bladder Cancer.” Drs. R. Svatek, A. Alva, and S. Lerner. Activated: 2/7/17; Permanently Closed: 12/15/2020.

S1605, “Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.” Drs. P. Black, P. Singh, and S. Lerner. Activated: 2/7/17; Permanently Closed: 7/5/19.

S2011, “Randomized Phase II Trial of Gemcitabine, Avelumab, and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin Ineligible Muscle-Invasive Urothelial Carcinoma.” Drs. Sonpavde, M. Liss, and S. Lerner, et al. Activated: 10/6/21. Closed to Accrual: 11/15/23.

Renal

Organ Site Chairs: Dr. Ulka Vaishampayan (Advanced) and Dr. Brian Shuch (Local).

Priority Study

S1931, “Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial).” Drs. H. Kim and U. Vaishampayan. Activated: 11/16/20.

Concepts in Development

S2419, “Phase III Double Blinded Trial of Immune-Based Therapy with a Live Biotherapeutic CBM588, or Placebo for Frontline Therapy of Advanced Clear Cell Renal Cell Carcinoma [BioFront Trial].” Drs. P. Barata and U. Vaishampayan. Development and submission to GUSC placed on hold until June (pending dose finding study results from Osel).

Active Studies

S2200, “A Phase II Randomized Trial of Cabozantinib (NSC #761968) with or without Atezolizumab (NSC #783608) in Patients with Advanced Papillary Renal Cell Carcinoma (PAPMET2)” Drs. B. Maughan and S. Pal. Activated 9/19/22.

CTSU/AREN1721, “A Randomized Phase 2 Trial of Axitinib/Nivolumab Combination Therapy vs. Single Agent Nivolumab for the Treatment of TFE/Translocation Renal Cell Carcinoma (tRCC) Across All Age Groups.” Dr. M. Parikh. Activated: 10/9/18; Temporarily Closed: 3/24/21; Re-activated: 2/7/22.

CTSU/A031704, “PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE].” Dr. T. Zhang. Activated: 5/9/19; Step 1 temporarily closed: 3/8/21; Step 1 re-activated: 3/26/21.

CTSU/A031801, “A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients with Advanced Renal Cell Carcinoma with Bone Metastasis (Radical).” Dr. M. Parikh. Activated: 12/13/19.

CTSU/A031901, “Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A randomized Phase 3 non-Inferiority Trial.” Dr. D. Vaena. Activated: 12/10/20.

Closed Studies

S1500, “A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005],

Genitourinary Committee

Savolitinib [NSC #785348], and Sunitinib [NSC #736511] in Metastatic Papillary Renal Carcinoma (PAPMET)." Drs. S. Pal and P. Lara. Activated 4/5/16; Permanently closed: 12/15/19.

S0931, "EVEREST: Everolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study." Drs. C. Ryan, E. Heath, P. Lara, et al. Activated: 4/1/11; Permanently Closed: 9/15/16.

CTSU/E2810, "Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease Following Metastectomy." Dr. S. Pal. Activated: 8/8/12; Permanently closed: 7/25/17.

CTSU/A031501, "Phase III Randomized Adjuvant study of Pembrolizumab in Muscle Invasive and Locally Advanced Urothelial Carcinoma (AMBASSADOR) Versus Observation." Dr. G. Sonpavde. Activated: 9/21/17; Permanently Closed: 8/24/21.

CTSU/EA8143, "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)." Drs. P. Lara and B. Shuch. Activated: 2/2/17; Permanently Closed: 6/9/21.

Prostate

Organ Site Chairs: Dr. Tonya Dorff (Advanced) and Dr. Daniel W. Lin (Local).

Priority Study

S2210, "Targeted neoadjuvant treatment for patients with localized prostate cancer and germline DNA repair deficiency." Dr. H. Cheng. Activated 8/14.

Concepts in Development

S2312, "A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature." Dr. Paul Corn. Will submit protocol and MCF to CTEP by end of February.

Active Studies

S1802, "Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer." Drs. B. Chapin, A. Aparicio, and R. Valicenti. Activated: 9/17/18.

CTSU/A031102, "A Randomized Phase III Trial Comparing Conventional-Dose Chemotherapy Using Paclitaxel, Ifosfamide, and Cisplatin (TIP) with High-Dose Chemotherapy Using Mobilizing Paclitaxel Plus Ifosfamide Followed by High-Dose Carboplatin and Etoposide (TI-CE) as First

Salvage Treatment in Relapsed or Refractory Germ Cell Tumors." Dr. D. Quinn. Activated: 7/1/15.

CTSU/EA8171, "Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer." Dr. M. Liss. Activated: 7/9/18.

CTSU/EA8184, "A Phase II Randomized Double Blinded Study of Green Tea Catechins (GTC) vs. Placebo in Men on Active Surveillance for Prostate Cancer: Modulation of Biological and Clinical Intermediate Biomarkers." Dr. R. Kopp. Activated: 5/10/21.

CTSU/NRG-GU002, "Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy with or Without Adjuvant Docetaxel." Dr. D. Raben. Activated: 12/30/16.

CTSU/NRG-GU008, "Randomized Phase III Trial Incorporating Abiraterone Acetate with Prednisone and Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *Intensifying Treatment for Node Positive Prostate Cancer by Varying the Hormonal Therapy." Dr. D. Lin. Activated: 3/5/20; Temporarily Closed: 6/24/21; Re-activated: 12/1/21.

CTSU/NRG-GU009, "Parallel Phase III Randomized Trials for High Risk Prostate Cancer Evaluating De-Intensification for Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (PREDICT-RT*)." Dr. S. Zhang. Activated: 10/15/20; Temporarily Closed: 6/24/21; Re-activated: 12/15/21.

Closed Studies

S1216, "A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer." Drs. N. Agarwal, A. Goldkorn, S. Gupta, et al. Activated: 3/6/13; Permanently Closed: 7/15/17.

CTSU/NRG-GU005, "Phase III IGRT and SBRT Vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer." Dr. A. Solanki. Activated: 11/16/17; Closed to accrual: 6/8/22.

CTSU/NRG-GU006, "A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or Without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate Cancer." Dr. J. Zeng. Activated: 4/27/18; Permanently Closed: 5/19/20.

CTSU/RTOG-0924, "Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A

Genitourinary Committee

Phase III Randomized Trial. Dr. T. Marshall. Activated: 7/7/11; Permanently Closed: 6/24/19.

CTSU/NRG-GU007, "Randomized Phase II Trial of Niraparib with Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (with Initial Phase I) (NADIR*) *Randomized Phase II Trial of Niraparib With Standard Combination Androgen Deprivation Therapy (ADT) and Radiotherapy In High Risk Prostate Cancer (With Initial Phase I)." Dr. D. VanderWeele. Activated: 6/3/19; Temporarily Closed: 5/5/21; Reactivated of dose level 2 (phase I) for 1 additional patient: 9/14/21; Temporarily closed to accrual for phase I dose level 2: 11/4/21; Re-activated to accrual for phase I/dose level 3: 12/6/21; Temporarily Closed: 7/11/2022.

CTSU/EA8153, "Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHARTED2 Trial." Dr. P. Corn. Activated: 2/8/18; Permanently Closed: 4/2/21; Tobacco use assessment sub-study permanently closed: 10/8/21.

CTSU/AGCT1531, "A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors." Dr. A. D'Souza. Activated: 5/8/17; PRO study Temporarily Closed: 2/12/21.

Translational Medicine

Chair: Dr. David McConkey

Co-Chair: Dr. Joshua Meeks

Bladder Chair: Dr. Joshua Meeks

Prostate Chair: Dr. Amir Goldkorn

Renal Chair: Dr. Sumanta "Monty" Pal

Cancer Control

Liaisons: Drs. Clara Hwang and Sarah Psutka

Active Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes." Drs. J. Hamilton-Reeves and J. Holzbeierlein. Activated: 2/21/19.

S1823, "A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients with Early Stage Germ Cell Tumors", PI: Craig Nichols- Activated 6/1/2020 GU Champions: Thomas Frye & Anishka D'Souza

S1931, (Companion Study): Examining Psychosocial and Emotional Issues for Metastatic Kidney Cancer. PI: Cristiane Bergerot.

S1937, (Companion Study): Assessment of Quality of Life for S1937: A Phase III Randomized Trial of Eribulin with or without Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy. QoL Study Chair: Dr. Afsaneh Barzi. On hold until accrual picks up on S1937.

Diverse Studies of Interest

S1609, "DART: Dual Anti-CTLA-4 and Anti-PD-1 blockade in Rare Tumors." Drs. S. Patel, Y. Chae, R. Kurzrock, et al. Activated: 1/13/17; Permanently Closed: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 13, 14, 15, 16, 17, 18, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 39, 41, 42, 43, 44, 45, 48, 51, 52, and 53; Temporarily Closed: 38, 40, 46, and 51.

CTSU/A031702, "A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)" Dr. S. Liu. Activated: 4/12/19; Temporarily Closed: Cohort A, B, C, E, F, G, I.

CTSU/EAY 131, "Molecular Analysis for Therapy Choice (MATCH)." Dr. V. Villalobos. Activated: 8/12/15; EAY131 (MATCH) Subprotocol Z1C, EAY131-Z1C, is permanently Closed to Accrual: 5/25/21; EAY131 (MATCH) Subprotocol M, or EAY131-M, is suspended, effective immediately: 8/3/21; AY131 Subprotocols A, C1, C2, E, L, V, Z1E, and Z1G are closed to accrual: 1/31/22; Subprotocol ZIG reactivated: 2/23/22

CTSU/EA8134, "InPACT- International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)." Dr. C. Pettaway. Activated: 9/8/17.

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702	A031704
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-	-	3
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	6	-	1	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	7	-	1	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	2	6	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	7	-	-
Cancer Research Consortium of West Michigan NCORP	2	7	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	1	6	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	1	1	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	10	2	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	3	-	2	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	2	4	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	3	4	-	3	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	5	2	-	-	-	-	-	-	-	1
Desert Regional Medical Center	1	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	19	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	1	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	2	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	80	73	1	-	-	1	-	-	-	-
Hawaii Minority Underserved NCORP	-	4	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	8	8	1	-	4	1	-	1	-	-
Henry Ford Hospital	25	4	-	1	-	-	-	-	2	6
Instituto Nacional De Cancerologia	1	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	1	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	18	-	2	-	-	-	-	-	-	60
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	6	-
Loyola University Medical Center	9	6	1	2	-	-	-	-	1	1
Mass Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	6	-	-	1	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	1	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	9	18	-	2	-	1	-	1	-	-
Montana Cancer Consortium NCORP	3	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	10	-	-	-	-	-	-	-	-	1
Nevada Cancer Research Foundation NCORP	1	-	-	-	-	-	-	-	1	-
New Mexico Minority Underserved NCORP	-	-	1	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	1

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1802	S1806	S1931	S1937	S2011	S2200	A031102	A031701	A031702	A031704
Northwestern University LAPS	-	8	1	-	-	-	-	-	-	2
Ohio State University Comprehensive Cancer Center LAPS	2	3	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	1	-	-	-	1	-	-	5	5
SCL Health Saint Joseph Hospital	2	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	8	1	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	3	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	9	-	-	-	-	-	-	1
UC Davis Comprehensive Cancer Center LAPS	12	9	2	3	-	-	-	9	-	3
UC Irvine Health/Chao Family Comprehensive Cancer Center	6	6	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	4	3	-	-	-	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	3	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	5	2	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	5	-	-	3	-	-	12	-	5	-
Univ. of Alabama at Birmingham / Deep South Research Consort LAPS	-	-	3	-	-	-	-	-	1	-
University of Arkansas for Medical Sciences	2	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	6	6	3	-	-	-	-	-	-	5
University of Colorado Cancer Center LAPS	5	6	-	3	1	-	-	-	-	11
University of Kansas Cancer Center - MCA Rural MU NCORP	7	7	-	-	-	-	-	-	1	7
University of Kentucky/Markey Cancer Center	-	3	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	-	17	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	1	-	1	-	-	1	-
University of Oklahoma Health Sciences Center LAPS	29	15	4	-	-	2	-	-	-	-
University of Rochester LAPS	24	-	2	-	-	-	-	-	3	8
University of Texas Health Science Center at San Antonio	9	-	2	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	81	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	19	-	1	-	-	-	-	-	-	-
Upstate Carolina Consort Community Oncology Research Program	3	2	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	6	5	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	1	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	2	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	10	6	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	1	4	-	-	-	-	-	-	-	1
ALLIANCE	103	32	4	1	-	1	-	-	-	-
ECOG-ACRIN	84	41	10	2	1	1	-	-	-	-
NRG	92	132	7	1	-	-	-	-	-	-
Total	751	462	83	23	6	9	12	18	26	116

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A031801	A031803	A031901	A031902	A032001	A032101	A222001	EA8134	EA8171	EA8183
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	1	-	-	-	-	-	-	48	-
Banner MD Anderson Cancer Center	-	-	-	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	1	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	4	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	4	12	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	16	-	-	-	-	-	-	11	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	2	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	2	-	-	-	-	-	1	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-	4
Loyola University Medical Center	-	-	-	-	-	-	-	-	-	-
Mass Veterans Epidemiology Research and Information Center	-	-	-	1	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A031801	A031803	A031901	A031902	A032001	A032101	A222001	EA8134	EA8171	EA8183
Northwestern University LAPS	-	-	-	-	-	1	-	-	-	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	-	-	-	-	-	-	-	12	-
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	-	-	-	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	7	5	-	-	2	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	-	-	-	-	1	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	11	-	-
Univ. of Alabama at Birmingham / Deep South Research Consort LAPS	1	8	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	2	-	1	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	8	-	-	-	-
University of Mississippi Medical Center	-	-	-	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	1	-	-	-	-	-
University of Texas Health Science Center at San Antonio	-	6	-	-	-	-	-	-	13	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	4	-	-	-	-	-	1	-	-	-
Upstate Carolina Consort Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-
Total	13	40	2	5	15	12	2	12	87	4

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Ascension Providence Hospitals - Southfield	-	-	-	-	-	-	-	-	-
Audie L Murphy VA Hospital	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	9	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-
Baylor College of Medicine/Duncan Comprehensive Cancer Center	-	-	-	3	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Desert Regional Medical Center	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	17	-	1	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-	-	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	1	-	-	42	1	4	14	6	2
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	-	-	-	-	-	-	-	-
Mass Veterans Epidemiology Research and Information Center	-	-	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	1	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	1	-	-	-	3	6	2	-

Genitourinary Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	EA8185	EA8191	EA8192	EA8212	NRGGU002	NRGGU008	NRGGU009	NRGGU010	NRGGU011
Northwestern University LAPS	-	-	-	-	-	-	-	4	-
Ohio State University Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	6	-	3	-	-	-	-	2
SCL Health Saint Joseph Hospital	-	-	-	-	-	-	-	3	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	-	-	-	-	-	-	1	3	-
Tulane University School of Medicine	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-	-	-	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	-	-	-	2	-	-	-
UC San Diego Moores Cancer Center	-	-	-	1	-	-	-	-	-
UCLA / Jonsson Comprehensive Cancer Center	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	3	-	-	-	-	-
Univ. of Alabama at Birmingham / Deep South Research Consort LAPS	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	-	2	-	1	-	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	1	3	1	-
University of Kentucky/Markey Cancer Center	-	-	-	1	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	-	-	-	-	-	-	-	1	-
University of Mississippi Medical Center	-	-	-	-	1	-	1	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	4	-
University of Texas Health Science Center at San Antonio	-	2	-	-	-	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	-	-	-	-	-	-	-
Upstate Carolina Consort Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Vanderbilt University - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-
Virginia Mason Medical Center	-	-	-	-	-	-	4	2	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	1	-	-	-	-
Western States Cancer Research NCORP	-	-	-	-	-	-	1	1	-
Wisconsin NCI Community Oncology Research Program	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	-	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-
Total	1	27	2	64	4	10	35	27	4

Immunotherapeutics Committee

Leadership

Co-Chairs:Siwen Hu-Lieskovan, MD, PhD
 Katerina Politi, PhD
 Executive Officer: Anne Chi-An Chiang, MD, PhD
 Statisticians: Michael LeBlanc, PhD
 Katie Minichiello, MS
 James Moon, MS
 Data Coordinator:..... Matt Gospe
 Pharmaceutical Science: Jordan P. McPherson, PharmD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Chris Kippola
 Clinical Trial Program Manager: Laura Gildner, MS

Time/Location

Thursday, April 4, 2024 1:00 p.m. - 3:00 p.m.
 Room: Chiliwack / 402 (Level 4)

Agenda

1:00 – 1:20 pm Developing Predictors of Immunotherapy using Big Data
 Eytan Ruppin, MD, PhD
 Senior Investigator, National Cancer Institute
 Chief, Cancer Data Science Laboratory

1:20 – 1:30 pm Q & A

1:30 – 1:40 pm S2101 iMATCH Pilot – Trial Update
 Paul Swiecicki, Katerina Politi, Siwen Hu-Lieskovan

1:40 – 1:45 pm Q & A

1:45 – 1:55 pm S2013 I-CHECKIT – Trial Update
 Krishna Soujanya Gunturu, MD
 Associate Chief, Clinical Trials & Correlative Science
 Research, Hartford HealthCare Cancer Institute

1:55 – 2:00 pm Q & A

2:00 – 2:10 pm A151804: Establishment of a National Biorepository to
 Advance Studies of Immune-Related Adverse Events –
 Trial Update
 David E. Kozono, MD, PhD
 A151804 Study Chair
 Assistant Professor of Radiation Oncology, Harvard
 Medical School
 Director, Thoracic Radiation Oncology

2:10 – 2:15 pm Q & A

2:15 – 2:25 pm SITC's Resistance Data Collection Effort, led by SITC's
 Immunotherapy Resistance Committee
 Harriet Kluger, MD
 Harvey and Kate Cushing Professor of Oncology and of
 Dermatology
 Director, Yale SPORE in Skin Cancer, Yale Cancer Center

Ryan Sullivan, MD
 Associate Professor of Medicine, Harvard Medical School
 Physician Investigator (CI), Cancer Center, Mass General
 Research Institute

Hussein Tawbi, MD, PhD
 Deputy Chair, Department of Melanoma Medical
 Oncology
 Co-Director, MD Anderson Brain Metastasis Clinic

2:25 – 2:30 pm Q & A

2:30 – 2:50 pm Genomic and Immunophenotypic Landscape of
 Acquired Resistance to PD-(L)1 Blockade in Non-Small-
 Cell Lung Cancer
 Mark Awad, MD, PhD
 Assistant Professor of Medicine, Harvard Medical School
 Director, Lowe Center for Thoracic Oncology, Dana-Farber
 Cancer Institute

2:50 – 2:55 pm Q & A

2:55 – 3:00 pm Closing Remarks

Active Study

S2101, "Biomarker Stratified Cabozantinib (NSC#761968) and Nivolumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Participants with Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study." Drs. Hu-Lieskovan, Swiecicki and Politi. Activation: 10/14/22.

Immunotherapeutics Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

<i>Essentia Health NCI Community Oncology Research Program</i>	1
<i>Heartland Cancer Research NCORP</i>	1
<i>New Mexico Minority Underserved NCORP</i>	1
<i>Northwestern University LAPS</i>	1
<i>Pacific Cancer Research Consortium NCORP</i>	1
<i>University of Michigan Comprehensive Cancer Center LAPS</i>	9
<i>University of Utah - Huntsman Cancer Institute LAPS</i>	5
ALLIANCE	4
ECOG-ACRIN	3
NRG	1
Total	27

S2101

Leukemia Committee

Leadership

Chair: Harry P. Erba, MD, PhD
 Vice-Chair: Anjali S. Advani, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Megan Othus, PhD
 Anna Moseley, MS

Scientific Leadership

Translational Medicine: Jerald P. Radich, MD
 Pathology: David R. Head, MD
 Cytogenetics Liaison: Min Fang, MD, PhD

Designates

Cancer Control: Stephanie B. Tsai, MD
 Veterans Affairs: Tsewang Tashi, MD
 Data Coordinators: Louise Highleyman, BA
 Matt Gospe, BS
 Oncology Research Professionals:
 CRA: Heather A. Thulean, BS
 Nurse: Natalie C. Sikes, MSN, RN
 Patient Advocate: Gail Sperling, MPH
 Pharmaceutical Science: Holly O. Chan, PharmD
 Ila M. Saunders, PharmD
 Sr. Protocol Project Manager: Sharon Palmer
 Sr. Protocol Project Manager - MyeloMATCH: Sarah Cantu
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Thursday, April 4, 2024 8:00 a.m. - 10:00 a.m.
 Room: Virtual Only

Agenda

1. Myelomatch—Harry Erba, Jerry Radich (60 minutes)
2. Update on Recent CML Trial and Where Should We Go
Kendra Sweet (30 minutes)
3. Updates in ALL Including Upcoming CTP Trial
Kristen O'Dwyer (30 minutes)

AML/MDS Studies

Active Studies

CTSU/A041701, "A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy." Dr. L. Liesveld. Activated: 1/16/19. Temporarily closed to accrual 11/19/2021

Closed Studies

S1612, "A Randomized Phase II/III Trial of "Novel Therapeutics" Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older." Drs. L. Michaelis, R. Walter, S. Assouline, et al. Activated: 12/22/17; Closed: 9/3/20.

S0919, "A Phase II Study of Idarubicin and Ara-C in Combination with Pravastatin for Poor-Risk Acute Myelogenous Leukemia (AML)." Dr. A. Advani. Re-Activated: 4/1/13; Closed: 9/15/17; Complete: 10/21/21.

S1203, "A Randomized Phase III Study of Standard Cytarabine Plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)." Drs. Garcia-Manero and Pagel. Activated: 12/15/12; Closed: 11/4/15; Complete: 03/29/22.

ALL Studies

Active Studies

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) / T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. A. Advani, N. Papadantonakis, and C. Yeung. Activated: 8/17/20.

CTSU/A041501, "A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL." Dr. A. Advani. Activated: 6/1/17. Temporarily closed to accrual: 05/24/22.

Developing Studies

S2306, "A Randomized Phase 2 Trial to Evaluate the Efficacy of Bcl-2 Inhibitor Therapy with Chemotherapy Compared to Chemotherapy Alone in Adult Patients with Newly Diagnosed T-Cell ALL and T-Cell Lymphoblastic Lymphoma." Drs. K. O'Dwyer, I. Aldoss, A. Advani, and W. Stock.

S2307, "A Phase 1B Study Assessing the Safety and Activity of SNDX-5613 (revumenib) in Combination with Age-Modified Chemotherapy in Newly Diagnosed patients with KMT2Ar acute lymphoblastic leukemia (ALL) or acute leukemia with ambiguous lineage (ALAL)." Drs. I. Aldoss, A. Advani, W. Stock, and C. Saygin.

Leukemia Committee

Closed Studies

S0333, “A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia with Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy.” Drs. Forman and O’Donnell. Activated: 4/15/05; Closed: 11/01/09.

S1312, “A Phase I Study of Inotuzumab Ozogamicin in Combination with CVP (Cyclophosphamide, Vincristine, Prednisone) for Patients with Relapsed/Refractory CD22-Positive Acute Leukemia (Including B-ALL, Mixed Phenotypic Leukemia, and Burkitt’s Leukemia).” Drs. A. Advani and Liedtke. Activated: 4/1/14; Closed: 8/2/19.

S1318, “A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphocytic Leukemia (ALL) and of Dasatinib, Prednisone and Blinatumomab for Patients ≥ 65 Years of Age with Newly Diagnosed Philadelphia-Chromosome Positive (Ph+) ALL and Philadelphia-Chromosome-Like Signature (Ph-like) ALL (Newly Diagnosed or Relapsed/Refractory) with Known or Presumed Activating Dasatinib-Sensitive Mutations or Kinase Fusions (DSMKF).” Drs. A. Advani and K. O’Dwyer. Activated: 1/12/15; Closed: 4/15/21.

CLL Studies

Active Studies

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL): EVOLVE CLL/SLL Study.” Drs. D. Stephens, B. Hill, J. Pagel, et al. Activated: 12/14/20.

Developing Studies

S2421, “A Randomized Phase II Study of Pirtobrutinib Plus R-CHOP vs. R-CHOP for Patients with Previously Untreated Richter Transformation (RT).” Drs. M. Shadman, D. Stephens, and A. Danilov.

Closed Studies

CTSU/EA9161, “A Randomized Phase III Study of the Addition of Venetoclax to Ibrutinib and Obinutuzumab Versus Ibrutinib and Obinutuzumab in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL).” Dr. M. Shadman. Activated: 1/3/19. Closed: 4/30/21.

CTSU/A041702, “A Randomized Phase III Study of Ibrutinib Plus

Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL).” Dr. B. Hill. Activation: 1/4/19. Closed: 01/04/19.

CML Studies

Closed Studies

S1712, “A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease.” Drs. K. Sweet and J. Radich. Activated: 7/20/18. Closed: 10/20/22.

MyeloMATCH

Proposed Studies

MYELOMATCH, “Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials.” Drs. J. Radich and S. Jiwani.

MM1YA-S01, “A Randomized Phase II Study Comparing Cytarabine + Daunorubicin (7+3) vs. (Daunorubicin and Cytarabine) Liposome, Cytarabine + Daunorubicin + Venetoclax, Azacitidine + Venetoclax, and (Daunorubicin and Cytarabine) Liposome + Venetoclax in Patients Aged 59 or Younger who are Considered High-Risk (Adverse) Acute Myeloid Leukemia as Determined by myeloMATCH; A myeloMATCH Clinical Trial.” Drs. P. Shami and T. Lin.

MM10A-S02, “A Phase II Study of Targeted Agents with the Oral DNMT1 Inhibitor C-DEC (ASTX727) for the Treatment of TP53-Mutated Acute Myeloid Leukemia: A myeloMATCH treatment trial.” Drs. R. Shallis, D. Sallman, and A. Zeidan.

MM10A-S03, “A Randomized Phase II trial of C-DEC, Venetoclax, and Enasidenib Compared with Azacitidine and Venetoclax for Newly Diagnosed Older Adults with IDH2 mutant AML: A myeloMATCH Treatment Trial.” Drs. U. Borate and E. Huseilton.

Leukemia Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1712	S1905	S1925	A041501	A041701	A041702	A041703	A042001	EA9152	EA9171	EA9181	EA9213
Banner University Medical Center - Tucson	-	-	-	-	-	5	-	-	-	-	-	-
Baptist Mem Health Care/Mid South MU-NCORP	1	-	-	-	-	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	1	6	4	-	5	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	1	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	3	1	-	-	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	1	-	-	-	-	-	-
Duke University - Duke Cancer Institute LAPS	3	-	1	-	-	-	-	-	-	-	1	-
Fred Hutchinson Cancer Research Center LAPS	1	4	1	-	-	-	-	-	-	-	-	3
Hawaii Minority Underserved NCORP	6	-	-	-	-	-	-	-	-	-	3	-
Heartland Cancer Research NCORP	5	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	-	2	-	4	3	-	-	-	-	-	-
Intermountain Medical Center	-	-	-	2	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	-	-	-	-	8	-	-	-	-	-	-
Lahey Hospital and Medical Center	-	-	-	-	-	1	-	-	-	-	-	-
Loyola University Medical Center	1	-	1	-	-	1	-	-	-	-	1	-
Medical U of S Carolina Minority Underserved NCORP	-	-	3	-	-	1	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	1	-	5	-	-	1	-	-	-	-	-	-
Moffitt Cancer Center	16	-	-	-	-	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	1	-	-	-	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	2	-	-	-	-	3	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	3	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	2	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	3	1	2	-	1	-	-	4	-
Oregon Health and Science University	3	1	-	8	-	5	-	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	-	-	1	-	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	1	-	-	-	-	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	8	-	11	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	2	2	-	-	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-	1	3	-	-	1	-	-	-	9	-
UC San Diego Moores Cancer Center	-	-	-	-	-	-	-	-	-	-	1	-
U of Alabama at Birm/Deep South Res Consort LAPS	-	-	-	1	-	-	-	1	-	-	-	-
University of Arkansas for Medical Sciences	-	-	-	-	4	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	2	-	-	-	-	1	-	-	-	1	-
University of Colorado Cancer Center LAPS	-	-	-	-	-	1	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	6	-	-	-	-	-	-
University of Rochester LAPS	7	1	7	7	27	1	3	-	-	-	6	-
University of Utah - Huntsman Cancer Institute LAPS	7	-	15	1	-	5	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	-	-	-	-	-	-	-	-	3	-
Western States Cancer Research NCORP	-	-	-	-	-	2	-	-	-	1	-	-
Yale University - Yale Cancer Center LAPS	-	-	-	5	-	3	-	-	2	2	1	-
ALLIANCE	13	2	17	-	-	-	-	-	-	-	-	-
CCTG	-	-	6	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	7	-	11	-	-	-	-	-	-	-	-	-
NRG	2	-	3	-	-	-	-	-	-	-	-	-
Total	81	14	85	44	38	65	5	2	2	3	30	3

Lung Committee

Leadership

Chair: Jhanelle E. Gray, MD
 Vice-Chair: Roy S. Herbst, MD, PhD
 Executive Officer: Anne Chiang, MD, PhD
 Statisticians: Mary Redman, PhD
 Michael Wu, PhD
 Yingqi Zhao, PhD
 Kari Chansky, MS
 Mia Hsieh, MS
 Katie Minichiello, MS
 Jieling Miao, MS
 James Moon, MS

Scientific Leadership

Translational Medicine:
 Biology/Pathology: Philip C. Mack, PhD
 Fred R. Hirsch, MD, PhD
 Ignacio I. Wistuba MD
 Imaging: Chadwick L. Wright MD, PhD
 Myrna C. Godoy, MD, PhD
 Radiation Oncology: Henry Park, MD
 Surgery: Wayne L. Hofstetter, MD
 Subcommittee Chairs:
 Early Stage Disease: Wayne L. Hofstetter, MD
 Raymond Osarogiagbon, MD
 Locally Advanced Disease: Shirish Gadgeel, MD (Early Therapeutics)
 Metastatic Disease: Ross Camidge, MD
 Karen Reckamp, MD
 Community Engagement: Paul J. Hesketh, MD
 Suzanne Cole, MD

Designates

Cancer Control Liaison: Gary E. Goodman, MD
 DEI Champion: Lucy Gansauer, MSN, RN, OCN, CCRP
 Veterans Affairs: Chao H. Huang, MD
 Cheryl M. Czerlanis, MD
 Data Coordinators: Amy Johnson, CCRP
 Kevin Moralda, BS
 Larry Kaye
 Louise Highleyman, BA
 Pasarlai Ahmadzai, MD, MPH
 Clinical Research Project Manager: TBD
 Oncology Research Professionals:
 CRA: TBD
 Nurses: Rosalie Zablocki, RN
 Lisa G. Davis, RN

Patient Advocate: Judy Johnson, MBA
 Pharmaceutical Science: Joyce Lee, PharmD
 Safae Ghouraichi, PharmD
 Protocol Project Managers: Justine Trevino
 Jennifer Beeler (Lung-MAP)
 Clinical Trials Program Manager: Mariah Norman, MS

Time/Location

Friday, April 5, 2024 8:30 a.m. - 11:30 a.m.
 Room: Quinault (Level 5)

Agenda

8:30 - 8:35 am **General Update:** Jhanelle E. Gray, MD

8:35 - 8:40 am **Patient Advocate Update:** Judy Johnson, MBA

8:40 - 8:45 am **Thoracic Surgery Session:** Eric Toloza, MD, PhD

8:45 - 8:50 am **Thoracic Radiation Session:** Megan Daly, MD

8:50 - 8:55 am **Translational Medicine Session:** Philip C. Mack, PhD

8:55 - 9:00 am **Community Engagement Core:** Paul J. Hesketh, MD

9:00 - 9:05 am **DEI Session:** Lucy Gansauer, MSN, RN

9:05 - 9:13 am **Encore Presentation of the ASCO S1929 Trial -**
 Nagla Abdul Karim, MD, PhD, Professor of Medicine, University of
 Virginia, and Director of Phase I Trials, Inova Schar Cancer Center

9:13 - 9:21 am **Evolution of Biomarkers for SCLC and New Study**
Concept - Triparna Sen, PhD, Associate Professor of Oncological
 Sciences, and Co-Director, Lung Cancer PDX Program, Icahn School of
 Medicine at Mount Sinai

9:21 - 9:26 am **S2409 PRISM Trial -** Anne Chiang, MD, Associate
 Professor of Medicine and Associate Cancer Center Director, Clinical
 Initiatives, Yale School of Medicine

9:26 - 9:46 am **Small Cell Lung Cancer: New Frontiers Panel Q&A**

Moderator: Jhanelle E. Gray, MD

Panelists: Nagla Abdul Karim, MD, PhD
 Sonam Puri, MD
 Triparna Sen, PhD
 Anne Chiang, MD
 Shakun Malik, MD
 David MacPherson, PhD

Lung Committee

9:46 - 10:18 am Thoracic Medical Oncology: Jhanelle Gray, MD

S2302, "Project Pragmatica-Lung Trial." Dr. Karen Reckamp. Activated: 3/6/23; Accrual Goal: 700; Accrual: 345

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung- Map Screening Study)." Drs. Karen Reckamp and David Gandara (SWOG). Activated: 1/28/19; Accrual Goal: 6000; Accrual: 3303.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN LUNG-MAP SUB- STUDY)." Dr. Karen Reckamp (SWOG), Dr. Suki Padda and Dr. David Gerber (ECOG). Activated: 4/2/21; Accrual Goal: 116; Accrual: 228.

S1900G, "A Randomized Phase II Study of Capmatinib plus Osimertinib (Tagrisso) with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung- MAP Sub-Study)". Dr. Sarah Goldberg and Dr. Ross Camidge (SWOG). Activated: 4/3/23; Accrual Goal: 66 (60 eligible); Accrual: 16.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small- Cell Lung Cancer (MAVERICK)." Dr. Chad Rusthoven (SWOG). Activated: 1/10/20; Accrual Goal: 668; Accrual: 202.

S1933, "A Pilot Trial of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Dr. Raid Aljumaily (SWOG). Activated: 6/15/20; Accrual Goal: 47; Accrual: 35.

S1914, "A Randomized Phase III trial of Induction/Consolidation Atezolizumab +SBRT versus SBRT Alone in High risk, Early Stage NSCLC." Dr. Megan Daly (SWOG). Activated: 3/25/20; Accrual Goal: 480; Accrual: 322.

EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Post-progression in Advanced Nonsquamous Non- Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Anne Chiang (SWOG). Activated: 2/28/19; Accrual Goal: 600; Accrual: 558 total: 83.

10:18 - 11:30 am Open Discussion

Active Studies

LUNGMAP, "A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)." Drs. Borghaei, Reckamp, Gandara, et al. Activation: 1/28/19.

S1900E, "A Phase II Study of Sotorasib (AMG 510) in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study)." Drs. Padda and Gerber. Activation: 4/2/21.

S1900G, "A Randomized Phase II Study of INC280 (capmatinib) plus Osimertinib with or without Ramucirumab in Participants with EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Goldberg and Camidge. Activation: 4/3/23.

S1900K, "A Randomized Phase II Study of Tepotinib with or without Ramucirumab in Participants with MET Exon 14 Skipping Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Paik and Le. Activation: 12/18/23.

S1701, "A Randomized Phase II Trial of Carboplatin-Paclitaxel with or without Ramucirumab in Patients with Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma." Drs. Tsao and Koczywas. Activation: 8/9/18.

S1827, "MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)." Drs. Rusthoven, Brown, Wefel, et al. Activation: 1/10/20.

S1914, "A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT versus SBRT Alone in High Risk, Early Stage NSCLC." Drs. Daly, Simone, Kelly, et al. Activation: 3/25/20.

S1933, "A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status." Drs. Aljumaily, Mitin, and Wozniak. Activation: 6/15/20.

S2302, "PROJECT PRAGMATICA: A Prospective Randomized Study of Ramucirumab (NSC 749128) Plus Pembrolizumab (MK-3475; NSC 776864) Versus Standard of Care for Participants Previously Treated With Immunotherapy for Stage IV or Recurrent Non-small Cell Lung Cancer in Standard Practice." Drs. Reckamp and Dragnev. Activation: 3/6/23.

Lung Committee

CTSU/EA5163/S1709, "INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis." Dr. Chiang. Activation: 2/28/19.

CTSU/A081801, "Integration of Immunotherapy into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)." Dr. Gray. Activation: 6/3/20.

CTSU/A151216, "Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)." Dr. Gandara. Activation: 8/18/14.

CTSU/E4512, "A Randomized Phase III Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Observation for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein." Dr. Li. Activation: 8/18/14.

CTSU/EA5181, "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC." Dr. Harkenrider. Activation: 4/9/20.

CTSU/EA5182, "Randomized Phase III Study of Combination AZD9291 (Osimertinib) and Bevacizumab Versus AZD9291 (Osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)." Dr. Goldberg. Activated:10/22/20.

CTSU/EA5191, "A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC." Dr. Massarelli. Activated: 5/22/20.

CTSU/NRG-LU002, "Maintenance Systemic Therapy versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial." Dr. Gomez. Activation: 4/7/17; Temporary closure: 11/12/21.

CTSU/NRG-LU005, "Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab." Dr. Hsu. Activation: 5/28/19; Closed to US and Canadian sites 6/23/22.

CTSU/NRG-LU007, "Randomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR Trial." Dr. Park. Activated: 8/17/20.

Closed Studies

CTSU/NRG-CC003, "Randomized Phase II/III Trial of Prophylactic Cranial

Irradiation with or without Hippocampal Avoidance for Small Cell Lung Cancer." Dr. Gaspar. Activation: 12/7/15; Temporary closure: 5/28/20; Reactivation: 7/27/20; Permanent closure: 6/21/22.

S1800A, "A Phase II Randomized Study of Ramucirumab Plus Pembrolizumab (MK-3475) Versus Standard of Care for Patients Previously Treated with Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Reckamp and Dragnev. Activation: 5/17/19. Permanently closed: 10/20/20.

S1800D, "A Phase II/III Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L1 Therapy (Lung-MAP Non-Match Sub-Study)." Drs. Wrangle and Husain. Activation: 2/15/22. Permanently closed: 3/10/23.

S1900A, "A Phase II Study of Rucaparib in Patients with Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Riess and Wheatley-Price. Activation: 1/28/19. Permanently closed: 2/2/21.

S1900B, "A Phase II Study of Selpercatinib (LOXO-292) in Patients with RET Fusion-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study)." Drs. Elamin and Gray. Activation: 2/10/20. Permanently closed: 5/1/21.

S1900C, "A Phase II Study of Talazoparib Plus Avelumab in Patients with Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)." Drs. Skoulidis and Suga. Activation: 1/16/20. Permanently closed: 12/18/20.

S1900E, "A Randomized Phase II Study of Carboplatin and Pemetrexed with or Without Selpercatinib (LY3527723) in Participants with Non-Squamous RET Fusion-Positive Stage IV Non-Small Cell Lung Cancer and Progression of Disease on Prior RET Directed Therapy (Lung-MAP Sub-Study)." Drs. Gray and Elamin. Activation: 7/25/22. Permanently closed: 6/27/23.

S1929, "Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination with Talazoparib in Patients with SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Karim, Reckamp, Gay, et al. Activation: 6/15/20; Step 1 Registration Permanently Closed 8/15/22; Step 2 Permanently Closed 10/15/22.

S1934, "NASSIST (Neoadjuvant Chemoradiation +/- Immunotherapy Before Surgery for Superior Sulcus Tumors): A Randomized Phase II Trial of

Lung Committee

Trimodality +/- Atezolizumab in Resectable Superior Sulcus Non-Small Cell Lung Cancer." Drs. Osarogiagbon, Huang, Decker, et al. Activation: 9/9/21; Temporary closure: 11/5/21; Reactivation: 2/15/22; Permanently closed 3/1/23.

NCI-Approved Concepts

S1900J, "A Phase II Study of Amivantamab-vmjw in Participants with MET Amplification-Positive Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Rolfo and Gadgeel.

S1800E, "A Randomized Phase II/III Study of Docetaxel and Ramucirumab with or without Cemiplimab for Participants Previously Treated with Platinum-based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)." Drs. Waqar and Li.

S2313, "Neoadjuvant chemo-durvalumab for clinical stage I, 2-3.9cm, non-small cell lung cancer: a randomized controlled trial." Drs. Gibney and Wrangle.

S2404, "Accelerating Drug Efficacy Evaluation thru Growth Rate and Overall Survival Correlations" Dr. Lawrence Schwartz and Dr. Karen Reckamp.

Concepts in Development

S1900M, "A Randomized Phase II Study of Trastuzumab Deruxtecan (T-DXd) in Participants with HER2 Wild-Type, HER2 (ERBB2) Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Sub-Study)." Drs. Saltos and Doroshov.

S2409, "PRISM: A Multicohort PREcision SCLC Subtype Maintenance Phase II Trial of Durvalumab Versus Biomarker-Directed Novel Agents in Combination with Durvalumab in Extensive Stage Small Cell Lung Cancer (ES-SCLC)." Drs. Chiang and Chiappori.

S2410, "A randomized phase II study of a PDL1 inhibitor and iadademstat (ORY-1001) versus investigator's choice of standard of care for second line treatment of extensive stage small cell lung cancer (SCLC)." Drs. Santana-Davila and Puri.

S2414, "Incorporating Pathologic Response in Patients with Early Stage Lung Cancer to Optimize Immunotherapy in the Adjuvant Setting (INSIGHT)." Drs. Cetnar and Osarogiagbon.

Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929	S1933	S2302	A081801
Ascension Providence Hospitals - Southfield	13	-	-	-	-	-	-	3	-	-	-
Ascension Via Christi Hospitals Wichita	1	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	-	-	1	-	-	-	-	-	-	1
Banner University Medical Center - Tucson	-	-	-	-	-	-	-	-	-	2	-
Baptist Mem Health Care/Mid South MU-NCORP	35	-	-	2	1	-	7	2	-	7	4
Baylor College of Medicine/Duncan CCC	-	-	-	2	-	-	-	-	-	-	-
Boston Medical Center	-	-	-	5	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	11	-	-	-	2	-	-	-	-	2	10
Ca Res Consort of W Mich NCORPP	3	-	-	-	-	-	4	-	-	1	-
Cancer Research for the Ozarks NCORP	34	-	3	-	-	-	4	2	3	3	-
Ca Res of Wisconsin and N Mich Consort	27	-	2	-	4	-	4	-	-	-	-
Carle Cancer Center NCORP	3	1	-	1	1	-	6	-	-	4	-
Cedars-Sinai Medical Center	17	-	-	-	1	-	1	-	-	6	-
City of Hope Comprehensive Cancer Center	5	1	-	1	-	-	-	-	-	2	-
Columbia U MU NCORP	11	-	-	-	-	-	-	-	-	2	-
Columbus NCORP	28	-	-	4	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	39	-	-	-	-	-	1	1	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-	-	-	-	-	-	-	-	-	-
Dayton NCORP	2	-	-	-	-	-	-	2	-	-	1
Essentia Hlth NCORP	16	-	2	-	-	-	3	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	4	-	-	-	-	-	-	-	-	-	-
Froedtert & the Med College of Wisconsin LAPS	2	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	6	-	-	1	-	-	2	3	1	-	-
Georgia NCORP	59	-	4	3	1	-	7	-	-	6	-
Gulf South Minority Underserved NCORP	22	-	1	1	-	-	3	1	-	4	1
Hawaii Minority Underserved NCORP	27	-	-	1	-	-	-	-	-	1	-
Heartland Cancer Research NCORP	145	-	9	5	5	-	32	19	4	26	-
Henry Ford Hospital	7	-	-	-	-	-	-	1	-	-	2
Houston Methodist Hospital	-	-	-	-	-	-	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	2	-	-	-	-	-	-	-
Kaiser Permanente NCORP	86	-	6	-	8	-	2	-	-	13	3
Lahey Hospital and Medical Center	32	-	-	-	-	-	4	1	2	9	-
Loma Linda University Medical Center	6	-	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	23	-	1	-	-	-	-	2	-	2	-
Massachusetts Veterans ERIC	62	-	3	3	1	-	-	-	-	2	10
Med U South Carolina MU NCORP	17	-	1	-	1	1	-	-	-	6	-
Mercy Medical Center - Des Moines	8	-	-	-	-	-	-	1	-	-	-
Michigan Cancer Research Consortium NCORP	107	-	4	2	7	1	9	3	-	7	-
Mission Hospital	1	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	16	2	1	1	1	1	-	-	-	17	17
Montana Cancer Consortium NCORP	25	-	-	-	1	-	-	3	1	-	-
Mount Sinai Hospital	-	-	-	-	-	-	9	1	-	1	-
NCORP of the Carolinas (Prisma Health NCORP)	19	-	-	-	1	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	LUNGMAP	S1701	S1800D	S1827	S1900E	S1900G	S1914	S1929	S1933	S2302	A081801
National Cancer Center-Korea	-	-	-	1	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	14	-	-	-	-	-	-	1	-	-	-
New Mexico Minority Underserved NCORP	83	-	-	1	2	-	6	5	1	1	-
Northwell Health NCORP	-	-	-	-	-	-	-	-	-	-	1
Northwestern University LAPS	26	1	2	1	-	-	-	4	-	8	-
Oregon Health and Science University	9	-	1	-	-	-	1	-	-	-	7
Pacific Cancer Research Consortium NCORP	17	-	-	-	-	-	-	3	-	-	-
SCL Health Saint Joseph Hospital	1	-	-	-	-	-	1	-	-	-	1
Salem Hospital	4	-	-	-	1	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	51	-	1	7	1	-	9	8	-	1	-
Sutter Cancer Research Consortium	29	-	-	-	1	-	-	-	-	-	-
The Don and Sybil Harrington Cancer Center	11	-	2	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	-	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	37	3	6	1	-	1	11	2	-	5	-
UC Irvine Hlth/Chao Family CCC	26	-	-	1	-	-	4	-	-	1	-
UC San Diego Moores Cancer Center	14	-	-	-	1	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	66	-	5	8	6	-	-	3	3	9	-
USC Norris Comprehensive Cancer Center LAPS	-	-	-	5	-	-	5	-	-	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	-	-	8	-
University of Arkansas for Medical Sciences	11	-	1	-	-	-	11	-	-	2	-
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	-	-	-	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	13	-	-	4	-	-	4	2	-	2	2
U Kansas CC - MCA Rural MU NCORP	93	-	1	1	1	-	-	-	-	1	1
University of Kentucky/Markey Cancer Center	50	-	-	1	-	-	-	-	-	3	-
U Michigan Comprehensive Cancer Center LAPS	1	-	-	-	-	-	-	-	-	2	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	33	-	-	1	-	-	3	2	11	2	-
University of Rochester LAPS	65	-	2	-	6	-	3	-	-	8	-
U Texas HSC at San Antonio	-	-	-	-	-	-	-	1	-	6	-
U Texas MD Anderson CC LAPS	3	6	-	3	-	-	1	4	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	3	-	-	3	1	-	1	-
Upstate Carolina NCORP	38	-	-	-	-	-	2	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	1	-
Wayne State U - Karmanos Ca Inst LAPS	1	-	-	-	-	-	-	-	-	-	-
Western States Cancer Research NCORP	2	-	-	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	-	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	40	-	-	1	1	-	9	-	-	2	-
Yale University - Yale Cancer Center LAPS	25	-	-	4	3	1	8	-	-	10	6
ALLIANCE	790	3	15	16	21	2	30	9	5	31	-
CCTG	-	-	-	23	-	-	-	-	-	-	-
ECOG-ACRIN	349	3	5	7	18	-	23	10	-	15	-
NRG	427	1	4	61	12	1	68	6	1	15	-
Total	3,249	21	82	185	109	8	300	106	32	257	67

Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	A171901	E4512	EA5162	EA5163	EA5181	EA5182	EA5191	NRGLU002	NRGLU005
Ascension Providence Hospitals - Southfield	-	15	-	1	1	2	3	-	1	-	-
Ascension Via Christi Hospitals Wichita	-	-	-	-	-	-	-	-	-	-	-
Banner MD Anderson Cancer Center	-	1	-	-	-	-	-	-	-	-	2
Banner University Medical Center - Tucson	-	7	-	2	-	-	10	-	-	-	1
Baptist Mem Health Care/Mid South MU-NCORP	-	26	-	-	-	1	1	2	-	1	4
Baylor College of Medicine/Duncan CCC	-	-	-	-	-	-	-	-	-	-	-
Boston Medical Center	-	3	-	-	-	-	2	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	54	-	-	-	17	21	1	4	-	-
Ca Res Consort of W Mich NCORPP	-	1	-	-	-	-	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	1	-	-	-	-	-	-	-	-	-
Ca Res of Wisconsin and N Mich Consort	-	-	-	-	-	-	-	-	-	-	-
Carle Cancer Center NCORP	-	-	-	-	-	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	-	-	-	-	-	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	5	-	-	-	-	-	-	-	-	-
Columbia U MU NCORP	-	-	-	-	-	-	1	-	-	-	-
Columbus NCORP	-	-	-	-	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	2	-	-	-	-	-	-	-	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	3	-	-	-	-	-	-	-	-	-
Dayton NCORP	-	8	-	-	-	-	-	-	-	-	-
Essentia Hlth NCORP	-	-	-	-	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	15	-	-	-	-	4	-	-	-	-
Froedtert & the Med College of Wisconsin LAPS	-	-	-	-	-	-	-	-	-	-	-
Georgia Cares Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Georgia NCORP	-	9	-	-	-	1	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	1	-	-	-	3	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-	-	-	1	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-	-	-	-	-	-	-	-
Henry Ford Hospital	-	29	-	-	-	-	-	-	-	-	-
Houston Methodist Hospital	-	8	-	-	-	1	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	-	-	-	-	-	-	-	-	-	-	-
Kaiser Permanente NCORP	-	203	-	5	-	8	-	4	-	-	-
Lahey Hospital and Medical Center	-	30	-	-	-	2	-	-	-	-	-
Loma Linda University Medical Center	-	10	-	-	-	-	-	-	-	-	-
Loyola University Medical Center	-	24	-	-	-	2	2	-	-	-	-
Massachusetts Veterans ERIC	-	31	-	-	-	3	-	-	2	-	-
Med U South Carolina MU NCORP	-	-	-	-	-	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	-	-	-	-	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mission Hospital	-	-	-	-	-	-	-	-	-	-	-
Moffitt Cancer Center	-	83	-	1	-	5	-	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-	-	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	1	1	-	-	1
NCORP of the Carolinas (Prisma Health NCORP)	-	1	-	-	-	-	-	-	-	-	-

Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	A082002	A151216	A171901	E4512	E45162	E45163	E45181	E45182	E45191	NRGLU002	NRGLU005
National Cancer Center-Korea	-	-	-	-	-	-	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	1	-	-	-	-	-	-	-	-
New Mexico Minority Underserved NCORP	-	-	-	-	-	-	-	-	-	-	-
Northwell Health NCORP	-	3	-	-	-	-	-	-	-	-	-
Northwestern University LAPS	-	-	-	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	23	-	-	-	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	-	4	-	-	-	-	-	-	-	-	-
SCL Health Saint Joseph Hospital	-	3	-	-	-	-	-	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-	-	-	-
Southeast Clin Onc Res Consort NCORP	-	-	-	-	-	-	-	-	-	-	-
Sutter Cancer Research Consortium	1	11	-	-	-	-	3	-	-	-	-
The Don and Sybil Harrington Cancer Center	-	-	-	-	-	-	-	-	-	-	-
James Graham Brown CC at U Louisville	-	5	-	-	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	2	44	-	1	-	6	-	1	-	-	-
UC Irvine Hlth/Chao Family CCC	-	15	-	1	-	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	5	-	-	-	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-	-	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-	-	-	-	-	-	-	-	-	-
University of Arkansas for Medical Sciences	-	3	-	1	-	1	3	-	-	-	1
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	24	-	1	-	2	-	1	-	-	-
University of Colorado Cancer Center LAPS	-	58	-	2	-	-	-	-	1	-	1
U Kansas CC - MCA Rural MU NCORP	-	31	-	-	-	7	-	-	3	-	2
University of Kentucky/Markey Cancer Center	-	5	-	-	-	-	-	-	-	-	-
U Michigan Comprehensive Cancer Center LAPS	-	62	-	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	26	-	-	-	-	-	-	-	-	-
U of Oklahoma Health Sciences Center LAPS	-	-	-	-	-	-	1	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	4	19	-	-	-	1
U Texas HSC at San Antonio	-	-	-	-	-	2	-	-	-	-	-
U Texas MD Anderson CC LAPS	-	2	-	1	-	-	-	-	-	-	-
U Utah - Huntsman Ca Inst LAPS	-	-	-	-	-	1	-	-	-	-	-
Upstate Carolina NCORP	-	-	-	-	-	-	-	-	-	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-	-	-	-	-	-	-	-	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	1	-	-	-	-	-	-	-	1	-
Western States Cancer Research NCORP	-	1	-	-	-	-	-	-	-	-	-
William Beaumont Hospital-Royal Oak	-	2	-	-	-	-	-	-	-	-	-
Wisconsin NCORP	-	-	-	-	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	56	-	4	-	13	-	-	-	-	-
ALLIANCE	-	-	-	-	-	-	-	-	-	-	-
CCTG	-	-	-	-	-	-	-	-	-	-	-
ECOG-ACRIN	-	-	-	-	-	-	-	-	-	-	-
NRG	-	-	-	-	-	-	-	-	-	-	-
Total	3	966	1	20	1	81	72	10	11	2	13

Lung Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	NRGLU006	R1308
Ascension Providence Hospitals - Southfield	-	-
Ascension Via Christi Hospitals Wichita	-	-
Banner MD Anderson Cancer Center	-	-
Banner University Medical Center - Tucson	-	-
Baptist Mem Health Care/Mid South MU-NCORP	-	-
Baylor College of Medicine/Duncan CCC	3	-
Boston Medical Center	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-
Ca Res Consort of W Mich NCORPP	-	-
Cancer Research for the Ozarks NCORP	-	-
Ca Res of Wisconsin and N Mich Consort	-	-
Carle Cancer Center NCORP	-	-
Cedars-Sinai Medical Center	-	-
City of Hope Comprehensive Cancer Center	-	-
Columbia U MU NCORP	-	-
Columbus NCORP	-	-
CommonSpirit Health Research Institute	-	-
Cotton O'Neil CC / Stormont Vail Hlth	-	-
Dayton NCORP	-	-
Essentia Hlth NCORP	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-
Froedtert & the Med College of Wisconsin LAPS	-	-
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCORP	-	-
Gulf South Minority Underserved NCORP	-	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Houston Methodist Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Kaiser Permanente NCORP	-	-
Lahey Hospital and Medical Center	-	-
Loma Linda University Medical Center	-	1
Loyola University Medical Center	-	-
Massachusetts Veterans ERIC	-	-
Med U South Carolina MU NCORP	-	-
Mercy Medical Center - Des Moines	-	-
Michigan Cancer Research Consortium NCORP	-	-
Mission Hospital	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-

	NRGLU006	R1308
National Cancer Center-Korea	-	-
Nevada Cancer Research Foundation NCORP	-	-
New Mexico Minority Underserved NCORP	-	-
Northwell Health NCORP	-	-
Northwestern University LAPS	-	-
Oregon Health and Science University	-	-
Pacific Cancer Research Consortium NCORP	-	-
SCL Health Saint Joseph Hospital	-	-
Salem Hospital	-	-
Southeast Clin Onc Res Consort NCORP	-	-
Sutter Cancer Research Consortium	-	-
The Don and Sybil Harrington Cancer Center	-	-
James Graham Brown CC at U Louisville	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-
UC Irvine Hlth/Chao Family CCC	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
U of Alabama at Birm/Deep South Res Cnsrt LAPS	-	-
University of Arkansas for Medical Sciences	-	-
U of Cincinnati Cancer Cntr-UC Medical Cntr	-	-
University of Colorado Cancer Center LAPS	-	-
U Kansas CC - MCA Rural MU NCORP	-	-
University of Kentucky/Markey Cancer Center	-	-
U Michigan Comprehensive Cancer Center LAPS	-	-
University of Mississippi Medical Center	-	-
U of Oklahoma Health Sciences Center LAPS	-	-
University of Rochester LAPS	-	-
U Texas HSC at San Antonio	-	-
U Texas MD Anderson CC LAPS	-	-
U Utah - Huntsman Ca Inst LAPS	-	-
Upstate Carolina NCORP	-	-
Vanderbilt U - Ingram Cancer Center LAPS	-	-
Wayne State U - Karmanos Ca Inst LAPS	-	-
Western States Cancer Research NCORP	-	-
William Beaumont Hospital-Royal Oak	-	-
Wisconsin NCORP	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
CCTG	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	3	1

Lymphoma Committee

Leadership

Chair: Jonathan W. Friedberg, MD
 Vice-Chair: Sonali M. Smith, MD
 Executive Officer: Susan M. O'Brien, MD
 Statisticians: Michael LeBlanc, PhD
 Hongli Li, MS
 Shay Bellasea, MS

Scientific Leadership

Translational Medicine: Alexey Danilov, MD, PhD
 Radiation Oncology: Nicholas Burden Figura, MD
 Imaging: Lawrence H. Schwartz, MD
 Immunotherapeutics: Sweetha Kambhampati, MD
 Pathology: Joo Y. Song, MD
 Early Therapeutics: Nasheed Mohammad Hossain, MD

Designates

Cancer Control: Hayder Saeed, MD
 Digital Engagement: Elizabeth A.G. Brem, MD
 Veterans Affairs: Helen Ma, MD
 Data Coordinators: Alex Rangel, BS
 Gabi Herbert, MS, BS
 Laura Wells, BA
 Daria Chugina, MD, CCRPS
 Oncology Research Professionals:
 CRA: Erin M. Cebula, MPH
 Nurse: TBD
 Patient Advocate: Hildy Dillon, MPH (Emeritus)
 Tricia Hernandez, MS
 Pharmaceutical Science: Holly O. Chan, PharmD
 Martina Fraga, PharmD
 Protocol Project Manager: Katarina Gasic
 Clinical Trials Program Manager: Crystal Miwa

Time/Location

Friday, April 5, 2024 2:15 p.m. - 4:15 p.m.
 Room: Elwha AB (Level 5)

Agenda

1. **Welcome:** Sonali Smith, MD
2. **Update on S1826:** Dr. Herrera
3. **Can We Cure Follicular Lymphoma?**
 - a. Legacy of S0016 Dr. Shadman
 - b. Opportunity of low tumor burden disease Dr. Friedberg
 - c. S2308 Dr. Ghosh

4. Committee Reports

- | | |
|-----------------------|-----------------|
| a. Patient Advocacy | Ms. Hernandez |
| b. Immunotherapeutics | Dr. Kambhampati |
| c. Cancer Control | Dr. Saeed |

5. Review of Selected Studies

- | | |
|-------------|--------------|
| a. S2207 | Dr. Amengual |
| b. S2114 | Dr. Hess |
| c. S1918 | Dr. Brem |
| d. S1608 | Dr. Barr |
| e. S1925 | Dr. Stephens |
| f. EA4151 | Dr. Till |
| g. AHOD2131 | Dr. Hu |
| h. AO51902 | Dr. Amengual |
| i. AO52101 | Dr. Phillips |
| j. ANHL1931 | Dr. Kamdar |

Proposed Studies

S2308, "Randomized Phase III Study of Mosunetuzumab vs. Rituximab for Low Tumor Burden Follicular Lymphoma." Drs. Ghosh and Friedberg.

Open Studies

S1608, "Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma." Drs. Barr and Burack. Activated: 8/10/17.

S1918, "A Phase II/III Randomized Study of R-miniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements." Drs. Brem and Smith. Activated: 3/19/21.

S2114, "A Randomized Phase II Trial of Consolidation Therapy Following CD19 CAR T-Cell Treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma." Drs. Hess and Hossain. Activated: 2/23/2023.

S2207, "Randomized phase II study of the addition of Targeted therapeutic agents to tafasitamab-based therapy in non-transplant-eligible patients with Relapsed/refractory Large B-cell Lymphoma." Drs. Amengual, Reagan, and Smith. Activated: 6/30/2023

CTS/EA4151, "A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients

Lymphoma Committee

with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission." Dr. Fenske. SWOG Champion: Dr. Till. Activated: 8/29/17.

CTSU/ANHL1931, "A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma." Dr. Roth. SWOG Champion: Dr. Kamdar. Activated 6/7/2021.

CTSU/A051902, "A Randomized Phase II Study of CHO(E)P vs Oral Azacitidine-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-cell Lymphomas." Dr. Mehta-Shah. SWOG Champion: Dr. Amengual. Activated 7/30/2021.

CTSU/A052101, "A Randomized Phase 3 Trial of Continuous vs. Intermittent Maintenance Therapy with Zanubrutinib as Upfront Treatment in Older Patients with Mantle Cell Lymphoma (INTERCON)." Dr. Beaven. SWOG Champion: Dr. Tysel. Activated 09/08/2023.

CTSU/AHOS2131, "A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma." Dr. Henderson. SWOG Champion: Dr. Hu. Activated 04/28/2023.

Closed Lymphoma Studies

CTSU/A051701, "Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas." Dr. Abramson. SWOG Champion: Dr. Vallurupalli. Activated: 8/7/19. Closed: 12/14/2023.

CTSU/EA4181, "A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CA-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients \leq 70 years Old with Untreated Mantle Cell Lymphoma." Dr. Wagner-Johnson. SWOG Champion: Dr. Spurgeon. Activated: 10/3/19. Closed: 4/7/2023

Open Leukemia Studies

S1925, "A Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study." Dr. Stephens. Activated: 12/14/20.

S1905, "A Phase I/II Study of AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL)/T-Cell Lymphoblastic Lymphoma (T-LBL)." Drs. Advani and Papadantonakis. Activated: 8/17/20.

Open Cancer Care Delivery Study

S1912CD, "A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT)." Dr. Shankaran. Activated 7/26/2021.

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1608	S1826	S1918	S2114	S2207	A051301	A051701	A051902	AH02131
Ascension Providence Hospitals - Southfield	-	5	-	-	-	-	-	-	-
Banner University Medical Center - Tucson	2	-	-	-	-	1	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	3	1	-	-	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-	-	1	-	-	-
Boston Medical Center	-	3	-	-	-	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	1	-	-	-	8	-	-
Cancer Research Consortium of West Michigan NCORP	3	13	-	3	-	-	-	-	1
Cancer Research for the Ozarks NCORP	1	5	-	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	2	-	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	3	1	-	1	-	-	-	-
City of Hope Comprehensive Cancer Center	8	21	8	-	-	1	-	-	6
Columbia University Minority Underserved NCORP	-	2	4	-	-	-	-	-	-
Columbus NCI Community Oncology Research Program	1	2	-	-	-	-	-	-	-
CommonSpirit Health Research Institute	-	4	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	3	-	-	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	-	-	-	1	-
Georgia Cares Minority Underserved NCORP	-	6	2	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	2	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	1	-	-	-	-	-	-
Heartland Cancer Research NCORP	1	20	-	-	-	-	-	-	-
Henry Ford Hospital	-	8	-	-	-	-	2	-	-
Kaiser Permanente NCI Community Oncology Research Program	3	11	2	-	-	-	-	-	-
King Faisal Specialist Hospital and Research Centre	-	-	-	-	-	4	-	-	-
Loyola University Medical Center	-	8	-	-	-	-	-	-	-
Medical University of South Carolina Minority Underserved NCORP	2	19	3	11	-	-	3	-	-
Michigan Cancer Research Consortium NCORP	1	6	4	-	-	-	-	-	-
Moffitt Cancer Center	-	15	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	8	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	11	-	-	-	-	-	-	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S1608	S1826	S1918	S2114	S2207	A051301	A051701	A051902	AH02131
Nevada Cancer Research Foundation NCORP	-	2	-	-	-	-	-	-	-
Northwell Health NCORP	-	-	-	-	-	-	1	-	-
Northwestern University LAPS	1	-	-	-	-	-	-	-	-
Oregon Health and Science University	-	4	-	1	-	-	2	-	-
Pacific Cancer Research Consortium NCORP	-	7	-	4	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	6	-	-	-	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	18	-	-	-	-	4	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	4	3	-	-	-	-	-	-
UC San Diego Moores Cancer Center	-	8	-	-	-	-	-	-	-
Uof Alabama at Birmingham / Deep South Research Consortium LAPS	-	12	-	-	-	-	3	-	-
University of Arkansas for Medical Sciences	-	1	-	-	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	9	-	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	-	4	-	-	-	1	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	-	-	-	-	-	-
University of Kentucky/Markey Cancer Center	-	2	-	-	-	-	-	-	-
University of Mississippi Medical Center	-	1	-	-	-	-	-	-	-
University of Rochester LAPS	16	33	-	4	2	3	11	-	4
University of Texas Health Science Center at San Antonio	-	17	-	2	1	-	-	-	-
University of Texas MD Anderson Cancer Center LAPS	3	34	-	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	14	3	-	-	-	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	1	7	-	-	-	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	4	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	11	-	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	7	-	-	-	-	-	-	-
ALLIANCE	16	134	29	3	-	-	-	-	-
CCTG	-	30	-	-	-	-	-	-	-
COG	-	313	-	-	-	-	-	-	-
ECOG-ACRIN	5	83	14	-	-	-	-	-	-
NRG	11	51	5	-	-	-	-	-	-
Total	77	994	83	28	4	12	34	1	11

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	ANHL1931	E4412	EA4151	EA4181
Ascension Providence Hospitals - Southfield	-	-	-	-
Banner University Medical Center - Tucson	-	-	1	2
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center	-	-	-	-
Boston Medical Center	-	-	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	17	14
Cancer Research Consortium of West Michigan NCORP	-	-	-	-
Cancer Research for the Ozarks NCORP	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-	-	-
City of Hope Comprehensive Cancer Center	6	-	18	-
Columbia University Minority Underserved NCORP	1	1	-	-
Columbus NCI Community Oncology Research Program	-	-	-	-
CommonSpirit Health Research Institute	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	14	-
Georgia Cares Minority Underserved NCORP	-	-	-	-
Gulf South Minority Underserved NCORP	-	-	-	-
Hawaii Minority Underserved NCORP	-	-	-	-
Heartland Cancer Research NCORP	-	-	-	-
Henry Ford Hospital	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	11	-	12
King Faisal Specialist Hospital and Research Centre	-	-	-	-
Loyola University Medical Center	-	-	3	-
Medical University of South Carolina Minority Underserved NCORP	-	-	2	-
Michigan Cancer Research Consortium NCORP	-	-	-	-
Moffitt Cancer Center	-	-	-	-
Montana Cancer Consortium NCORP	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	1	-	2	-

Lymphoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	ANHL1931	E4412	E44151	E44181
Nevada Cancer Research Foundation NCORP	-	1	-	-
Northwell Health NCORP	-	-	-	-
Northwestern University LAPS	1	-	-	-
Oregon Health and Science University	-	-	6	5
Pacific Cancer Research Consortium NCORP	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	-	-	-	-
UC Davis Comprehensive Cancer Center LAPS	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	1	-	-	-
UC San Diego Moores Cancer Center	-	-	1	-
University of Alabama at Birmingham / Deep South Research Consortium LAPS	-	7	5	-
University of Arkansas for Medical Sciences	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	2	3
University of Colorado Cancer Center LAPS	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	-	-	1
University of Kentucky/Markey Cancer Center	-	-	2	-
University of Mississippi Medical Center	-	-	-	-
University of Rochester LAPS	5	-	10	18
University of Texas Health Science Center at San Antonio	-	-	13	-
University of Texas MD Anderson Cancer Center LAPS	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-	18	12
Upstate Carolina Consortium Community Oncology Research Program	-	-	-	-
Wayne State University - Karmanos Cancer Institute LAPS	-	-	1	6
Wisconsin NCI Community Oncology Research Program	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	5	-
ALLIANCE	-	-	-	-
CCTG	-	-	-	-
COG	-	-	-	-
ECOG-ACRIN	-	-	-	-
NRG	-	-	-	-
Total	15	20	120	73

Melanoma Committee

Leadership

Chair: Sapna P. Patel, MD
 Vice-Chair: Roger S. Lo, MD, PhD
 Executive Officer: Christopher W. Ryan, MD
 Statisticians: Michael Wu, PhD
 James Moon, MS
 Shay Bellasea, MS

Scientific Leadership

Translational Medicine: William E. Carson, III, MD
 Radiation Oncology: Evan J. Wuthrick, MD
 Surgery: John Robert Hyngstrom, MD
 Dermatology: Clara Curiel-Lewandrowski, MD
 Imaging: Ari M. VanderWalde, MD
 Medical Oncology: Sapna Pradyuman Patel, MD
 Pathology: TBD
 Non-Melanoma Skin Cancer: Nikhil I. Khushalani, MD
 Early Therapeutics: Jeffrey A. Sosman, MD
 SWOG's ECOG Liaisons: Thach-Giao Truong, MD
 ECOG's SWOG Liaisons: David H. Lawson, MD
 Andrew Poklepovic, MD
 Digital Engagement: Zeynep Eroglu, MD

Designates

Cancer Control Liaison: Sancy Leachman, MD, PhD
 Thach-Giao Truong, MD (Survivorship)
 Data Coordinator: Matt Gospe, BS
 Michele Counts, BS
 Tonya Johnson, BS
 Oncology Research Professionals:
 CRA: Kathryn Allen, BA, CCRP
 Nurse: Lisa S. Morgan, RN, OCN
 Patient Advocate: Samantha Guild, J.D.
 Pharmaceutical Science: Sun "Coco" Yang, PharmD, PhD
 Kimberly McConnell, PharmD
 Protocol Project Manager: Catrina De Los Santos-Mireles
 Clinical Trials Program Manager: Laura Gildner, MS

Time/Location

Thursday, April 4, 2024 10:00 a.m. - 12:00 p.m.

Room: Virtual Only

Agenda

Targeting RAScals in solid tumor oncology, David Hong, MD, The University of Texas MD Anderson Cancer Center

Active Studies

S2015, "Melanoma Margins Trial (MelMarT): A Phase III, Multi-Centre, Multi-National Randomised Control Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma." Dr. Mammen. Activated: 04/08/22.

S2000, "A Randomized Phase II Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases." Dr. Eroglu. Activated: 09/23/2020.

CTSU/EA6174, "STAMP: Surgically Treated Adjuvant Merkel Cell Carcinoma with Pembrolizumab, a Phase III Trial." SWOG Champion: Dr. Hsu. Activated: 10/01/2018. Temporarily Closed to Accrual as of 04/07/2023

CTSU/EA6141, "Randomized Phase II/III Study of Nivolumab plus Ipilimumab plus Sargramostim versus Nivolumab plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma." SWOG Champion: Dr. K. Kim. Activated: 09/10/2015.

CTSU/EA6192. "The BAMB2 (BRAF, Autophagy, MEK Inhibition in Melanoma) Study: A Randomized Double Blind Phase II Study of Dabrafenib and Trametinib with or Without Hydroxychloroquine in Advanced BRAF V600E/K Melanoma with Elevated LDH". SWOG Champion: Dr. Truong. Activated: 10/23/2020.

A091903, A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma. SWOG Champion: K. Tsai, MD (SWOG) Activated 06/01/2022. Temporarily Closed to Accrual as of 10/10/2023

Closed Studies

S1801, "A Phase II Randomized Study of Adjuvant Versus Neoadjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High Risk Melanoma." Dr. Patel. Activated: 12/06/18. Closed: 05/05/2022.

S1512, "A Phase II and Pilot Trial of PD-1 Blockade with MK-3475 (Pembrolizumab) in Patients with Resectable or Unresectable Desmoplastic Melanoma (DM)." Drs. Kendra and Hu-Lieskovan. Activated: 10/20/16. Closed: 06/04/2021.

S1607, "A Phase II Study of Combining Talimogene Laherparepvec (T-VEC) (NSC-785349) and MK-3475 (Pembrolizumab) in Patients with Advanced Melanoma who have Progressed on Anti-PD1/L1 Based Therapy." Dr. Hu-Lieskovan. Activated: 10/02/17. Closed: 11/1/20.

S1616, "A Phase II Randomized Study of Nivolumab (NSC-748726) with Ipilimumab (NSC-732442) or Ipilimumab Alone in Advanced

Melanoma Committee

Melanoma Patients Refractory to an Anti-PD1 or Anti-PD-L1 Agent." Dr. VanderWalde. Activated: 07/17/2017. Closed: 07/15/2020.

S1404, "A Phase III Randomized Study of MK3475 versus High-Dose Interferon a-2b for Resected High-Risk Melanoma." Dr. Patel. Activated: 10/15/2015. Closed: 11/02/2017.

CTSU/EA6134, "DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial." SWOG Champion: Dr. Chmielowski. Activated: 7/13/15. Closed: 9/30/2021.

CTSU/EA6183, A Phase II Neoadjuvant Study of Encorafenib with Binimetinib in Patients with Resectable Locoregional Metastases from Cutaneous or Unknown Primary Melanoma (Stages III N1B/C/D). SWOG Champion: C. D. Lao, MD, MPH Activated: 02/18/2020. Closed: 09/23/2022.

ECOG Liaison Updates

Patient Advocate Updates

Melanoma Committee

Accrual from trials that are open as of 12/31/2023 or have closed in the prior 18 Months by Institution and Study

	S2000	S2015	A091903	EA6141	EA6174	EA6192	EA6194
Banner MD Anderson Cancer Center	-	6	-	-	-	-	-
Banner University Medical Center - Tucson	-	-	-	-	3	-	-
CWRU Case Comprehensive Cancer Center LAPS	-	-	-	-	16	-	-
Cancer Research Consortium of West Michigan NCORP	-	60	-	-	-	-	-
Cancer Research for the Ozarks NCORP	1	-	-	1	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	-	-	-	-	-	-
Cedars-Sinai Medical Center	-	15	-	-	-	-	-
City of Hope Comprehensive Cancer Center	-	-	-	3	-	-	-
Dayton NCI Community Oncology Research Program	1	-	-	2	-	-	-
Duke University - Duke Cancer Institute LAPS	-	9	-	-	-	-	-
Fred Hutchinson Cancer Research Center LAPS	-	-	-	-	1	-	-
Froedtert and the Medical College of Wisconsin LAPS	-	4	-	-	-	-	-
Georgia NCI Community Oncology Research Program	-	3	-	-	-	-	-
Intermountain Medical Center	-	7	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-	-	26	-	-	-
Medical University of South Carolina Minority Underserved NCORP	-	9	-	-	-	-	-
Moffitt Cancer Center	16	33	-	-	-	-	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	1	-	-
Northwell Health NCORP	-	2	-	-	-	-	-
Northwestern University LAPS	-	21	-	1	1	5	-
Ohio State University Comprehensive Cancer Center LAPS	1	20	-	-	3	3	-
SCL Health Saint Joseph Hospital	-	-	-	-	1	-	-
Sutter Cancer Research Consortium	-	-	-	6	1	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	5	-	4	8	-	1
UPMC Hillman Cancer Center LAPS	1	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-	1	-	3	-	-
University of Arkansas for Medical Sciences	-	3	-	-	-	-	-
University of Cincinnati Cancer Center-UC Medical Center	-	-	-	2	4	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	30	-	-	1	-	-
University of Kentucky/Markey Cancer Center	-	3	-	-	-	-	-
University of Michigan Comprehensive Cancer Center LAPS	2	7	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	-	1	-	-	-	-	-
University of Rochester LAPS	-	3	-	3	1	-	-
University of Texas Health Science Center at San Antonio	-	1	-	1	-	-	-
University of Texas MD Anderson Cancer Center LAPS	-	11	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	20	-	-	8	-	-
Western States Cancer Research NCORP	-	-	-	1	-	-	-
Wisconsin NCI Community Oncology Research Program	-	6	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	16	-	8	1	-	-
ALLIANCE	1	37	-	-	-	-	-
ECOG-ACRIN	4	95	-	-	-	-	-
NRG	1	41	-	-	-	-	-
Total	29	468	1	58	53	8	1

Radiation Oncology Committee

Leadership

Chair: Chul Ha, MD
 Vice-Chair: Lisa Kachnic, MD
 Executive Officer: Lisa Kachnic, MD

Designates

Breast Committee Liaison: Reshma Jagsi, MD, DPhil
 Cancer Care Delivery Committee Liaison: Eileen Connolly, MD
 Prevention & Epidemiology Committee Liaison: Eileen Connolly, MD
 CNS Working Group Liaison: Tony Wang, MD
 Genitourinary Committee Liaison: James Yu, MD
 Gastrointestinal Committee Liaison: David Horowitz, MD
 Lung Committee Liaison: Henry Park, MD
 Lymphoma Committee Liaison: Nick Figura, MD
 Melanoma Committee Liaison: Evan Wuthrick, MD
 Symptom Control & QOL Committee Liaison: Erin Gillespie, MD, MPH
 Statistical Liaison: Sam Callis, MS

Time/Location

Saturday, April 6, 2024 9:30 a.m. - 11:30 a.m.
 Room: Ashnola/301 (Level 3)

Agenda

- 9:30 - 9:35 am Welcome - Chul S. Ha, MD
- 9:35 - 9:40 am Report from Executive Officer - Lisa Kachnic, MD
- 9:40 - 9:45 am Update from IROC - T.J. FitzGerald, MD
- 9:45 - 9:50 am Update from NCI - Jacek Capala, Ph.D., DSc
- 9:50 - 11:15 am Reports by Committees

Breast Report by Liaison: Reshma Jagsi, MD, DPhil

- A Phase II Randomized Trial of Olaparib Administered Concurrently with RT vs RT Alone for Inflammatory Breast Cancer (S1706)- Reshma Jagsi, MD, DPhil
- Randomized phase III trial of multimodality therapy in each subtype of stage IV oligometastatic breast cancer vs palliative therapy- Shane Stecklein, MD
- Re-radiation trial for in-breast recurrence - Eileen Connolly, MD
- CDK 4/6 inhibition concurrent with RT for ER+ locally advanced breast cancer – Corey Speers, MD
- Hope Foundation Proposal- Rachel Jimenez, MD & Corey Speers, MD

CNS Report by Liaison: Tony Wang, MD

- Phase II study of atezolizumab and tocilizumab with radiotherapy in patients with newly diagnosed MGMT unmethylated glioblastoma - Tony Wang, MD
- TRC102 and temozolomide in patients with refractory and first line GBM - Tony Wang, MD
- Spine SBRT protocol in concept stage - Tony Wang, MD

Gastrointestinal Report by Liaison: David Horowitz, MD

- Induction immunotherapy for localized anal cancer - David Horowitz, MD

Genitourinary Report by Liaison: James Yu, MD

- The ART of Bladder Preservation - Leslie Ballas, MD
- Phase III randomized trial of standard systemic therapy +/- definitive therapy (surgery or radiation) of the primary tumor in metastatic prostate cancer (S1802) - Richard Valicenti, MD
- Phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer (S1806) - Sameer Jhavar, MD
- Secondary Analysis of SWOG 9312/1314/8710 - Steven Seyedin, MD

Lung Report by Liaison: Henry Park, MD

- Sequencing of immunotherapy and chemotherapy in unresectable stage III non-small cell lung cancer - Henry Park, MD
- A randomized phase III trial of induction/consolidation Atezolizumab + SBRT versus SBRT alone in high risk, early-stage NSCLC (S1914) - Megan Daly, MD
- MRI brain surveillance alone versus MRI surveillance and prophylactic cranial irradiation: a randomized phase III trial in small-cell lung cancer (S1827) - Chad Rusthoven, MD
- A pilot study of hypofractionated radiotherapy followed by Atezolizumab consolidation in stage II or III NSCLC patients with borderline performance status (S1933) - Raid Aljumaily, MD
- NRG CC009: Phase III trial of SRS versus hippocampal-avoidant whole brain radiotherapy for 10 or fewer brain metastases from small cell lung cancer - Chad Rusthoven, MD

Radiation Oncology Committee

Lymphoma Report by Liaison: Nicholas Figura, MD

Melanoma Report by Liaison: Evan Wuthrick, MD

- Secondary analysis for S1404 - Evan Wuthrick, MD

Sarcoma

- Phase III Randomized Study Testing Non-Inferiority of Shorter-Course Radiation Versus Standard Fractionation for High-Risk, Resectable Sarcoma (S2310) - Jeremy Harris, MD

Cancer Control & Prevention Committee/ Cancer Care Delivery

Committee Report by Liaison: Eileen Connolly, MD

- Radiation therapy for high-risk asymptomatic bone metastases: A pragmatic multicenter randomized phase III clinical trial - Erin Gillespie, MD
- Harnessing implementation science and digital health to promote evidence-based management of cancer related fatigue - Erin Gillespie, MD

Symptom Control & Quality of Life Committee Report by Liaison:

Erin Gillespie, MD

11:15-11:20 pm Announcements

Search for liaisons for Cancer Survivorship Committee, Immunotherapeutics Committee, and Early Therapeutics & Rare Cancer Committee.

11:20-11:25 pm Open Forum

11:25-11:30 pm Closing Remarks - Chul S. Ha, MD

Publication List by Committee

The publications listed below were received by the Group Chair's Office as published (including online), accepted, or submitted since the SWOG Fall 2023 Group Meeting. Conference abstracts are not included.

Because of journal embargo policies, journal names are omitted for submitted or accepted manuscripts

ADOLESCENT AND YOUNG ADULT (AYA) COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

BARLOGIE-SALMON MYELOMA COMMITTEE

Published/Accepted Manuscripts

S2209 Clinical trial design change implementation for inclusive studies. Espinoza Gutarra M, Aiello J, Orłowski R, Ailawadhi S. Lancet Hematology Dec;10(12):e953-e954, 2023. <https://pubmed.ncbi.nlm.nih.gov/38030317/>

Submitted Manuscripts

None this cycle

BREAST COMMITTEE

Published/Accepted Manuscripts

S0221 Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221 Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puztai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. Journal of the National Comprehensive Cancer Network Nov;21(11):1172-1180.e3, 2023. <https://pubmed.ncbi.nlm.nih.gov/37935109/> [see also SCQL and Pharmaceutical Sciences Committees]

S0307 Evaluating the Utility and Privacy of Synthetic Breast Cancer Clinical Trial Data Sets. El Kababji S, Mitsakakis N, Fang X, Beltran-Bless AA, Pond G, Vandermeer L, Radhakrishnan D, Mosquera L, Paterson A, Shepherd L, Chen B, Barlow WE, Gralow J, Savard MF, Clemons M, El Emam K. JCO Clin Cancer Inform. 2023 Sep;7:e2300116. doi: 10.1200/CCI.23.00116. <https://pubmed.ncbi.nlm.nih.gov/38011617/>

S9313 Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. Stecklein S, Barlow W, Puztai L, Timms K, Kennedy R, Logan G, Seitz R, Badve S, Gökmen-Polar Y, Porter P, Linden H, Tripathy D, Hortobagyi G, Godwin A, Thompson A, Hayes D, Sharma P. JCO Precis Oncol Sep;7:e2300197. doi: 10.1200/PO.23.00197. .2023. <https://pubmed.ncbi.nlm.nih.gov/37972336/>

Multiple Studies* Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics. Welter L, Zheng S, Setayesh S, Morikado M, Agrawal A, Nevarez R, Naghdloo A, Pore M, Higa N, Kolatar A, Sharma P, Moore H, Richer J, Elias A, Pienta K, Zurita A, Gross M, Shishido S, Hicks J, Velasco C, Kuhn P. Cancers (Basel) Aug 3;15(15):3949, 2023. [*S1222,S1416,OTHER] <https://pubmed.ncbi.nlm.nih.gov/37568766/>

Submitted Manuscripts

S1207 Results from a phase III randomized, placebo-controlled clinical trial evaluating adjuvant endocrine therapy +/- 1 year of everolimus in patients with high-risk hormone receptor-positive, HER2-negative breast cancer: SWOG S1207. Chavez MacGregor M, Miao J, Puztai L, Goetz M, Rastogi P, Ganz P, Mamounas E, Paik S, Bandox H, Razaq W, O'Dea A, Kaklamani V, Silber A, Flaum L, Andreopoulou E, Wendt A, Carney J, Sharma P, Gralow J, Lew D, Barlow W, Hortobagyi G. Submitted, 2024.

CANCER CONTROL AND PREVENTION

CANCER CARE DELIVERY COMMITTEE

Published/Accepted Manuscripts

S1204 Universal Viral Screening of Newly Diagnosed Cancer Patients in the United States: A Cost Efficiency Evaluation. Vaidya R, Unger J, Loomba R, Hwang J, Chugh R, Tincopa M, Arnold K, Hershman D, Ramsey S. Cancer Research Communications 3(9):1959-1965, 2023. <https://pubmed.ncbi.nlm.nih.gov/37707388/>

S1415CD Impact of Treatment Experience on Patient Knowledge of Colony Stimulating Factors Among Patients Receiving Cancer Chemotherapy: Evidence from S1415CD, A Large Pragmatic Trial. Lyman G, Bansal A, Sullivan S, Arnold K, Barlow W, Hershman D, Lad T, Ramsey S. Supportive Care in Cancer 598 Sep 28;31(10):598, 2023. <https://pubmed.ncbi.nlm.nih.gov/3770704/>

S1415CD Intervention non-adherence in The TrACER (S1415CD) study, a pragmatic randomized trial of a standardized order entry for colony stimulating factor prescribing. Hershman DL, Bansal A, Barlow W, Arnold K, Watabayashi K, Bell-Brown A, Sullivan S, Lyman G, Ramsey S. JCO Oncology Practice Dec;19(12):1160-1167, 2023. <https://pubmed.ncbi.nlm.nih.gov/37788414/>

Multiple Studies Association of Baseline Measures of Socioeconomic Deprivation and Healthcare Utilization in Patients Enrolled in SWOG

Publication List by Committee

Cancer Clinical Trials. Hershman D, Vaidya R, Till C, Barlow W, LeBlanc M, Ramsey S, Unger J. Accepted 2024.

None Sponsors' Perspectives on the Impact of the COVID-19 Public Health Emergency on Interventional Cancer Clinical Trial Protocols and Data Quality. Unger J, Stires H, Levit L, Stewart M, McKelvey B, Canin B, Connelly N, Dressler E, Flaherty K, Fredette P, Jones L, McCann P, Miller T, Ontilio A, Palmieri F, Patel T, Paul R, Smith G, Bruinooge S, Garrett-Mayer E, Lei X, Alva A, Schenkel C. *JCO Oncol Pract* Oct;19(10):907-916, 2023. <https://pubmed.ncbi.nlm.nih.gov/37643386/>

Submitted Manuscripts

Multiple Studies* Neighborhood Socioeconomic Deprivation and Patient-Reported Outcomes in Symptom Management Trials for Breast Cancer Patients. Vaidya R, Till C, Henry NL, Fisch M, Hershman D, Unger J. Submitted 2023. [*S0927,S1200,S1202]

CANCER SURVIVORSHIP COMMITTEE

Published/Accepted Manuscripts

IBCSG 48-14 Fertility preservation and assisted reproductive technologies in breast cancer patients interrupting adjuvant endocrine therapy to attempt pregnancy. Azim HA, Jr, Niman SM, Partridge AH, Demeestere I, Ruggeri M, Colleoni M, Saura C, Shimizu C, Satersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset Jablonski C, Borstnar S, Takei J, Eon Lee J, Walshe JM, Ruiz Borrego M, Moore HCF, Saunders C, Bjelic Radisic V, Susnjar S, Cardoso F, Klar NJ, Spanic T, Ruddy K, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagni O, Peccatori FA. Accepted/In press, 2024.

Submitted Manuscripts

None this cycle

PALLIATIVE AND END OF LIFE CARE COMMITTEE

Published/Accepted Manuscripts

S1820 SWOG S1820: A Pilot Randomized Trial of the Altering Intake, Managing Bowel Symptoms Intervention in Survivors of Rectal Cancer (AIMS-RC). Sun V, Guthrie KA, Crane T, Arnold K, Colby S, Freylersthe S, Braun-Inglis C, Topacio R, Messick C, Carmichael J, Muskovitz A, Nashawaty M, Bajaj M, Cohen S, Flaherty D, O'Rourke M, Jones L, Krouse R, Thomson C. *Cancer*, 2024. Published online: <https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.1002/cncr.35264>

Submitted Manuscripts

S1316 Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a

randomized trial. CA Thomson CA, KB Arnold KB, Anderson G, Sun V, Secord A, Yung A, Al-Kaspoles M, Nfonsam V, Grant M, Deutsch G, . Deneve J, Krouse R. Submitted 2024.

S1820 Baseline Characteristics and Recruitment for SWOG S1820: Altering Intake, Managing Bowel Symptoms in Survivors of Rectal Cancer (AIMS-RC). Sun V, Thomson C, Crane T, Arnold K, Guthrie K, Freylersthe S, Braun-Inglis C, Jones L, Carmichael J, Messick C, Flaherty D, Ambrale S, Cohen S, Krouse R. Submitted 2023.

PREVENTION AND EPIDEMIOLOGY COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

S0000/Other Shedding light on the association between genetically-defined BMI and early-onset colorectal cancer in a pooled analysis. [Brief Communication], Archambault A, Gruber S, Le Marchand L, Hsu L, Peters U, Hayes R, (P Goodman C Tangen GECCO). Submitted 2023.

S0000/S9217 Long-term side effects and complications after prostate cancer treatment. Unger J, Till C, Tangen C, Hershman D, Goodman P, Leblanc M, Barlow W, Vaidya R, Minasian L, Parnes H, Thompson IM. Submitted, 2024.

SYMPTOM CONTROL AND QUALITY OF LIFE COMMITTEE

Published/Accepted Manuscripts

S0221 Vitamin D insufficiency as a risk factor for paclitaxel-induced peripheral neuropathy in White and Black patients in SWOG S0221. Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puzstai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. *Journal of the National Comprehensive Cancer Network* Nov;21(11):1172-1180.e3, 2023. <https://pubmed.ncbi.nlm.nih.gov/37935109/> [see also Breast and Pharmaceutical Sciences Committees]

Submitted Manuscripts

S1316 Intake and Nutritional Adequacy in Cancer Patients Diagnosed with Malignant Bowel Obstruction: A secondary analysis of a randomized trial. CA Thomson CA, KB Arnold KB, Anderson G, Sun V, Secord A, Yung A, Al-Kaspoles M, Nfonsam V, Grant M, Deutsch G, . Deneve J, Krouse R. Submitted 2024.

DIGITAL ENGAGEMENT COMMITTEE

Published/Accepted Manuscripts

None this cycle

Publication List by Committee

Submitted Manuscripts

None this cycle

EARLY THERAPEUTICS AND RARE CANCERS COMMITTEE

Published/Accepted Manuscripts

S1609 A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in patients with gestational trophoblastic neoplasia. Patel S, Othus M, Chae Y, Dennis M, Gordon S, Mutch D, Samlowski W, Robinson W, Sharon E, Ryan C, Lopez G, Plets M, Blanke C, Kurzrock R. *Clinical Cancer Research* Jan 5;30(1):33-38, 2024. <https://pubmed.ncbi.nlm.nih.gov/37882676/>

S1609 Correlation Between Tumor Size Change and Outcome in a Rare Cancer Immunotherapy Basket Trial. Othus M, Patel S, Chae YK, Streicher H, Sharon E, Kurzrock R. *Journal of the National Cancer Institute* Jan 18:djae009. doi: 10.1093/jnci/djae009. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38243705/>

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 48) in Patients with Advanced Gallbladder Cancer. Patel S, Guadarrama E, Chae Y, Dennis M, Powers B, Liao C-Y, Ferri W, George T, Sharon E, Ryan C, Othus M, Lopez G, Blanke C, Kurzrock R. *Cancer* Feb 15. doi: 10.1002/cncr.35243. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38358334/>

Submitted Manuscripts

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Salivary Gland Tumor Cohort. Chae Y, Sun R, Patel S, Giles F, Ohr J, Worden F, Suga J, Naing A, Cohen E, Wallace J, Fenton S, Il-Young Chung L, Kang H, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Othus M, Blanke CD, Kurzrock R. Submitted 2023.

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Adrenocortical Carcinoma Cohort., Patel S, Othus M, Chae Y, Huynh T, Tan B, Kuzel T, Vogelzang N, McLeod C, Lopez G, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Submitted, 2024.

S1609 SWOG/NCI S1609 Phase II Basket Trial Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer. Chae Y, Othus M, Patel S, Wilkinson K, Whitman-Purves E, Lea J, Schallenkamp J, Adra N, Appleman L, Alden M, Thomes Pepin J, Ellerton J, Poklepovic A, Walter A, Rampurwala M, Robinson W, Il-Young Chung L, Kim H, McLeod C, Lopez G, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Submitted 2023.

S1609 Phase II Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG/NCI Experience: Invasive Mucinous or Non-mucinous Lepidic Adenocarcinoma of the Lung (Formerly Bronchioloalveolar Carcinoma). Chae Y, Othus M, Patel S, Gerber D, Tanvetyanon T, Il-Young Chung L, Kim H, McLeod C, Lopez G, Chen H, Sharon E, Streicher H, Ryan C, Blanke C, Kurzrock R. Submitted, 2024.

S1609 A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: The Desmoid Tumors. Chae Y, Othus M, Patel S, Powers B, Hsueh C, Govindarajan R, Bucur S, Kim H, Il-Young Chung L, McLeod C, Chen H, Sharon E, Streicher H, Ryan C, Blanke CD, Kurzrock R. Submitted, 2024.

EXECUTIVE COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

GASTROINTESTINAL COMMITTEE

Published/Accepted Manuscripts

S1505 Intra-tumoral cell neighborhoods coordinate outcomes in pancreatic ductal adenocarcinoma. Wattenberg M, Colby S, Garrido-Laguna I, Xue Y, Chang R, Delman D, Beg M, Wang-Gillam A, Wade J, Guthrie K, Chiorean EG, Ahmad S, Lowy A, Philip PA, Sohal D, Beatty G. *Gastroenterology* Jan 18:S0016-5085(24)00049-0. doi: 10.1053/j.gastro.2024.01.013. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38244727/>

S1505 Body Composition Measurements and Clinical Outcomes in Patients with Resectable Pancreatic Adenocarcinoma: Analysis from SWOG S1505 [Brief Report]. Sohal D, Boutin R, Lenchik L, Kim J, Beg S, Wang-Gillam A, Wade J, Guthrie KA, Chiorean E, Ahmad S, Lowy A, Philip P, Chang V. Accepted 2024.

S1505 Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505. Cloyd J, Colby S, Guthrie KA, Lowy A, Chiorean E, Philip P, Sohal D, Ahmad S. Accepted 2023.

S2104 Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors [Research Letter]. Ryan C, Saif A, Rocha F, Philip P, Hernandez J, Ahmad S, Soares H. *Ann Surg Oncol*. Mar;30(3):1302-1304, 2023. <https://pubmed.ncbi.nlm.nih.gov/36474095/>

Publication List by Committee

C/S80405 Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer. Arai H, Yang Y, Millstein J, Denda T, Ou F, Innocenti F, Takeda H, Kubota Y, Doi A, Horie Y, Umemoto K, Izawa N, Wang J, Battaglin F, Jayachandran P, Algaze S, Soni S, Zhang W, Zhang W, Goldberg R, Hall M, Scott A, Hwang J, Lou E, Weinberg B, Marshall J, Goel S, Xiu J, Korn M, Venook A, Sunakawa Y, Lenz H-J. *Eur J Cancer* Feb 10;201:113914. doi:10.1016/j.ejca.2024.113914. Online ahead of print, 2024.. <https://pubmed.ncbi.nlm.nih.gov/38359495/>

C80802 CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C infection in Patients with advanced hepatocellular carcinoma. Abou-Alfa G, Geyer S, Nixon A, Innocenti F, Shi Q, Jacobson S, El Dika I, Yaqubie A, Lopez J, Hwang B, El-Khoueiry A, Tang Y, Wen Y, Schwartz L, Bertagnolli M, Meyerhardt J, O'Reilly E, Venook A. *Cancer Res Commun* Feb 16. doi: 10.1158/2767-9764.CRC-22-0516. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38363156/>

Submitted Manuscripts

S0809 The Effect of Radiation Modality on Outcomes of Patients Receiving Adjuvant Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Secondary Analysis of SWOG S0809. Horowitz D, Colby S, Gholami S, Guthrie KA, Ben-Josef E, El-Khoueiry A, Blanke CD, Philip P, Chiorean E, Rocha F, Ahmad S, Kachnic L. Resubmitted 2023.

N0147 Cetuximab reduces patient quality of life when administered with mFOLFOX6 as adjuvant treatment following complete resection of KRAS wild-type tumors for stage III colorectal cancer (N0147 Alliance). Mahoney MR, Sloan JA, Hubbard JM, Tan AD, Liu H, Goldberg RM, Nair SG, Shields AF, Gill S, Jahagirdar B, Benson A, Sargent DJ, Alberts SR. Submitted 2023.

GENITOURINARY COMMITTEE

Note: All PCPT and SELECT publications are listed under Cancer Control & Prevention Committees

Published/Accepted Manuscripts

S1314 Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Lerner S, McConkey DJ, Tangen C, Meeks JJ, Flaig T, Hua X, Daneshmand S, Alva A, Lucia MS, Theodorescu D, Goldkorn A, Milowsky M, Choi W, Bangs R, Gustafson D, Plets M, Thompson IM. *Clinical Cancer Research* Nov 15. doi: 10.1158/1078-0432.CCR-23-0602. Online ahead of print, 2023. <https://pubmed.ncbi.nlm.nih.gov/37966367/>

S1216 Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, LeBlanc M, Thompson I, Agarwal N. Accepted, 2024.

Submitted Manuscripts

S0931 Association of adjuvant everolimus with outcomes in patients with localized non-clear cell renal cell carcinoma (RCC): Subgroup analysis from the phase-III EVEREST trial (SWOG S0931). Gulati S, Tangen C, Ryan C, Vaishampayan U, Shuch B, Barata P, Pruthi D, Bergerot C, Tripathi A, Lerner S, Thompson I, Lara P, Pal S. Submitted, 2024.

S0931 Adjuvant everolimus in patients with completely resected very high-risk renal cell cancer and clear cell histology: results from the phase III placebo-controlled SWOG S0931 (EVEREST) trial. Lara P, Tangen C, Heath E, Gulati S, Stein M, Meng M, Alva A, Pal S, Puzanov I, Clark J, Choueiri T, Agarwal N, Uzzo R, Haas N, Synold T, Plets M, Vaishampayan U, Shuch B, Lerner S, Thompson I, Ryan C. Submitted, 2024.

S1011 Standard vs. Extended Lymphadenectomy for Muscle Invasive Bladder Cancer. Lerner S, Tangen C, Svatek R, Daneshmand S, Pohar K, Skinner E, Schuckman A, Sagalowsky A, Smith N, Kamat A, Kassouf mW, Plets M, Bangs R, Koppie T, Alva A, La Rosa F, Pal S, Kibel A, Canter D, Thompson I. Submitted, 2024.

S1216 Baseline circulating tumor cell count as a prognostic marker of overall survival in metastatic hormone sensitive prostate cancer (SWOG S1216). Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Jr., Hussain M, Quinn D, Dorff T, Thompson I, Jr, Agarwal N. Submitted 2024.

S1216 Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D, LeBlanc M, Thompson I, Agarwal N. *Prostate Cancer Prostatic Dis.* Feb 29. doi: 10.1038/s41391-024-00813-3, 2024. <https://pubmed.ncbi.nlm.nih.gov/38424319/>

S1216 Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): a subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel. Lara P, Mayerson E, Gertz E, Tangen C, Goldkorn A, Van Loan M, Hussain M, Gupta S, Zhang J, Parikh M, Twardowski P, Quinn D,

Publication List by Committee

LeBlanc M, Thompson I, Agarwal N. Prostate Cancer Prostatic Dis. Feb 29. doi: 10.1038/s41391-024-00813-3, 2024.

<https://pubmed.ncbi.nlm.nih.gov/38424319/>

S1314 S1314 correlative analysis of ATM, RB1, ERCC2 and FANCC mutations and pathologic complete response after neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Plimack E, Tangen C, Plets M, Kokate R, Xiu J, Nabhan C, Ross E, Grundy E, Choi W, Dinney C, Lee I, Fong M, Lucia M, Daneshmand S, Theodorescu D, Goldkorn A, Lerner S, Flaig T, McConkey D. Submitted, 2024.

S1314 DNA Damage Response Gene Alterations Predict for Neoadjuvant Chemotherapy Sensitivity in Muscle-Invasive Bladder Cancer: A Correlative Analysis of the SWOG S1314 Trial. Iyer G, Tangen C, Sarfaty M, Regazzi A, Lee I, Fong M, Choi W, Dinney C, Flaig T, Thompson I, Lerner S, McConkey D, Rosenberg J. Submitted, 2024.

E3805 Effect of Metformin and Body Mass Index on Quality of Life and Survival in the E3805 CHARTED Trial. Jerrard D, Chen Y, Morgans A, Carducci M, Liu G, Eisenberger M, Wong Y-N, Hahn N, Bryce A, Cooney M, Dreicer R, Vogelzang N, Picus J, Shevrin D, Hussain M, Garcia J, DiPaola R, Sweeney C. Submitted 2023.

IMMUNOTHERAPEUTICS COMMITTEE

Published/Accepted Manuscripts

None this cycle

Submitted Manuscripts

None this cycle

LEUKEMIA COMMITTEE

Published/Accepted Manuscripts

S1203 Standard versus high-dose cytarabine with or without vorinostat for AML. Garcia-Manero G, Podoltsev N, Othus M, Pagel J, Radich J, Fang M, Rizzieri D, Marcucci G, Strickland SA, Litzow MR, Savoie M, Medeiros B, Sekeres M, Lin TL, Uy G, Powell BL, Kolitz JE, Larson RA, Stone RM, Claxton D, Essell J, Luger S, Mohan S, Moseley A, Appelbaum F, Erba HP. *Leukemia* Jan;38(1):58-66, 2024.

<https://pubmed.ncbi.nlm.nih.gov/37935977/>

Multiple Studies Clinical Evaluation of Complete Remission (CR) with Partial Hematologic Recovery (CRh) in Acute Myeloid Leukemia: A Report of 7,235 Patients from Seven Cohorts. Appelbaum J, Wei A, Mandrekar S, Tiong I, Chua C, Teh T, Fong C, Ting S, Weber D, Benner A, Hill H, Saadati M, Yin J, Stone R, Garcia-Manero G, Erba H, Yy G, Marcucci G, Larson R, Thomas A, Freeman S, Marquez Almuina N, Dohner K,

Thomas I, Russel N, Dohner H, Othus M, Estey E, Walter R. *Leukemia* Feb;38(2):389-392,2024. <https://pubmed.ncbi.nlm.nih.gov/38263433/>

A041202 Long Term Follow-up from A041202, A Phase 3 Study of Bendamustine/Rituximab vs Ibrutinib or Ibrutinib/Rituximab Shows Continued Efficacy and Safety of Ibrutinib in Older Adults with CLL Woyach J, Burbano G, Ruppert A, Miller C, Heerema N, Zhao W, Wall A, Ding W, Bartlett N, Brander D, Barr P, Rogers K, Parekh S, Stephens D, Brown J, Lozanski G, Blachly J, Nattam S, Larson R, Erba H, Litzow M, Lugar S, Owen C, Kuzma C, Abramson J, Little R, Dinner S, Stone R, Uy G, Stock W, Mandrekar S, Byrd J. *Blood* Jan 12:blood.2023021959. doi: 10.1182/blood.2023021959. Online ahead of print, 2024.

<https://pubmed.ncbi.nlm.nih.gov/38215395/>

Submitted Manuscripts

None this cycle

LUNG COMMITTEE

Published/Accepted Manuscripts

LUNGMAP Representativeness of Patients Enrolled in the Lung Cancer Master Protocol (Lung-MAP). Vaidya R, Unger J, Qian L, Minichiello K, Herbst R, Gandara D, Neal J, Leal T, Patel J, Dragnev K, Waqar S, Edelman M, Sigal E, Adam S, Malik S, Blanke C, LeBlanc M, Kelly K, Gray J, Redman M. *JCO Precision Oncology* Sep;7:e2300218, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37677122/>

LUNGMAP Novel Approach to Accelerate Lung Cancer Research: LungMap and the Potential of Public-Private Partnerships. Herbst RS, Blanke CD, Sigal E. *Clinical Cancer Research* Oct 30. doi: 10.1158/1078-0432.CCR-23-2690. Online ahead of print, 2023.

<https://pubmed.ncbi.nlm.nih.gov/37903180/>

S1400I Multi-omics profiling reveals molecular and immune features associated with benefit from immunotherapy for advanced squamous cell lung cancer patients from the phase III SWOG Lung-MAP S1400I trial. *Clinical Cancer*. Parra E, Duose D, Zhang J, Redman M, Lazcano Segura R, Marques-Puibelli M, Fernandez C, Zhang B, Lindsay J, Moravec R, Kannan K, Luthra R, Al-atrash G, Herbst R, Wistuba I, Gettinger S, Bazhenova L, Lee J, Zhang J, Haymaker C, Manyam G, Zhang J, Song X, Rojas F, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Van Nostrand D, Provencher J, Yu J, Cerami E, Huang H, Xie H, Patel M, Nie K, Harris J, Argueta K, Biswas R, Kim-Schulze S, Kelly K, Gnjjatic S. *Clinical Cancer Research* Jan 26. doi: 10.1158/1078-0432.CCR-23-0251. Online ahead of print., 2024.

<https://pubmed.ncbi.nlm.nih.gov/38277235/>

Publication List by Committee

Submitted Manuscripts

S0819 External validation of a novel computed tomography-based prognostic radiomic signature in patients with metastatic non-small cell lung cancer:correlative analysis of SWOG S0819 phase III randomized trial. Derle L, Gomez D, Zhao B, Hama J, Kelly K, Redman M, Gandara D, Schwartz L, Gray JE. Submitted, 2023.

S1400 Lung-MAP Next Generation Sequencing Analysis of Advanced Squamous Cell Lung Cancers (SWOG S1400). Kozono D, Hua X, Wu M, Tolba K, Waqar S, Dragnev K, Cheng H, Hirsch FR, Mack P, Gray JE, Kelly K, Borghaei H, Herbst RS, Gandara DR, Redman M. Submitted, 2024.

LYMPHOMA COMMITTEE

Published/Accepted Manuscripts

Multiple Studies* Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children. Lo A, Liu A, Liu Q, Yasui Y, Castellino S, Kelly K, Herrera A, Friedberg JW, Friedman D, Schwartz C, Pi Q, Kessel S, Bergeron-Gravel S, Dama H, Roberts K, Constone L, Hodgson D. *JAMA Network Open* Jan 2;7(1):e2351062., 2024. [*S1826 and other] <https://pubmed.ncbi.nlm.nih.gov/38241048/>

Submitted Manuscripts

C51101 Myeloablative Versus Non-Myeloablative Consolidation for Newly Diagnosed Primary CNS Lymphoma: Results of Alliance 51101. Batchelor T, Giri S, Ruppert A, Geyer S, Smith S, Mohile N, Swinnen L, Friedberg JW, Kahl B, Bartlett N, Hsi E, Cheson B, Wagner-Johnston N, Nayak L, Leonard J, Rubenstein J.. Submitted 2023.

MELANOMA COMMITTEE

Published/Accepted Manuscripts

S1221 A phase 1 study of triple targeted therapy with BRAF, MEK and AKT inhibitors for patients with BRAF mutated cancers. Algazi AP, Moon J, Lao C, Chmielowski B, Kendra K, Lewis K, Gonzalez R, Kim K, Godwin JE, Curti B, Latkovic-Taber M, Lomeli S, Gufford B, Scumpia P, Lo R, Othus M, Ribas A. *Cancer* Jan 23. doi: 10.1002/cncr.35200. Online ahead of print, 2024. <https://pubmed.ncbi.nlm.nih.gov/38261444/>

Submitted Manuscripts

S1801 Endpoint and design considerations for a randomized comparison of neoadjuvant-adjuvant versus adjuvant-only cancer immunotherapy (SWOG S1801).Othus M, Sharon E, Wu M, Sondak V, Ribas A, Patel S. Submitted, 2024.

PHARMACEUTICAL SCIENCES COMMITTEE

Published/Accepted Manuscripts

S0221 Vitamin D Insufficiency as a Risk Factor for Paclitaxel-Induced Peripheral Neuropathy in SWOG S0221Chen C, Zirpoli G, McCann S, Barlow W, Budd GT, Puzstai L, Henry NL, Godwin A, Thompson A, Ambrosone C, Stringer K, Hertz D. *Journal of the National Comprehensive Cancer Network* Nov;21(11):1172-1180.e3, 2023. <https://pubmed.ncbi.nlm.nih.gov/37935109/> [see also SCQL and Breast Committees]

Submitted Manuscripts

None this cycle

